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Abstract 
Context 
Ultrafine particulate matter contribution to cardiovascular disease is not known and not 
regulated. PM up to 500 nm are abundant in urban air and alveolar deposition is significant. 
Objective 
Effects beyond the alveolar barrier within the body or in vitro tissues exposed to particles 
<500 nm.  
Methods and results 
Databases: MEDLINE; Ovid-MEDLINE PREM; Web of Science; PubMed (SciGlobe). 127 
articles. Results in tables:‘subject type exposed’, ‘exposure type’, ‘technique’.  
Conclusion 
Heart rate, vasoactivity, atherosclerotic advancement, oxidative stress, coagulability, 
inflammatory changes are affected. Production of reactive oxygen species is a useful target 
to limit outcomes associated with UFP exposure. 
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Non-standard Abbreviations and Acronyms
8-OHdG- 8-hydroxy-2’deoxyguanosine 
ALT- alanine aminotransferase  
AST- aspartate aminotransferase 
AMP- accumulation mode particle 
CAD- coronary artery disease 
CAP- concentrated ambient particle 
CD- cellular differentiation 
CMD- count mode diameter 
COX- cyclooxygenase  
CRP- C -reactive protein 
DCeE- diesel and cerium spiked 
exhaust 
EC50- concentration of substance 
required to achieve half the difference 
between baseline and maximum 
response in the independent variable 
EDHF- endothelium-derived 
hyperpolarizing factor 
Emax- maximum possible effect of 
exposure substance 
GSH/GSSH- glutathione/glutathione 
disulphide (oxidized form) 
GP2b3a- glycoprotein 2b3a 
HRT- heart rate turbulence 
HRV- heart rate variability 
KO- gene knockout 
LDLR- low density lipoprotein receptor 
L-NMMA- nitric oxide synthase 
LCA- left carotid artery inhibitor  
MCP-1- monocyte chemotactic 
protein-1  
NAC- N-acetyl cysteine 
PCDW- platelet component distribution 
width 
QTc- corrected QT interval 
RAS- renin-angiotensin system 
rMSSD- mean square root of the sum 
of squared differences between 
adjacent normal-to-normal heart beat 
intervals 
SBP- systolic blood pressure 
SDNN- standard deviation of normal-
normal heart beat intervals 
TAT- thrombin-antithrombin 
TCPP- meso-tetra-(p-carboxyphenyl) 
porphyrin 
TpTe- time from the peak to the end of 
a T-wave 
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Introduction 
Airborne particulate matter (PM) is the solid component of air pollution and contributes to 
excess mortality from pulmonary and cardiac causes in urban environments. The biological 
mechanisms by which particulate matter acts on the cardiovascular system are poorly 
defined in the current medical literature. In their recent update, the American Heart 
Association has stated that the overall evidence is consistent with a causal relationship 
between PM2.5 exposure and cardiovascular morbidity and mortality (Brook et al., 2010). 
Smaller particles comprised of low toxicity, low solubility materials such as carbon black and 
titanium dioxide have been found to have greater toxicity than larger, respirable particles 
made of the same material and the upper cut-off size for this increased toxicity is around 200 
nm, although the cut-off may not be sharp (Donaldson et al., 2000). The term ultrafine 
particles (UFP) does not have a universally agreed definition but is widely accepted as 
describing particles of less than 100 nm in diameter. The greater proportion of UFP in urban 
air derive from combustion sources, notably traffic related ((HEI), 2010).  
For PM10, the latest UK Government legislation (2010) has set 40 µg/m
3 as the yearly 
average limit, and 50 µg/m3 as the daily limit, which is only allowed to be exceeded 35 times 
in one year ((DEFRA), 2010). Statutory limits surrounding PM2.5 are more complex and 
standards for UFP are not in existence, but ambient UFP typically exists in concentrations 
<20 μg/m3 in urban centres (Ning et al., 2007, Moore et al., 2007, Pakkanen et al., 2001). 
The authors of the Six Cities study demonstrated an overall cardiac mortality increase of 
26% between the most and least polluted cities for PM2.5 in their cohort study (Dockery et al., 
1993). The APHEA-2 and NMPAS studies found a 0.69% (Katsouyanni et al., 2001) and 
0.31% (Samet et al., 2000) increase, respectively, in daily cardiovascular mortality per 10 
µg/m3 increase in PM10. The adverse effects of PM2.5 in the epidemiological literature are 
likely to be driven by combustion derived nano-particles (CDNP) and for CDNP three 
properties appear important: surface area, organics and metals (Duffin et al., 2007). Ambient 
concentration of UFP does not correlate well with the larger fractions (Mills et al., 2011, Hoek 
et al., 2010, Pekkanen and Kulmala, 2004) and the effects of UFP on cardiovascular health 
are independent from larger particle fractions due to differential and diverse toxicities (Nel, 
2005). Although the percentage alveolar deposition of inhaled nano-particles peaks around 
50 nm there is an appreciable percentage deposition in the size range 100 nm to 500 nm 
(Carvalho et al., 2011, Oberdorster, 2001). Further to this, measurements of total particle 
number (TPN) by size demonstrate that, in urban air, the TPN in the size range 100 nm to 
500 nm is not insignificant compared to TPN in the size range 20 nm to 100 nm (Beddows et 
al., 2009, Avino et al., 2013, Harrison et al., 2000). Therefore to assess the cardiovascular 
public health risk presented by CDNP in urban air, it is appropriate to review biological 
effects for NPs up to a 500 nm size rather than just for the somewhat arbitrarily defined UFP. 
It is important that the mechanisms underlying this excess cardiac mortality are understood. 
Such understanding could assist in identifying suitable biomarkers of effect which could then 
be used in epidemiological studies to delineate the truly affected and those at increased 
cardiovascular risk but prior to diagnosis of disease. This is of particular relevance given that 
individual exposure measurements are impractical and expensive. It could further provide 
evidence of associations between specific physical and/or chemical constituents of 
particulate matter and effects which could be addressed by primary prevention policies.  
Many different mechanisms have been proposed to elucidate the excess mortality. Early in 
vitro (Veronesi et al., 1999, Jimenez et al., 2002) and experimental animal trials (Sun et al., 
2005, Costa and Dreher, 1997, Tousoulis et al., 2012, Oberdürster, 2000) have detected 
significant changes in multiple biomarkers for acceleration of atherosclerosis ((HEI), 2002, 
(DoH), 2005). Further studies, including human volunteer trials, followed with varying results, 
and several mechanisms were proposed to link UFP with atherosclerotic deaths. The most 
notable include; suppression of heart rate variability (HRV), reduced coronary flow, oxidative 
stress leading to endothelial dysfunction, platelet activation and acute phase protein 
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response which all potentially contribute to cardiovascular mortality (Pope et al., 2002, 
Delfino et al., 2011, Brook, 2008). Currently, the mechanisms leading to atherosclerotic 
deaths have not yet been defined clearly and uncertainty remains surrounding causal 
relationships. An American Heart Association writing group, the Health Effects Institute and 
UK Department of Health all recognize determining causal pathways for future preventive 
strategies as an essential area of future research(Brook et al., 2004, (HEI), 2002, (DoH), 
2005).  
This review will systematically examine the effector mechanisms linking inhalation of 
ultrafine particulate matter to increased incidence of atherosclerotic deaths in human and 
animal subjects. 
 
Methods 
Devising search terms 
To construct the search strategy, a method was adapted from the German Institute for 
Quality and Efficiency in Health Care (Hausner et al., 2012). The authors initially used basic 
search terms (ultrafine, nanoparticle, particulate matter, heart, cardiovascular system and 
vascular) to return a preliminary set of 42 papers related to the review topic. From these 42 
papers, a 2/3 (test group) 1/3 (validation group) split was made using 2:1 restricted 
randomization on random allocation software (Gerard, 2008). 28 were randomized to the test 
group and 14 to the validation group. The 2/3 test group was used to construct a search 
strategy by retrieving “particulate matter” search terms and “biological mechanism” search 
terms from the article abstracts. These two groups of search terms were combined using the 
OVID interface to search the Medline database in an attempt to return the test group. See 
table 1 for the constructed search. All 28 test references were returned, proving 
methodological effectiveness of combining the extracted “particulate matter” search terms, 
with the “biological mechanism” search terms. The author conducting the search was blinded 
against the validation group. The search was validated by searching for the 14 previously 
unused references. All 14 were returned using the same search strategy. See figure 1 for a 
diagrammatic representation of the search construction.  
 
Article search methods.  
1. An electronic search of the MEDLINE database (1946-present) via Ovid, and Ovid-
MEDLINE(R) In-Process & Other Non-Indexed Citations (PREM) as well as Web of 
Science database via Web of Knowledge was performed on 24/01/13. “Particulate 
matter” search terms were combined with “biological mechanism” search terms using 
the operator AND. Results were limited to post 1980 as relevant epidemiological work 
started around 1980 (Dockery et al., 1993, Samet et al., 2000, Katsouyanni et al., 
2001).  
 
2. PubMed was searched via the SciGlobe search engine. SciGlobe is a novel search 
engine which discerns the intent of the author to link search terms and uses modern 
linguistic technology to return focused publications from few keywords. The search 
terms “ultrafine and cardiovascular”, “air pollution and cardiovascular” and 
“nanoparticle and cardiovascular” were used to find articles where SciGlobe identified 
relationships existing between the two. The database was searched on 29/01/13. 
Selection Criteria 
All articles returned from manual and electronic search strategies were assessed for 
inclusion or exclusion against the criteria in table 2. Included articles featured both human 
and animal studies. 
 
Inclusion assessment  
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Abstracts were extracted to EndNote, de-duplicated and viewed on-line. These articles were 
assessed for relevance based on the inclusion/ exclusion criteria and relevant articles were 
obtained in full. Two authors independently reviewed articles against the selection criteria for 
inclusion or exclusion. To make evident the transparency of the search method, all search 
returns and subsequent exclusions are presented as a QUORUM flow chart in figure 2.  
). (40).  
Study Quality assessment 
The study design which best controls for any known or unknown confounding of the 
exposure-response relationship is that of controlled exposure of humans or animals. These 
data have the obvious advantage over in vitro studies in that the response is measured 
which most closely resembles the response of real interest i.e. response in a human subject. 
Other study designs are subject to a greater potential for confounding variables obscuring 
true relationships of exposure and effect.  
 
Results 
Findings of the critical appraisal are presented in tabular format for the different categories of 
study design reviewed:  
Table 3.a - Randomized controlled trials in humans (Inhalation of nanoparticles)  
Table 3.b - Randomized controlled trials in animals (Inhalation of nanoparticles)  
Table 4 - Human longitudinal cohort studies 
Table 5.a - Controlled animal experiments (instillation of suspended nanoparticles)  
Table 5.b - Controlled animal experiments (injection of nanoparticles into circulation)  
Table 6.a - Controlled In vitro experiment (human tissues)  
Table 6.b - Controlled In vitro experiment (animal tissues)  
For each included article; subjects, exposure type and technique, outcomes and results, 
critical appraisal of the article, and conclusions are highlighted within the tables.  
 A summary of the detailed appraisals across the different study designs is presented below 
under the headings, “Vasoactivity”, “Heart Rate Blood Pressure and Autonomic Modulation”, 
“Thrombosis”, “Plaque Advancement”, “Acute Phase Protein and Cytokine Release”, and 
“Oxidative Stress”.  
Vasoactivity 
Acetylcholine and bradykinin are endothelium dependent vasodilators (Mills et al., 2011, 
Mikkelsen et al., 2011). The best evidence for endothelium dependent vasoactivity exists as 
a cross-over trial using 16 human inhalation exposures of carbon black (CB) at 70 μg/m3 
which showed no change for acetylcholine or bradykinin dependent arteriolar dilation (Mills 
et al., 2011).  A 10 μg pulmonary deposition of TiO2 nanoparticles attenuated endothelium 
dependent vasodilation in rats, with prostanoid dysfunction being a probable contributor 
(LeBlanc et al., 2010). Controlled inhalation exposure to an identical TiO2 dose also found 
impaired reaction of arterioles to endogenous prostanoids (Knuckles et al., 2012). One 
strong experiment used inhalation exposure of nickel nanoparticles, over a time period 
designed to reflect occupational exposure and found the effect of acetylcholine attenuated 
(Cuevas, 2010). The strongest evidence using Ca2+ donation to mediate relaxation shows 
that TiO2 nanoparticles attenuate this effect (LeBlanc et al., 2009, Nurkiewicz et al., 2008).  
Nitric oxide (NO) responsiveness is an endothelium-independent mechanism (Nurkiewicz et 
al., 2009). The strongest available evidence, human controlled inhalation at levels similar to 
those experienced in heavy traffic, reported normal NO function for CB, but impairment after 
ambient UFP exposure at 5 times the CB concentration (348 μg/m3) (Mills et al., 2011). TiO2 
exposure through inhalation at doses relevant to occupational exposure showed no effect on 
NO dependent vasodilation (LeBlanc et al., 2009, Nurkiewicz et al., 2009), but did show a 
reduction in endothelial NO production (Nurkiewicz et al., 2009). 
Two strong studies used controlled inhalation of TiO2 nanoparticles in rodents (Knuckles et 
al., 2012) and CB in humans (Shah et al., 2008). In both, reactive hyperaemia blunted, 
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indicating an arterial dilation failure. Impaired tonic sympathetic influence was also seen 
(Knuckles et al., 2012).  
Reduced coronary flow after infusion of UFP occurred in all isolated heart perfusion models 
(Hwang et al., 2008, Tong et al., 2010, Wold et al., 2006, Simkhovich et al., 2007, Cho et al., 
2009). Infarct size was extended post-exposure to UFP and carbon nanotube exposure in an 
isolated heart perfusion model (Cho et al., 2009). In two cohorts of stable CAD patients, ST-
depression correlated with ambient UFP levels (Delfino et al., 2011, Pekkanen et al., 2002).  
β-blockers may have been protective for ST-depression (Pekkanen et al., 2002).   
The potent vasoconstrictor endothelin-2 was raised approximately 20% in rats after direct 
inhalation of UFP from a roadside for 3 days (Elder et al., 2004a).  
 
Targets for future intervention 
In 45 subjects, 72 exercise induced ST-segment depressions >0.1 mV over 6 months were 
recorded in a risk assessment study of UFP exposure. Those patients using β-blocker 
medication conferred a weaker association between ST-segment depression and UFP 
exposure compared with non β-blocker medicated patients. No heart rate difference existed 
between groups suggesting that β-blockers may exert a protective effect by different 
mechanisms than the assumed heart rate modulation (Pekkanen et al., 2002). 
Summary 
Strong evidence exists to indicate endothelium-dependent and independent pathways, 
including altered prostanoid and hormone expression, mediate UFP induced 
vasoconstriction. Autonomic impairment may also occur. Coronary circulation is reduced 
post-UFP exposure. Ischaemic effects may be limited by β-blocker use. 
 
Heart rate, blood pressure and autonomic modulation 
Altered autonomic function and increased cardiac demand are associated with ischaemic 
deaths, as is increased blood pressure (Avino et al., 2013). The strongest evidence for 
nanoparticle-induced heart rate change exists as controlled inhalation exposure to CB. Heart 
rate was increased after >24 hr exposure to concentrations of 15.6 mg/m3 (Niwa et al., 
2008), 180 μg/m3 (Harder et al., 2005) and 172 µg/m3 (Upadhyay et al., 2008) in rats, but no 
change was seen in humans at 50 µg/m3 for 2 hours, nor for SBP, but when SBP and HR 
changes were considered as an arithmetical product, a statistically significant increase 
existed between exposed and control males (Shah et al., 2008). 
 Ambient exposure over 10 weeks in a cohort of myocardial infarction survivors found a 
small but significant increase in SBP (0.9 mmHg)(Rich et al., 2012). Controlled 
experimentation in rodents found that SBP  was increased after exposure concentration and 
duration >180μg/m3 and> 24 hours (Niwa et al., 2008, Upadhyay et al., 2008), but not below 
these (Harder et al., 2005). The greatest exposure, 15.6mg/m3 over 4 weeks, increased SBP 
by 30mmHg at 14 and 28 days in rodents (Niwa et al., 2008).  
Reduced heart rate variation (HRV), a marker of autonomic imbalance, is causally implicated 
in coronary disease and sudden cardiac death(Xhyheri et al., 2012). Controlled exposure 
trials in young patients showed HRV increases post exposure to UFP (Zareba et al., 2009, 
Samet et al., 2009). Respiratory influences on HRV decline with age, and combined with 
these findings suggest HRV modulation by UFP is dependent on baseline parasympathetic 
tone (Samet et al., 2009, Demeersman, 1993). Accordingly, all observational studies in 
human subjects aged >60 years (Folino et al., 2009, Weichenthal et al., 2011, Wu et al., 
2012) and in elderly cardiac disease patients (Rich et al., 2012, Timonen et al., 2006) 
showed HRV reductions. Controlled exposure in cardiac disease patients however, showed 
no change (Routledge et al., 2006). 
 
Summary 
Increases in heart rate and SBP are both plausible in animal models. SBP may be slightly 
increased after ambient exposure. Reductions in HRV may occur in the elderly and cardiac 
diseased, post exposure.  
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Thrombosis 
The best available evidence describing thrombosis formation is mostly formed by intra-
tracheal instillation or injection of polystyrene nanoparticles, and not via inhalation 
exposures.  Polystyrene particles are charged, like most UFP, but are otherwise unreactive 
(Nemmar et al., 2002, Cohen et al., 1998). In a photo-chemically induced vascular injury 
model, instilled 60 nm positively-charged polystyrene particles enhanced thrombus formation 
in vivo at concentrations of 50 -500 µg/kg (Nemmar et al., 2002, Nemmar et al., 2003, Silva 
et al., 2005, Bihari et al., 2010) and 50 mg/kg(Silva et al., 2005). 400 nm (500 µg/kg) instilled 
particles enhanced  thrombus formation after photochemical injury in one experiment 
(Nemmar et al., 2004a).These particles partly enhanced platelet function in another 
instillation experiment which was limited by excessive aggregation caused by use of a very 
small solute volume (205 μl)(Nemmar et al., 2003).  Negatively-charged 60 nm nanoparticles 
had no thrombotic effect (Nemmar et al., 2003, Silva et al., 2005) and may have had an 
inhibitory effect (Nemmar et al., 2002, Bihari et al., 2010) when examined in the 
photochemical injury model. 20 nm negatively-charged particles were associated with 
microscopic thrombi in mice, indicating a direct effect on thrombotic pathways (Furuyama et 
al., 2009).  
Summary 
It is likely that thrombosis is enhanced by nanoparticle or UFP exposure, but it is not known 
if this occurs at ambient inhalation concentrations. Charge may play an important role. 
Plaque advancement 
Exposure to ambient UFP for 40 days increased atherosclerotic plaque size in mice 
compared with controls (Araujo et al., 2008). Oropharyngeal or intra-tracheal instillation of 
particles also accelerated atherosclerotic advancement in mice (Mikkelsen et al., 2011, Niwa 
et al., 2007, Cassee et al., 2012). 
 
In one intra-tracheal instillation of CB in ApoE-/- mice, no change in plaque morphology was 
seen. However, the exposure was limited by possible pollution with larger particles (PM2.5). 
Disproportionately high mortality rates in the exposure group occurred also (Vesterdal et al., 
2010).  
 
Targets for future intervention  
Cerium oxide is a fuel additive designed to increase fuel combustion efficiency (Sajith et al., 
2010). Recently, a vulnerable murine model was exposed to diluted diesel exhaust (DE) of 
1.7 mg/m3 or diesel exhaust of 1.7 mg/m3 spiked with 9 parts per million ultrafine CeO2 
particles (DeCe), intermittently for 4 weeks (Cassee et al., 2012). DeCe significantly limited 
plaque complexity compared to the DE group, suggesting a protective effect.  
Summary 
It is likely that atherosclerotic plaque size is advanced in animals exposed long term to UFP. 
Cerium oxide nanoparticle spiked diesel fuel may limit the deleterious effects of diesel 
exhaust.  ( 
 
Acute phase response and cytokine release 
IL-6 is a known mediator of atherosclerosis (Huber et al., 1999). Seventeen experiments 
using a variety of nanoparticles or UFP showed IL-6 expression increased 2 hours-28 days 
post exposure after in vitro and in vivo exposures (Nemmar et al., 2011, Park et al., 2009, 
Niwa et al., 2008, Corbalan et al., 2011, Aung et al., 2011, Delfino et al., 2010, Delfino et al., 
2009, Downs et al., 2012, Karoly et al., 2007, Mo et al., 2009a, Mo et al., 2012, Nishimori et 
al., 2009, Park et al., 2010, Srinivas et al., 2011, Zhu et al., 2011, Nishanth et al., 2011). Of 
the strongest evidence, a controlled inhalation exposure study using CeO2 nanoparticles at  
641 mg/m3 showed an increase of IL-6 in rodents (Srinivas et al., 2011), but lower 
concentrations of CB in rodents and humans did not (0.05-0.150 mg/m3) (Elder et al., 2004b, 
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Stewart et al., 2010). All instillations in rodents showed an increase (Nemmar et al., 2011, 
Park et al., 2009, Niwa et al., 2008, Mo et al., 2012, Park et al., 2010), bar one (Kim et al., 
2012).  
CRP is an independent causal factor in atherosclerosis (Bisoendial et al., 2007). Human and 
animal studies using controlled inhalation at low concentrations (50-172 μg/m3) (Upadhyay 
et al., 2008, Rich et al., 2012, Routledge et al., 2006, Stewart et al., 2010), ambient 
exposure (Rich et al., 2012, Folino et al., 2009), and intra-tracheal instillation (Jia et al., 
2012) showed no change in CRP levels after UFP, CB or carbon nanotube exposure. Very 
high inhalation exposure of 15.6 mg/m3 CB in rodents compared to other inhalation studies 
(Upadhyay et al., 2008, Routledge et al., 2006, Stewart et al., 2010) caused an increase at 
28 days (Niwa et al., 2008).  
TNF-α is an important mediator in atherosclerosis (Yoshizumi et al., 1993). Nine in vivo 
experiments constitute the best available evidence. Three moderate strength studies using 
nanoparticle instillation exposures in animals found no TNF-α increase (Nemmar et al., 
2011, Park et al., 2010). Six similar experiments found significant TNF-α protein or genetic 
expression with a range of nanoparticle or UFP exposures(Delfino et al., 2010, Downs et al., 
2012, Nishimori et al., 2009, Park et al., 2010, Srinivas et al., 2011) . In a longitudinal cohort, 
for subjects prescribed clopidogrel and statins, correlation of UFP with TNF-α and 
inflammatory P-selectin was reduced, compared with those non-medicated (Delfino et al., 
2009).  
 
Targets for future intervention 
In a cohort study, 64 coronary disease patients were followed up weekly for six weeks. 
Results showed significant correlations between UFP concentration (<250 nm) and 
inflammatory biomarkers (sTNF-RII and sP-selectin). The association between UFP and sP-
selectin was weaker for patients on clopidogrel (Delfino et al., 2009). sP-selectin activates 
endothelial cells, leukocytes and promotes interaction of these cells with platelets (Blann et 
al., 2003). A similar more pronounced correlation reduction was seen for sTNF-RII in 
patients using statins (Delfino et al., 2009).  
 
Summary 
IL-6 and TNF-α are likely expressed after UFP or nanoparticle exposure. CRP expression 
might be increased at high exposure concentrations. Observational work suggests cardiac 
drugs may provide a protective effect against inflammatory biomarker increases. 
Oxidative Stress 
Three inhalation exposure trials exist for CB exposure, an important surrogate for ambient 
UFP. One showed no change in rodents exposed to 114 and 268 nm CB particles by 
continuous inhalation for 7 hrs at 1 mg/m3 (Gilmour et al., 2004). Smaller particles (25-36 
nm) caused oxidative stress in humans (Huang et al., 2010b) and rodents (Elder et al., 
2004b) after reduced exposures (both exposures <150 µg/m3 at <6 hours). Weaker evidence 
from intra-tracheal instillation in mice (Hwang et al., 2010), oral instillation in mice (Sharma 
et al., 2012) and controlled inhalation exposures (LeBlanc et al., 2010, Nurkiewicz et al., 
2009) in rodents also showed an increase oxidative stress after ZnO nanoparticle exposure.  
 
Lipid peroxidation is a result of oxidative stress, can lead to cell membrane break down, and 
is implicated in atherosclerosis (Mylonas and Kouretas, 1999).The strongest available 
evidence exists as controlled inhalation of ambient UFP at a busy roadside in rodents over 
40 days (Araujo et al., 2008), where an increase in liver peroxidation was seen. Instillation of 
TiO2 over 60 days also showed an increase (Cui et al., 2010).  A marker of lipid peroxidation, 
heart malondialdehyde, was not raised post intra-tracheal instillation of CB after six days. 
Before instillation, very large CB agglomerates in the micrometre range were visualised by 
dynamic light scattering analysis, implying limited particle surface area (Jia et al., 2012).  
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Targets for future intervention 
Radical scavengers and anti-oxidants administered to cells exposed to UFP and engineered 
nanoparticles eliminated previously observed inflammatory cytokine expression (Mo et al., 
2009a, Wan et al., 2008), cytotoxicity (Mo et al., 2009a), and endothelial function (Vesterdal 
et al., 2012).  
 
Recently, a vulnerable murine model was exposed to diluted diesel exhaust (DE) of 1.7 
mg/m3 or diesel exhaust of 1.7 mg/m3 spiked with 9 parts per million ultrafine CeO2 particles 
(DeCe), intermittently for 4 weeks (Cassee et al., 2012). Addition of DeCe particles to the 
fuel reduced particle number by 30% and a reduction of 10% surface area.  
Compared to DE, CeO2 supressed the production of reactive oxygen species in murine 
macrophages by 44% and induced resistance to cell cytotoxicity by 37% when cells were 
pre-treated with CeO2 for 8 hours before exposure to DE (p<0.01) (Xia et al., 2008).  
Summary 
It is highly likely that UFP induces oxidative stress in the cardiovascular system. Oxidative 
stress is important in moderating downstream outcomes and presents a useful target. 
Cerium oxide spiked fuels may limit oxidative stress secondary to diesel ultrafine particulate.   
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Discussion 
Studies that use suspended environmental samples for research into their biological effects 
usually require a preparation step prior to investigation, the purpose of which is to disrupt 
particle agglomerates into more representative constituent particles.  The method most 
commonly applied is sonication.  However, it should be noted that there is considerable lack 
of standardisation in the application of sonication and few studies accurately report the pre-
dosing, in vitro or in vivo preparation procedure (Berube et al., 1999, Taurozzi et al., 2011). 
To consider this and related aspects of sample preparation is beyond the scope of this 
review, however it is important that the concept and the variation in particle preparation is 
recognized.  Future research should therefore consider applying standardised 
methodologies and reporting mechanisms to sample preparation with special attention being 
paid to ultrasonic dispersion as differences in the pre-analytical dispersion methods likely 
lead to variability in results when comparing data between studies. 
 
It is likely that coronary flow is reduced after injection of UFP and nanoparticles into ex vivo 
isolated heart models (Hwang et al., 2008, Tong et al., 2010, Wold et al., 2006, Simkhovich 
et al., 2007, Cho et al., 2009). Ultimately, myocardial infarction size was increased in these 
models (Cho et al., 2009). It is unclear if a reduction in coronary flow occurs after ambient 
exposure to UFP in the same manner as that after injection of UFP or nanoparticles, but the 
included data suggest that vasoconstriction is accentuated and vasodilation blunted in most 
major arteries after inhalation of UFP in humans (Mills et al., 2011, Shah et al., 2008).  
Evidence from animal models (Harder et al., 2005, Niwa et al., 2008, Upadhyay et al., 2008) 
and limited controlled human experimentation (Rich et al., 2012, Shah et al., 2008) suggest 
that increases in heart rate and blood pressure are biologically plausible sequelae after UFP 
exposure. HRV modulation probably occurs post UFP exposure, but risk of confounding from 
the observational studies which form the bulk of the evidence in older patients, and the 
impact of age in relation to baseline parasympathetic influence limits confidence in the 
magnitude and direction of HRV change (Samet et al., 2009, Demeersman, 1993).  
Clearly, exposure to 60-400 nm positively charged nanoparticles enhanced thrombosis in 
artificial thrombus models (Nemmar et al., 2002, Nemmar et al., 2003, Cohen et al., 1998, 
Silva et al., 2005, Bihari et al., 2010). In vitro work suggests a thrombotic effect may exist 
(Radomski et al., Kendall et al., 2011), but a strong conclusion is limited by poor 
generalizability from use of surrogate particles in artificially induced thrombus models to 
inhalation of UFP in the real world.  
Most of the included literature examined whether UFP produced excessive reactive oxygen 
species, overwhelming cellular defences. Strong studies concerning animals exposed to 
feasible UFP concentrations experienced in ambient air support a role of oxidative stress in 
UFP mediated toxicity (Araujo et al., 2008, Elder et al., 2004b, Huang et al., 2010b, Cui et 
al., 2010). Few studies have causally linked oxidative stress to potential secondary effectors 
such as interleukin release or endothelial dysfunction (Mo et al., 2009a, Mo et al., 2012, 
Vesterdal et al., 2012, Wan et al., 2008).  
 
In vitro and intra-tracheal exposures tended to show IL-6, and TNF-α increases, but 
controlled exposures often did not. CRP was only raised in one very high exposure 
inhalation trial. It is unclear whether this effect is important at ambient exposure levels.  
Oxidative stress mediates inflammatory, endothelial and vasoactive pathology, and this may 
be an important target for future prevention strategy. Cerium oxide fuel additives may also 
limit deleterious processes secondary to UFP exposure. Also relevant for prevention, 
multiple cardiac drugs conferred a protective effect in medicated patients (Folino et al., 2009, 
Delfino et al., 2009, Corbalan et al., 2011).  
 
When considering the effect of long term inhalation of UFP on the cardiovascular system, 
the strongest evidence would include human exposures of a long duration to ambient UFP or 
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its major constituents at levels considered feasible in an outdoor urban environment. The 
strongest available evidence exists as short term human volunteer exposures of 2-6 hours 
(Mills et al., 2011, Shah et al., 2008, Routledge et al., 2006, Zareba et al., 2009, Samet et 
al., 2009, Stewart et al., 2010, Frampton, 2007, Pietropaoli et al., 2004, Huang et al., 2010a) 
or longer exposures of 28-40 days in vulnerable murine and rodent models (Araujo et al., 
2008, Cassee et al., 2012, Niwa et al., 2008). Controlled inhalation exposures failed to show 
positive findings for vasoactivity (Mills et al., 2011), inflammatory responses (Elder et al., 
2004b, Stewart et al., 2010), oxidative stress (Gilmour et al., 2004) or cellular adhesion 
molecules (Elder et al., 2007), but in vitro experiments found positive results for inflammatory 
responses (Corbalan et al., 2011, Karoly et al., 2007, Zhu et al., 2011), oxidative stress 
(Nishanth et al., 2011, Vesterdal et al., 2012, Trpkovic et al., 2010) and cellular adhesion (Li 
et al., 2007, Li et al., 2010b, Vesterdal et al., 2012). It is possible that for exposure to UFP at 
ambient concentrations, 1) a larger sample is needed to show small statistically significant 
changes or 2) the differences between in vitro and in vivo conditions allow spurious in vitro 
findings.  
 
The ability of UFP to react with the experimental medium or absorb nutrients was a 
recognized limitation of in vitro experimentation (Han et al., 2011, Clift et al., 2010, Guo et 
al., 2008), as was the risk of particle aggregation in vitro. This limitation was also 
appreciated during intra-tracheal instillation (Gilmour et al., 2004, Bourdon et al., 2012, 
Khandoga, 2004, Gosens et al., 2010). Attempt has been made to correlate findings from in 
vivo and in vitro experiments to enhance comparability(Sayes et al., 2007), but further 
validation of in vitro systems is needed to meaningfully correlate results. 
 
Most studies are credited with using exposures well-defined by particle mass and size to 
determine UFPs’ biological effects. Few included studies additionally analysed the 
synergistic and anti-synergistic interaction between UFP and ambient co-pollutants, for 
example bacterial lipopolysaccharide and gaseous pollutants (Mills et al., 2011, Elder et al., 
2004a, Elder et al., 2004b). This is important considering excessive lung inflammation from 
lipopolysaccharide exposure may widen alveolar pores allowing more particles to cross 
(Bannerman and Goldblum, 1999), or gaseous components may react with nanoparticles 
forming compounds or varying volatility (Kelly and Fussell, 2012).  
 
An advisory paper by the Health Effects Institute (HEI) describes broad research steps in 
addressing the limitations of current research. Extending long term animal inhalation designs 
to humans was recommended ((HEI), 2013). Findings from this review allow more defined 
recommendations. Further experimental research should investigate: 
 
 The possible protective effect of anti-inflammatory medicines, and particularly anti-
oxidant medicines, on UFP mediated cardiovascular disease. The data in this review 
suggested oxidative stress was an important mediator in several measured 
outcomes. Recently, effort has been made to limit free radical production caused by 
concentrated ambient particulate matter inhalation with omega-3 supplementation 
(Tong et al., 2012). 
 Different susceptibilities of systemically inflamed populations, such as COPD 
patients, to certain mechanisms. Particularly any enhanced inflammatory effect from 
UFP, seen sub-clinically in the healthy population (Delfino et al., 2009, Delfino et al., 
2010, Downs et al., 2012, Karoly et al., 2007).  
 Possible direct interaction between UFP and hepatocytes to stimulate the synthesis 
of coagulation factors which are raised post-exposure to nanoparticles (Khandoga, 
2004).  
 UFP mediated change in biomarkers specific to vascular constriction; endothelin-1/2, 
ACE and angiotensin. Building on limited work, controlled experimentation may yield 
these as useful epidemiological biomarkers, particularly the potent, specific 
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vasoconstrictors endothelin-1/2 and ACE which both rose 20- 25% after ambient 
exposure to UFP (Elder et al., 2004a).  
 The effect of chronic exposures in animals and humans, particularly to well-defined 
combustion products or controlled exposures to ambient UFP. A controlled trial 
combining a concentrated ambient exposure relevant to public health and of 28 days 
duration serves as an example of rodents exposed chronically to UFP (Araujo et al., 
2008). 
 
Conclusion 
Review of a large literature set has indicated that ultrafine particles of different compositions 
do cause toxicity to cardiovascular tissues, but uncertainty remains over which materials are 
the most toxic. There is limited strong evidence to support individual mechanisms leading to 
excess cardiac mortality but it seems likely that increased oxidative stress plays a role, and 
may mediate other effects of impaired vasodilation, inflammation and endothelial activation. 
Whilst animal studies played a useful role, further research using longer term randomized 
controlled trials in humans is recommended in strengthening these findings. Several 
included articles indicate oxidative stress mediates downstream effects of inflammation and 
endothelial dysfunction, presenting a useful target for prevention of mortality.  
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Table 1. Search terms 
Particulate matter terms 
pm25/ or pm10/ or ufp/ or ultrafine particle/ or cap/ or concentrated ambient particle/ 
or nanoparticle/ or particulate matter/ or particle exposure/ or diesel exhaust/ or air 
pollution/ or particulate emission/ or traffic exhaust/ or vehicle emission/ 
 
Biological mechanism terms 
thrombosis/ or systemic inflammation/ or crp/ or c?reactive protein/ or fibrinogen/ or 
fibrinolysis/ or platelet activation/ or platelet aggregation/ or endothelial d?sfunction/ 
or fibrinolysis/ or oxidative stress/ or nrf2/ or antioxidant/ or vasoconstriction/ or 
vascular function/ or tissue plasminogen activator/ or plaque/ or endothel$ 
inflammation/ or myocardial infarction/ or acute phase response/ or atherosclerosis/ 
or oxidative stress/ or Hdl/ or ldl/ or cholesterol/ or carotid intima medial thickness/ or 
cimt/ or pmn/ or polymorphonuclear/ or superoxide anion/ or endothelin/ or 
Endothelial progeinator/ or MTHF/ or NADPH oxidase/ or EOHF/ or Vascular cell 
adhesion molecule 1/ or lectin-like oxidized low density lipoprotein receptor 1/ or 
thiobarbituric acid reactive substance/ or homocysteine/ or nitrotyrosine/ or 
isoprostane/ or il-1/ or il-6/ or il-8/ or crp/ or heart rate varia?/ or HRV/ or autonomic/   
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Table 2. Selection Criteria 
Inclusion criteria  Exclusion criteria  
Original research 
0-500 nm particles used in exposure 
Outcome consequent to exposure is 
measured systemically i.e. outcomes 
detected beyond the alveolar barrier,  
Outcome consequent to exposure 
measured on systemic tissues such as 
vascular endothelial cells or 
lymphocytes.  
Outcome measure related to 
atherosclerotic advancement. 
No biological mechanism investigated. 
Particles >500 nm. 
Pulmonary outcomes i.e. outcomes 
occurring before UFPs have crossed the 
alveolar barrier. 
Outcome consequent to exposure 
measured on non-systemic tissues such as 
bronchial epithelial cells. 
Outcomes measured systemically, but 
related to non-cardiovascular related 
outcomes i.e. neurological. 
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Table 3a. Randomized controlled trials in humans (Inhalation of nanoparticles). The tables are ordered by strength of evidence, and alphabetically within 
tables. All positive outcomes are reported positive at a p=0.05 significance level regardless of the included study’s definition of significance. Where subject age 
or gender is reported by the study it is included in column two and the age at the start of the study is used.  Where subjects have been randomized, this is 
referred to as a randomized trial, and a controlled trial if not. Definitions: ↑= increase, ↓= decrease, ─ =no change, expts= experiments, hrs= hours,  mins= 
minutes.  
 
Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion  
Frampton 
et al 2006 
Randomiz
ed 
crossover 
trial 
(Frampton 
et al., 
2006). 
56 non-
smokers 18-
40 years old. 
16 with 
asthma.  
Mouthpiece 
inhalation 
exposure. 
UPREST. 12 
subjects 
exposed to 
10 µg/m3 CB 
(25 nm) or air 
for 2 hrs  
CD3+, 
CD11a, 
CD18, CD25, 
CD49d, 
CD54 CD62 
Numbers of 
monocytes, 
basophils, 
eosinophils. 
Reduced CD54 on monocytes 
p=0.0012. Expression of CD54 
on PMNs decreased p=0.031. 
Reduction in CD62L showed 
exposure–sex interaction, rising 
in females and dropping in 
males for monocytes p=0.0006. 
Expression of CD62L on PMNs 
increased in males only p=0.01. 
UFP blunted increase in CD18 
on monocytes p=0.0002. CD11a 
expression on PMNs increased 
p=0.037. CD25 expression on 
CD3+ T cells increased in 
females. Exposure increased 
CD25 expression on T cells 
p=0.001. Monocyte numbers in 
Females decreased p=0.035; 
exposure–sex interaction, 
p=0.002. A decrease in female 
blood basophils in females was 
also seen p=0.015. In 
asthmatics, UFPs reduced 
CD11b on monocytes and 
eosinophils p=0.029 p=0.015. 
Basophils and eosinophils 
decreased, p=0.02. UFP 
exposure did not change platelet 
counts. 
 
 
Within 
subject 
controls, 
randomized 
to exposure 
order. 
Multiple 
experimental 
protocols 
which 
showed 
consistent 
effects to 
support data. 
Exposure 
concentration
s reflect real 
world 
conditions. 
Carryover 
effect occurred 
in some 
patients.  
Peripheral blood 
monocytes, 
basophils 
eosinophils and 
cellular 
adhesion 
molecules are 
reduced on 
some 
monocytes and 
PMNs when 
exposed to CB 
UFP. 
 
      
UPDOSE. 12 subjects 
exposed to 10 µg/m3, 25 
µg/m3 CB or air for 2 hrs. 15 
min exercise/half hour to 
achieve 20 L/min ventilation 
 
      
UPASTHMA. 16 mild 
asthmatic subjects exposed 
to 10 µg/m3 CB or air for 2 
hrs with the exercise.  
 
      
UP50. 16 subjects exposed 
to 50 µg/m3 CB or air for 2 
hrs with the exercise.  
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Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Huang et 
al 2010 
Randomiz
ed cross-
over trial 
(Huang et 
al., 
2010b). 
6 healthy 19-
32 year olds. 
Mouthpiece 
inhalation 
exposure 
CB 25 nm 
at 50 µg/m3 
exposure 
for 2 hours 
with 15 min 
exercise 
intermittentl
y (n=3). 
Control-
filtered air 
(n=3) Tests 
conducted 
0 and 24 
post 
exposure. 
Inflammation-
related gene 
expression. 
Vascular 
growth-
related 
pathways. 
Oxidative 
stress gene 
expression. 
Genetic 
expression of  
Ingenuity 
signalling 
and 
toxicological 
pathways 
Many genes up-regulated 
across the following areas. 
Superoxide release and 
metabolism; Peroxidase activity, 
oxidoreductase activity, Other 
genes involved in oxidative 
stress, Inflammation genes, 
Apoptosis inducers, cell division 
relevant genes. 
Standardized 
ventilation. 
Validated 
procedure. 
Small subject 
numbers. 
Inhalation of 
ultrafine carbon 
up-regulated 
oxidative stress 
and 
inflammation 
relevant genes. 
Mills et al 
2011. 
Randomiz
ed double 
blind 
cross-
over trial 
(Mills et 
al., 2011). 
16 healthy 
male subjects 
between 18 
and 32 years 
of age 
exposed on 4 
separate 
occasions 2 
weeks apart 
to filtered air, 
carbon 
nanoparticles
, diesel 
exhaust 
nanoparticles 
and exhaust 
gases 
Whole body 
exposure. 
70 µg/m3 
carbon 
nanoparticl
es mean of 
37 nm. 
Diesel 
exhaust 
mean of 67 
nm at 348 
µg/m3. 2 
hours of 
exposure. 
Assessmen
ts carried 
out 6 hours 
later. 
Blood 
pressure, 
vasoactivity 
(endothelium 
dependent 
and 
independent 
mechanisms) 
Fibrinolytic 
function. 
 Blood pressure ↑ from the 
control of 133 mmHg to 145 
mmHg with UFP exposure. They 
also attenuated vasodilatation to 
bradykinin, sodium nitroprusside 
and acetylcholine.  Carbon 
nanoparticles ─ effect. 
Fibronolytic function was 
unaffected by any exposure. 
Centrifuged 
for 30 mins. 
Within 
subject 
controls. 
Exposure 
concentration 
similar to real 
world 
conditions.   
No 
assessments 
carried out 
immediately 
after exposure. 
The 
attenuation of 
dilation in 
arteries is 
assessed, not 
vaso-
constriction.  
Diesel 
nanoparticles 
reduce 
vasoreactivity 
by both 
endothelium 
dependent and 
independent 
mechanisms 
and raise blood 
pressure. 
Carbon 
nanoparticles 
have no such 
effect and 
fibrinolytic 
function is 
unaffected.  
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Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Pietropaol
i et al 
2004. 
Randomiz
ed cross-
over trial 
(Pietropao
li et al., 
2004).  
16 non-
smokers 18-
40 years old.  
Mouthpiece 
inhalation 
exposure. 
50 µg/m3 
CB or air 
for 2 hrs 
with 
intermittent 
exercise.  
Carbon 
monoxide 
diffusing 
capacity 
(vascular 
function). 
At 21 hrs, carbon monoxide 
diffusing capacity ↓ in CB group.  
Double 
blinded.  
Particle size 
determined 
immediately 
prior to 
inhalation. 
Gender equal 
across 
groups, and 
order of 
presentation 
randomized 
separately by 
gender.  
Diffusion 
capacity also 
affected by 
haemoglobin 
reactivity, and 
gas diffusion.  
While carbon 
monoxide 
diffusing 
capacity is 
affected by 
other factors 
than vascular 
reactivity, a 
transient effect 
was seen.  
Routledge 
et al 2006 
Randomiz
ed 
controlled 
trial 
(Routledg
e et al., 
2006). 
20 human 
volunteers 
with stable 
CAD and 20 
healthy 
patients. 
Sealed 
cylinder 
around 
volunteer's 
head.  
10-300 nm 
mode=20-
30 nm at 50 
µg/m3 for 1 
hour.  5 
exposed to 
air, 5 
exposed to 
CB, 5 
exposed to 
SO2, and 5 
to both 
pollutants 
for both 
groups. 
HRV and 
baroreflex 
sensitivity. 
Platelet count 
and 
aggregation. 
White cell 
count. CRP, 
fibrinogen 
and D-dimer. 
No change in cardiac vagal 
control, blood counts or 
systemic inflammatory 
response. 
Double 
blinded 
concentration
s used 
equivalent to 
1 hour 
exposure of 
high urban 
pollution. 
Mode of 
experimental 
UFP 
comparable 
to roadside 
mode of UFP 
Patients 
medicated 
throughout 
trial, including 
aspirin. Mixed 
population. 
Study powered 
to detect a 
marker of 
HRV, not 
ischaemic 
mechanisms. 
CRP was 
higher in the 
CAD group vs 
healthy group 
at baseline 
p<0.01. 
 
Low exposure 
concentrations 
used in small 
numbers of high 
risk medicated 
human subjects 
did not alter 
autonomic or 
coagulatory 
function.  
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Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Samet et 
al 2009 
RCT 
(Samet et 
al., 2009). 
19 healthy 
volunteers 
18-35 years 
old. 
Whole body 
exposure 
chamber. 
20 l/min 
ventilation 
of 1.2 x 
10^5 UFP 
particles/m3 
between 20 
and 250 nm 
over 2 
hours. 
Exposed to 
filtered UFP 
(n=10) and 
air 
(n=9).Tests 
conducted 
before, at 0 
and 18 
hours post 
exposure. 
Coagulation 
makers. 
Blood 
cholesterol 
and 
triglyceride. 
QT duration 
and variance, 
HRV. 
D-dimer levels increased 0 and 
18 hours post exposure. 
Triglycerides and VLDL reduced 
0 hours post exposure. Total 
cholesterol/HDL ratio increased 
at 18 hours. Mean QT duration 
reduced at 18 hours. QT 
variance increased 0 hours post 
exposure. Low and high 
frequency indices of HRV 
increased. 
Randomized, 
concealed 
experiment 
and 
participants 
unable to 
distinguish 
between 
exposures in 
preliminary 
tests.  
Short exposure 
time. Low risk 
group.  
Fibrin 
degradation 
increased post 
exposure, 
suggesting its 
increased 
production. 
Transient 
beneficial 
changes in 
lipids occurred. 
Heart rate 
control and 
repolarization 
affected by 
UFPs in a way 
which suggests 
vagal tone 
increased. 
Shah et al 
2008 
Randomiz
ed cross-
over trial 
(Shah et 
al., 2008). 
16 healthy 
human 
volunteers.  
Mouthpiece 
exposure 
system. 
Inhaled air 
or 50 μg/m3 
carbon UFP 
for 2 hr, 
with inter-
mittent 
exercising. 
(mean 
particle size 
25 nm) 
Measureme
nts at 0, 3.5 
hr, 21 hr, 
and 45 hrs. 
 
Peak forearm 
blood flow 
after 
ischemia. 
HR, BP. 
Nitrite and 
nitrate levels.  
UFP had no effect on pre-
ischaemia flow or resistance or 
post ischaemic total flow. Post 
ischaemia, peak forearm blood 
flow blunted by UFP. Mean 
blood pressure divided by 
forearm blood flow↓ with air, but 
not UFP. HR, BP─.HR x BP↑ in 
males, but not females. Venous 
nitrate levels↓, nitrite─. 
Double 
blinded. No 
infection 
history. 
Realistic 
particle 
concentration 
Mouthpiece 
alters 
breathing 
patterns.  
Small sample 
number.  
UFP reduces 
reactive 
hyperaemia 
peak flow in 
healthy non-
smokers. NO 
may not be 
important in 
reactive 
hyperaemia.  
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Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Stewart et 
al 2010 
Randomiz
ed cross-
over trial 
(Stewart 
et al., 
2010). 
19 non-
smokers 30-
60 years old 
with Type 2 
diabetes.  
Mouthpiece 
inhalation 
exposure. 
50 μg/m3 
CB UFPs of 
median size 
32 nm and 
filtered air 
for 2 hours. 
3 weeks 
between 
inhalations. 
Measureme
nts made 
3.5 hrs post 
exposure.  
Platelet 
expression of 
CD40L, 
CD62P and 
leukocyte 
expression of 
CD62P+. 
sCD40L, 
vWF CRP, 
IL-6 levels. 
Compared with control, CD40L↑ 
at 3.5 hours. CD40L showed 
significant UFP-time interaction. 
Platelet CD62P levels correlated 
with CD40L. Leukocytes 
expressed CD62P+. vWF 
expression─. sCD40L ↓. IL-6, 
CRP ─. All markers showed sex 
interaction and CD62P+, age 
interaction. Older males more at 
risk. There were no significant 
UFP effects on soluble C-
reactive protein, E-selectin, L-
selectin, CD62P, intercellular 
cell adhesion molecule (ICAM-
1), vascular cell adhesion 
molecule (VCAM-1), serum 
amyloid A (SAA), or the 
coagulation markers (D-dimer, 
Factors VII and IX). 
Single 
particle type, 
but 
concentration 
reflects real 
world daily 
exposures. 
Within 
subject 
controls. 
Double 
blinded. 
Diabetics 
restricted to 
narrow age 
range, no 
cardiovascular 
disease nor 
any lipid or 
platelet active 
drugs. Not 
representative 
of most 
diabetics.   
Short term 
exposure to CB 
for 2 hours 
transiently 
activates blood 
platelets, 
possibly 
leukocytes and 
vascular 
endothelium. 
Vinzents 
et al 2005 
Randomiz
ed cross-
over trial 
(Vinzents 
et al., 
2005).  
10 healthy 
males and 5 
females. 25 
years of age.  
Cycling 
through rush 
hour traffic on 
pre-defined 
routes. Other 
indoor 
particulate 
matter 
exposures 
were 
recorded. 
UFP 
exposure 
recorded on 
5 days over 
4 months. 
mean 
cycling time 
93 mins per 
day during 
rush hours. 
Day 6-
similar 
exercise in 
laboratory. 
Oxidative 
DNA damage 
in 
mononuclear 
cells.   
Regression co-efficient of a 
mixed effect model of level of 
DNA damage with subjects as 
random factor were estimated 
as 0.37 x10-3 to 1.77 x 10-3 for 
indoor exposure, and 1.50 x 10-3 
to 2.42 x 10-3 for outdoor 
exposure. R2=50.3. 
Portable 
measuring 
device 
validated 
against 
stationary 
device. Study 
method 
validated in 
inter-
laboratory 
trials. 
Physiological 
exposure. 
Low risk 
participants 
undergoing 
strenuous 
exercise, not 
reflecting the at 
risk population. 
Oxidative stress 
markers are 
raised in 
mononuclear 
cells post 
exposure to 
UFP. 
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Author 
and study 
type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Weichent
hal et al 
2011 
Randomiz
ed cross-
over trial 
(Weichent
hal et al., 
2011). 
42 healthy 
adults. 
Ambient 
particulate 
exposure.  
Cycled on 
high and low 
traffic routes. 
>100 nm 
ambient 
UFP, high 
traffic route, 
low traffic 
route. 
LF, HF, 
LF:HF ratio, 
SDNN, 
rMSSD, 
pNN50 
HF↓ with UFP at 2 and 4 hours. 
PNN50↓ at 2 hours. No other 
changes. 
Personal 
exposure. 
Realistic 
exposure. 
5 day between 
trial cross-over 
periods. Other 
controlled trials 
show >5 day 
effects after 
UFP exposure. 
Few positive 
findings with 
multiple 
comparison 
testing. 
Decreased 
parasympatheti
c modulation of 
the heart occurs 
post UFP 
exposure. 
Zareba et 
al 2009 
Randomiz
ed cross-
over trial 
(Zareba et 
al., 2009). 
24 healthy 
18-40yrs 
subjects. 
Mouthpiece 
inhalation 
exposure. 
25 nm CB 
exposure. 
Period 1. 
10 μg/m3 
UFP or air. 
Period 2.  
10 μg/m3, 
25 μg/m3 or 
filtered air. 
Exercise 
took place 
with each 
exposure.  
HRV=RR, 
SDNN, 
rMSSD, Low 
and high and 
low/high 
frequency. 
Repolarizatio
n= Qtc, T-
wave 
amplitude, 
PCA, ST 
level.  
SDNN↑ Low and high and 
low/high frequency↑ rMSSD no 
change. Qtc↓ T=wave 
amplitude↑ 
Exercise 
increased 
ventilation to 
standardized 
rate.  
Young, healthy 
subjects. Both 
very low doses 
used.  
Mild increase in 
para-
sympathetic 
tone at lower 
but not higher 
dose.  
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Table 3.b.Controlled animal experiments Inhalation of nanoparticles. The table is ordered alphabetically. All positive outcomes are reported positive at a p=0.05 
significance level regardless of the included study’s definition of significance. Where subject age or gender is reported by the study it is included in column two and the 
age at the start of the study is used.  Where animals have been randomized to groups, this is included in column 7 under study strengths, and the trial is referred to as 
a controlled trial. Subject numbers reported in this table are taken from the subject numbers used only for included experiments. Definitions: ↑= increase, ↓= decrease,  
─ =no change, hrs= hours, expts=experiments, mins= minutes.  
Author, 
study type 
Subject 
type 
Exposure 
technique 
Exposure type Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Amatullah 
et al 2012 
Controlled 
trial 
(Amatullah 
et al., 
2012). 
14 Female 
BALB/c 
mice 6-8 
weeks old. 
Nasal 
exposure  
Ambient UFP 
av. 401µg/m3 
of <200nm 4hr 
exposure or 
air at 2L/min. 
Heart rate. 
SDNN. 
Heart rate↓ less than 
control post exposure. 
SDNN↓ 
Ambient 
roadside 
UFP 
concentrate
d. Nasal 
inhalation 
limits 
dermal 
effects of 
particles, 
which can 
occur at 
high 
concentrati
ons. 
HR for coarse 
and fine UFP 
groups dropped 
significantly 
from baseline, 
indicating a 
systematic 
cardiovascular 
change by use 
of exposure 
chambers.  
Heart rate variability 
decreases with ambient 
UFP exposure compared 
to air. Heart rate might 
increase.  
Araujo et al 
2008 
Controlled 
trial(Araujo 
et al., 
2008).  
51 ApoE-/- 
male mice. 
4 weeks old 
on normal 
diet. 
Ambient 
UFP 
inhalation 
300m 
from a 
freeway. 
 17 mice 
exposed to air, 
17 to UFP 
matter and 17 
to PM2.5. 1-
180nm at 2-6 
x ambient 
levels of UFP. 
75 hours over 
40 days of 
exposure. 
Tests 
conducted 1-2 
days later. 
 
 
Atherosclerotic 
change. HDL 
protectiveness 
via monocytic 
infiltration. 
Oxidative 
stress was 
assessed. 
UFP exposure resulted in a 
55% increase in 
atherosclerotic lesion than 
control and 25% against 
PM2.5. UFP increased 
plaque monocytic 
infiltration compared to 
control. MDA, Nrf2, 
catalase, GST-Ya, NQO-1, 
SOD2 and ATF4 gene 
mRNA all increased over 
control. 
Large study 
population 
with a long 
exposure 
time. All 
animals 
accounted 
for. 
Exposure 
represented 
real 
particulate 
matter. 
 Controls 
exposed to 
ambient PM 
when being 
transported 
each day. 
Particle 
concentration 
was 2-6 x higher 
than normal 
exposure. Did 
not measure 
UFP in 
circulation. 
 
 
Atherosclerotic 
advancement is caused by 
UFP exposure. Anti-
inflammatory HDL is 
reduced and anti-oxidant 
mRNA expression is 
increased. 
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Author and 
study type 
Subject 
type 
Exposure 
technique 
Exposure type Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Cassee et 
al 2012 
Controlled 
trial 
(Cassee et 
al., 2012). 
11 week old 
20 male 
and 20 
female 
ApoE-/- 
mice  
Nasal 
exposure  
 DE control 
group, and DE 
exposure 
group, a DCeE 
control group 
and a DCeE 
exposure 
group.1741µg/
kg DCeE. 
1740µg/kg for 
DE. Both had 
a mean size of 
82.5nm. 
Exposure of 5 
days/week for 
28 days. (n=10 
per group) 
Atherosclerotic 
change. Pro-
inflammatory 
cytokines. 
Haematologica
l cell changes. 
More adjoining plaques 
occurred at high DE 
compared to control. DCeE 
reduced total particulate 
number by 30%. No 
significant changes in 
atherosclerosis were seen 
compared to control.  No 
difference in response to 3 
day and 17 day murine 
examinations. Hepatic pro-
inflammatory cytokines 
were reduced with DCeE 
exposure compared to DE 
alone. No haematological 
cell changes occurred. 
Realistic 
diesel 
exposure 
concentrati
on over a 
long study 
period. 
Tightly 
controlled 
exposure 
concentrati
ons. Nasal 
inhalation 
limits 
dermal 
translocatio
n of 
particles. 
Exhaust 
exposure was 
regulated by 
exhaust mass, 
so the engine 
running 
conditions 
changed 
throughout the 
experiment. See 
Li 2010 for an 
example of the 
effect.  
Atherosclerosis was 
markedly different 
between DE and control. 
DCeE reduced the size 
and number of 
atherosclerotic lesions 
compared to DE but not 
significantly. Cerium 
reduces both particle 
number and surface area 
by agglomeration. 
Cuevas et 
al 2010 
controlled 
trial(Cueva
s, 2010). 
Male 
C57bl/6 
mice 12 
weeks old. 
Whole 
body 
exposure 
chamber. 
40nm nickel. 
5hr/day for 1,3 
or 5 days to 
100,150 or 
900μg/m3. 
Test 
conducted 24 
hours later.  
Vasoconstrictio
n 
(phenylepherin
e). Ach 
dependent 
vasorelaxation. 
In the carotid artery, Ach 
dependent vasorelaxation 
was impaired and 
phenylepherine dependent 
constriction was 
accentuated. 
designed to 
represent 
occupation
al 
exposures 
No assessment 
of NO 
dependent 
mechanisms. 
vasorelaxation is blunted. 
Vasoconstriction is 
accentuated.  
Elder et al 
2004 
Controlled 
trial(Elder 
et al., 
2004a). 
Male F344 
rats 21 
months old.  
Controlled 
exposure 
to ambient 
exposure  
6hr/day over 1 
or 3 days. 37-
106 μg/m3. 
Tests 
conducted 
18hrs post 
exposure. 
Filtered air 
control 
ICAM-1 on 
blood cells. 
Blood 
fibrinogen. 
Blood 
endothelin-2. 
Only results for UFP vs. 
control. No increase in 
ICAM-1. Fibrinogen 
increased. Endothelin-2 
increased.  
Physiologic
al exposure 
to real-
world 
concentrati
ons for a 
long 
duration.  
Artificial 
temperature in 
an otherwise 
real-life 
environment. 
Vasodilatation and 
coagulability are impaired 
in compromised rats 
exposed to ambient UFP.  
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Study 
weaknesses 
Conclusion 
Elder et al 
2004 
controlled 
trial (Elder 
et al., 
2004b). 
MaleF344 
rats 23 
months old 
and 
spontaneou
sly 
hypertensiv
e rats 11-14 
months old. 
Whole 
body 
exposure 
chamber. 
36nm CB at 
150μg/m3 for 
6 hours was 
the exposure. 
Exposure 
groups. 1) 
Intraperitoneal 
(IP) injected 
saline 
+inhaled air. 2) 
IP injected 
saline 
+inhaled 
particles. 3)  
IP injected 
bacterial 
lipopolysaccha
ride (LPS) 
+inhaled air. 4) 
IP injected 
LPS +inhaled 
particles. 
Tests 
conducted at 
24 hours. 
Oxidative 
stress (DCF). 
Acute phase 
response and 
coagulability. 
Only results for UFP vs 
control (protocol 2). PMN 
oxidative stress increased 
in old F-344 rats only. 
Fibrinogen increased in F3-
44 rats. Thrombin-
antithrombin (TAT) 
complexes reduced. 
Fibrinogen decreased in 
SH rats. TAT complexes 
increased. No change in 
cell number, viscosity, IL-6. 
High 
number of 
subjects 
used. 
Infection/infl
ammation 
simulated 
with LPS. 
Vulnerable 
old rats 
reflect at 
risk human 
groups. 
No 
measurements 
at 0-24 hours 
post exposure. 
CB nanoparticles can 
enhance inflammatory 
effects and alter 
coagulation protein levels  
Gilmour et 
al 2004 
Controlled 
trial 
(Gilmour et 
al., 2004). 
12 week old 
male Wister 
rats. 
Whole 
body 
exposure 
chamber. 
Rats exposed 
to 114nm or 
268nm CB or 
air for 7 hours 
at 1mgm3. 
Assessment 
made at 0, 16 
and 48 hours 
post exposure.  
BAL cell and 
mRNA. Blood 
coagulation 
and leukocyte 
levels. 
Oxidative 
stress (DCFH) 
Leukocytes increased by 
130% at 0hrs and 135% at 
48 hours p<0.05, no 
change at 16hrs. No 
change in Factor VII, 
fibrinogen or vWF. No 
systemic oxidative stress 
imparted. 
Well 
characteriz
ed particles 
by chemical 
make-up, 
charge and 
density. 
Inhalation 
used as 
delivery 
method. 
UFPs 
agglomerated 
reducing surface 
area and 
transfer across 
the alveolar 
barrier. Short 
exposure time.  
Baseline 
recordings not 
reported.  
 
CB exposure causes show 
a leukocyte increase in 
vivo.  
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Exposure 
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Study 
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Harder et 
al 2005 
Controlled 
trial 
(Harder et 
al., 2005). 
Male Wister 
rats 12-15 
weeks old. 
Whole 
body 
exposure 
chamber. 
38nm CB 
180μg/m3 6 
mice as 
control, 6 in 
exposure 
group. 24hr 
exposure to 
CB. Tests 
conducted at 
24 hours. 
Mean blood 
pressure. 
Plasma 
fibrinogen. 
Coagulation 
markers.  
Fibrinogen blood─.  Factor 
7a ─. Mean blood pressure 
(BP)─. Heart rate↑. No 
cardiac inflammation or 
cardiomyopathy.  Blood 
coagulation and clot lysis 
factors─. 
Immediate 
analysis 
after a long 
exposure. 
Useful 
particle 
type. 
Expriment 
reflects 
real-world 
exposure 
concentrati
on. 
Small subject 
numbers. 
Blood coagulability is not 
altered with CB exposure. 
The autonomic system 
affected post NP 
exposure..  
Khandoga 
et al 2010 
Controlled 
trial 
(Khandoga 
et al., 
2010). 
Female 
C57B1/6 
mice 5-7 
weeks old.  
Whole 
body 
exposure 
chamber. 
CB 440μg/m3 
48nm mean.  
24 hour 
exposure or 
filtered air. 
Sacrificed 2 or 
8 hr post 
exposure. 
Systemic 
measures at 2 
hours into 
exposure. 
Platelet 
adherence and 
platelet 
accumulation 
in arterioles 
and venules. 
Sinusoidal 
damage. 
Fibrinogen. 
Cytokines. 
Blood cell 
number. 
Platelet 
activation. In 
vitro platelet 
activation by 
CB 
 
 
 
 
 
 
 
 
Platelet adherence and 
platelet accumulation in 
sinusoids in arterioles and 
venules. No platelet rolling. 
No leukocyte adherence. 
No sinusoidal damage. 
Fibrinogen deposited in 
liver and heart. No cytokine 
change. No increase in 
blood cell number. Platelet 
size and platelet 
component distribution 
width increased +markers 
of platelet activation. 
CD62P expression 
increased in vitro.   
Physiologic 
exposure 
type. Many 
aspects of 
thrombogen
esis 
measured. 
Attempted 
to mimic 
earlier intra-
arterial 
exposure 
with same 
amount 
particles 
potentially 
trans 
locating 
from lung to 
circulation  
High exposure 
concentration 
used.  
Inhaled nano-sized CB 
enhances thrombogenesis 
in healthy murine 
microcirculation. This may 
not be associated with an 
inflammatory reaction. 
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Knuckles 
et al 2012 
Controlled 
trial 
(Knuckles 
et al., 
2012).  
Sprague-
Dawley rats 
7-9 weeks 
old. 
Whole 
body 
exposure 
chamber. 
138nm TiO2 
particles at 
5.7mg/m3 for 
4 hrs over 1 
day. Tests 
conducted at 
24 hrs.  
Hyperaemia. 
Arteriole 
responsivenes
s to 
sympathetic 
stimulation 
post 
phentolamine 
and L-NMMA 
treatment. 
Thromboxane 
and 
prostacyclin 
mimetics.  
Phentolamine 
blockade.  
Nanoparticle exposure ↓ 
vasodilation with NOS and 
COX inhibitors. L-NMMA 
and Phentolamine ↑ 
sensitivity to α-adrenergic 
blockade. Thromboxane 
led to ↑ constriction and 
prostacyclin to ↓ dilation 
with nanoparticle exposure. 
Exposure caused 
persistent blunting of 
dilation when sympathetic 
effect removed. 
Agglomerati
on effect 
restricted 
by use of 
Venturi 
vacuum 
pump.  
Multiple 
baseline 
imbalances.  
Nano TiO2 exposure 
decreased NO influence 
on sympathetic arteriolar 
constriction, arteriolar 
response to metabolic 
stimuli and sensitivity to 
COX products. α-
adrenergic receptor 
sensitivity increased.  
LeBlanc et 
al 2009 
Controlled 
trial(LeBlan
c et al., 
2009). 
Sprague-
Dawley rats 
10-12 
weeks old. 
Whole 
body 
exposure 
chamber.  
TiO2 100nm. 
240 min at 6 
mg/m3 or 
filtered air for 
same time. 
Ex-vivo 
Coronary 
resistance 
vessels used 
for 
experiments 
post exposure.  
Myogenic 
responsivenes
s (arteriolar 
diameter at 
different 
internal 
pressures). 
Vasodilation to 
shear stress. 
Ach, Ca2+and 
SNP (NO) 
dependent 
vasodilation.  
 
 
 
 
 
 
No difference in myogenic 
responsiveness. Shear 
stress ─ . Both groups 
showed similar flow/shear 
stress relationships. Shear 
stress individually; TiO2 
relaxed less (slight 
constriction) vs. control and 
relaxed less per flow rate. 
Ach, Ca2+ dependent 
vasodilation ↓ with TiO2. 
NO donation─. 
Previously 
validated 
method. 
Multiple 
comparison 
statistical 
adjustment 
made. 
Vessels isolated 
from hormonal 
and nervous 
input. Very high 
exposure dose 
used. 
TiO2 exposure causes 
coronary arterioles to 
demonstrate increased 
tone, and reduced 
vasoreactivity to shear 
stress, ACh, and Ca2+. 
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Study 
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Conclusion 
LeBlanc et 
al 2010 
controlled 
trial 
(LeBlanc et 
al., 2010). 
83 
Sprague-
Dawley 
rats. 10-12 
weeks old.  
Whole 
body 
exposure 
chamber.  
100nm TiO2 at 
6mg/m3. n=33 
control. N=50 
nanoparticle.  
Ex-vivo 
Coronary 
resistance 
vessels used 
for 
experiments 
post exposure.  
Ach 
vasorelaxation.  
Indomethacin 
(prostaglandin) 
and L-NMMA 
vasorelaxation. 
Arachidonic 
acid 
metabolism. 
Thromboxane 
A2. Oxidative 
stress 
(ethidium 
bromide 
fluorescence). 
ACH vasorelaxation 
impaired with TiO2, 
restored with ROS 
scavenging. Indomethacin 
and L-NMMA response 
blunted with UFP. 
Arachidonic acid caused 
vasoconstriction in 
exposed group vs. dilation 
in control. Thromboxane no 
effect.  Increased oxidative 
stress in arteriole wall.   
Validated 
exposure 
concentrati
on. 
Occupation
al 
relevance.  
Vessels isolated 
from hormonal 
and nervous 
input.  
Coronary arterioles- ACH 
relaxation dependent on 
PG and NO. TiO2 drives 
vasoconstrictor production 
of arachidonic acid. 
Response to thromboxane 
unaltered. Oxidative stress 
increased.  
Liberda et 
al 2010 
Controlled 
trial 
(Liberda et 
al., 2010). 
C57BL/6 
mice 10-12 
weeks old 
Whole 
body 
exposure.  
Nickel 10hr/2 
days 
1237μg/m3.  
15hr/3 days 
725μg/m3, 
25hrs/5day at 
86 μg/m3. 
VEGF and 
human stromal 
cell-derived 
factor (SDF1-
α). Bone 
marrow EPC 
numbers. Tube 
formation and 
chemotaxis. 
Function impaired no 
change in VEGF and SDF-
1α.  Bone marrow EPC ↓. 
Tube formation and 
chemotaxis↓ 
Physiologic 
exposure 
mechanism
. 
1/2 day gap 
between 
exposure ending 
and sacrifice.  
Blood cells important for 
endothelial repair are 
reduced in numbers in the 
bone marrow, suggesting 
vascular recruitment.  
Niwa et al 
2008 
Controlled 
trial (Niwa 
et al., 
2008). 
Sprauge-
Dawley 
rats. 6 
weeks old. 
Whole 
body 
exposure 
chamber. 
120nm CB at 
15.6mg/3 for 6 
hours/day, 5 
days/week for 
4 weeks. 
Randomised 
to carbon 
black (n=25) 
or filtered air 
(n=25)Tests 
conducted at 
1- 30 days 
MCP-1, IL-
6,CRP, 8-
OHdG, blood 
cell number, 
heart rate, 
systolic blood 
pressure, CB 
presence in 
tissues. 
MCP-1, IL-6, CRP all ↑ in 
CB group at 28 days. No 
other biochemical changes. 
Heart rate↑ at day 14 and 
SBP at days 14 and 28. No 
CB found in liver, spleen or 
aortic tissue. 
Randomizat
ion of mice 
to groups. 
Physiologic
al exposure 
of long 
duration  
Very high 
exposure dose. 
No liver injury was seen. 
Inflammatory markers, 
heart rate and blood 
pressure rose after a very 
high CB exposure. 
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Nurkiewicz 
et al 2008 
Controlled 
trial(Nurkie
wicz et al., 
2008). 
Male 
Sprauge-
Dawley 
rats. 6-7 
weeks old. 
Whole 
body 
exposure 
chamber. 
One group 
exposed to 
TiO2 at 
100nm, 
depositing 
between 3.7-
37.6 μg/rat. 
Another group 
to 710nm, 
depositing 
between 8.26-
89.80µg/rat. 
One control 
group. 
Experiments 
conducted 24 
hrs later. 
Endothelium 
dependent 
arteriolar 
dilation  (Ca2+ 
dependent 
endothelial NO 
formation) 
Systemic arteriolar dilation 
impaired 24 hours post 
exposure at doses 10, 19 
and 38μg. Vasoactivity 
impairment dependent on 
time-concentration product 
of nanoparticle exposure.  
Several 
steps taken 
to avoid 
agglomerati
on. Multiple 
arterioles 
sampled 
per rat 
better 
represents 
within 
arteriole 
heterogenei
ty and 
increases 
sample 
size..   
Age difference 
existed between 
the ultrafine 
TiO2 group and 
all other groups 
p<0.05. No 
randomisation 
reported.  
Ultrafine particles have a 
greater blunting effect on 
vasodilation, even causing 
vasoconstriction. The 
effect is dependent on 
alteration of the 
concentration-time product 
of exposure, not its 
individual parts.  
Nurkiewicz 
et al 2009 
Controlled 
trial 
(Nurkiewic
z et al., 
2009). 
Male 
sprague-
Dawley 
rats. 
Whole 
body 
exposure 
chamber. 
100nm TiO2 at 
1.5–16 mg/m3 
for 4-12 hours 
to produce 5 
doses. 67µg 
PM2.5 group, 
20µg nano-
TiO2 and 
control group.  
Nitric oxide 
levels and 
oxidative 
stress 
measurements 
(ethidium 
bromide 
fluorescence). 
Nitrotyrosine 
staining. Nitric 
oxide 
production. 
Radical 
scavenging 
Sodium nitroprusside had 
equal effect on arteriolar 
dilatation in all exposures. 
Ca2+ ionophore limited 
arteriole dilation to 23% vs. 
original diameter. Ethidium 
bromide fluorescence 0.09 
AU greater vs. control. 
Nitrotyrosine expression 
2200µm2/section greater 
vs. control. 
Nitrotyrosine/vWF 
expression 8x higher vs. 
control. Nitric oxide 
production reduced at 4 
and 6µg. Nitric oxide 
production and Ca2+ 
ionophore dependent 
vasodilation increased 4x 
by radical scavenger. 
Externally 
validated 
method. 
Dosing 
equivalent 
to high 
doses 
reported in 
industry 
exposure. 
Validated 
use of time-
concentrati
on product 
for dosing. 
Demonstrat
ed NO 
uncoupling 
dependent 
on ROS. 
UV stimulation 
of particles in 
practice was not 
reflected in a 
sealed chamber. 
Background 
electrical noise 
affected NO 
probes. 
Inhalation of TiO2 
nanoparticles attenuated 
endothelium-dependent 
arteriolar dilation but 
vascular smooth muscle 
sensitivity NO unaffected. 
Oxidative/ nitrosative 
stress was caused. NO 
production reduced. Both 
effects involve radical 
production.  
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Srinivas et 
al 2011 
Controlled 
trial(Sriniva
s et al., 
2011). 
72 healthy 
Wister rats, 
8 weeks 
old. 
Nasal 
inhalation 
36 (equal 
Male/female 
ratio) control 
rats. 36 (equal 
Male/female 
ratio) exposed 
to CeO2 
(55nm mean) 
at 641mg/m3. 
4 hour 
exposure. 
Tests 
conducted at 
24, 48 hours 
and 14 days. 
Liver function. 
Cholesterol. IL-
1β, TNF- α and 
IL-6.  
Liver function─. 
Cholesterol↑ in female rats 
at 14 days. IL-1β, TNF- α, 
IL-6↑ max 24hrs, high for 
14 days.  
Large study 
population 
with a long 
exposure 
time. Long 
follow-up 
time. Nasal 
inhalation 
limits 
dermal 
effects of 
particles, 
which can 
occur at 
high 
concentrati
ons. 
Few outcomes 
of relevance in 
this study. Very 
high exposure 
concentration. 
Systemic inflammation is 
imparted by inhalation of 
cerium oxide nanoparticles  
Upadhyay 
et al 2008 
Controlled 
trial(Upadh
yay et al., 
2008). 
Spontaneou
sly 
hypertensiv
e rats. 6-8 
months old. 
Whole 
body 
exposure 
chamber. 
8 rats exposed 
to a CB of 
31nm at 
172µg/m3 for 
24 hours. 8 
were controls. 
Assessment 
was made 1-5 
days later.  
Blood pressure 
and heart rate. 
Cardiac 
histopathology. 
Acute phase 
response. 
Haematologica
l change. RAS 
involvement.  
Blood pressure ↑ by 
6mmHg vs. control, 
returning to baseline 4 
days post exposure. Heart 
rate ↑ 17bpm 1 day post 
exposure, and returned to 
baseline by day 4. No 
histological change in the 
heart. No CRP, 
haptoglobin or fibrinogen. 
Neutrophil and leukocyte 
blood concentrations ↑ 1 
day post exposure. No 
significant change occurred 
in renin-angiotensin system 
measurements.  
Measured 
mediators 
of 
hypertensio
n changes 
(Renin-
angiotensin 
system) 
changes. 
Useful 
surrogate 
for ambient 
UFP.  
Within animal 
control for 
cardio 
physiologic 
analysis. 
Nano-sized CB raises 
blood pressure and heart 
rate after inhalation 
without any acute phase 
changes.  
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Table 4. Human longitudinal studies. The tables are ordered alphabetically. All positive outcomes are reported positive at a p=0.05 significance level regardless 
of the included study’s definition of significance. Where subject age or gender is reported by the study it is included in column two and the age at the start of the 
study is used. Definitions: ↑= increase, ↓= decrease, ─ = no change,  hrs= hours,  mins= minutes.  
 
Author, 
study type 
Subject type Exposure 
technique 
Exposure 
type 
Outcomes Results Study strengths Study 
weaknesses 
Conclusion 
Delfino et 
al 2009. 
Longitudin
al cohort 
(Delfino et 
al., 2009). 
64 human 
population 
subjects. 
Non-
smokers, 
previous 
CAD, >65 
years of 
age.  
6 weeks 
exposure in 
warm 
weather, 
and 6 in 
colder 
weather.   
≤250nm 
sized 
particles at 
10.27 µg/m3 
in warm, 
µg/m3 in 
cold season. 
1,3 and 5 
day lags 
measured. 
IL-6, TNF-α, 
sTNF-receptor 
2, CRP, sP-
selectin. 
Erythrocyte 
antioxidant 
enzymes, 
glutathione 
peroxidase-1 
and copper-
zinc SOD.  
IL-6 and sTNF-receptor 2 
were correlated with 
ultrafine particles. sP-
selectin was not. The two 
antioxidant enzymes were 
inversely associated with 
ultrafine particles on days 1 
and 3. Statins were 
associated with a reduced 
sTNF-receptor 2 effect and 
clopidogrel with reduced 
sP-selectin.  
Reported 
measures at 
subject level. 
Physiological and 
real time 
exposure. 
Removed data 
associated with 
reported illness.  
Observational 
data does not 
allow 
individual air 
components to 
be attributed 
to disease. 
Confounding 
and bias risk.  
Subjective 
reporting of 
home data. 
Quasi-ultrafine 
particles are 
associated with 
increased systemic 
inflammation, 
platelet activation 
and a reduction in 
antioxidant 
enzymes activity. 
protective effect of 
clopidogrel and 
statin were noted. 
Delfino et 
al 2011. 
Longitudin
al cohort 
(Delfino et 
al., 2011). 
66 human 
population 
subjects. 
Non-
smokers, 
previous 
CAD, >65 
years old.  
6 weeks 
exposure in 
warm 
weather, 
and 6 in 
colder 
weather.   
≤250nm 
sized 
particles 
(quasi 
ultrafine) at 
9.77 µg/m3 
average over 
whole trial 
period.  
Association of 
≥1mm ST 
depression 
with quasi-
ultrafine 
particles. 
Relative rate of ST-
segment depression was 
positive over 2-day 
averages particulate matter 
1.57, and for 1-day 
averages, Relative rate = 
1.17. 
Comprehensive 
exclusion of all 
who could have 
demonstrated 
spurious ST 
changes.  
28/66 dropped 
out. 
Confounding 
risk of 
observational 
data. 
Subjective 
reporting of 
home data. 
 
Quasi ultrafine 
particles are 
associated with ST 
depression. 
Delfino et 
al 2010. 
Longitudin
al cohort 
(Delfino et 
al., 2010). 
Human 
population. 
Non-
smokers, 
Previous 
CAD, >60 
years of 
age.  
6 weeks 
exposure in 
warm 
weather, 
and 6 in 
colder 
weather.   
≤250nm 
sized 
particles 
(quasi 
ultrafine) at 
9.51 µg/m3 
in warm, 
8.65 µg/m3 
in cold 
season. 
Association of 
IL-6, TNF-α 
with quasi-
ultrafine 
particles. 
Polycyclic aromatic 
hydrocarbons and hopane 
parts of ultrafine PM 
associated with both 
biomarkers. 
Within subject 
control. A priori 
adjustment for 
infection.  
PAH could 
correlate with 
an 
unmeasured 
species.  
In observational 
data, inflammatory 
markers correlate 
with polycyclic 
aromatic 
hydrocarbon and 
hopane levels of 
quasi-ultrafine 
particles.  
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Folino et al 
2009 
Longitudin
al cohort 
(Folino et 
al., 2009).  
39post-MI 
patients of 
mean age 
60 years. 
Ambient 
exposure  
Three 24hr 
assessments 
in spring- 
winter. 
≤250nm 
NPs. 
SDNN average 
NN, RMSSD, 
pH, LTB4, 
endothelial 
NO, PTX3, 
CRP, CC16, 
IL-8 
SDNN and SDANN 
negatively correlated with 
PM0.25. RMSSD no change. 
No significant results for 
patients on β-blockade. 
Only PTX3 showed a 
negative correlation,  CRP, 
CC16, IL-8 no change 
Personal 
exposure and 
Holter device 
monitors. 
Medication use 
adjusted for. 
Β-blocker use. 
Short lag time.  
P0.25 correlates 
with HRV changes. 
No convincing 
inflammatory 
response was 
seen.  
Rich et al 
2012 
Longitudin
al cohort 
(Rich et al., 
2012). 
76 non-
smokers 
with 
previous MI 
but without 
other sever 
cardiac 
disease. 
Ambient 
exposure 
 Particle 
categories; 
10–100 
nm(UFP),  
100–
500nm(AMP)  
and  ≤ 2.5 
μm (PM2.5). 
 rMSSD, 
SDNN , TpTe 
Mean normal-
normal beat 
time, QTc, 
HRT, 
deceleration 
capacity, blood 
pressures, 
CRP, white 
blood cell 
count. 
 IQR increases in AMP in 
previous 6 and 24 hr 
reduced rMSSD, TpTe; 
fibrinogen; HRT in the 
previous 24-47 hours. 
Each IQR increase in UFP 
24–47 hr  decreased 
SDNN and rMSSD and 
increased fibrinogen. 
Diastolic blood pressure 
associated with each IQR 
increase in UFP, AMP, and 
PM2.5 at almost all lags. 
TpTe, HRT, and fibrinogen 
changes associated with 
UFP or PM2.5 reduced 
when controlling for AMP, 
except for HRT, which was 
larger. CRP, fibrinogen, 
systolic bp, Mean normal-
normal beat time, QTc, 
blood cell count had no 
associations 
Patients were not 
limited in drug 
regimens or 
relevant co-
morbidities. 
PM monitoring 
sites 
potentially up 
to 21km from 
patients 
homes.  
Subclinical 
modulation of 
autonomic balance 
occurs with 
exposure to UFP 
and AMP. Systemic 
inflammation does 
not.  
Rückerl et 
al 2007 
Longitudin
al cohort 
(Rückerl et 
al., 2007). 
57 >50 
years olds 
with Current 
CHD. 
6 months 
exposure. 
Bi-monthly 
measurem
ents. 
10-100nm 
(UFP) and 
100-1000nm 
(AP).  
Plasma 
sCD40L. Blood 
cell count 
sCD40L ↑, and leukocytes 
dropped at 0 days for UFP 
and AP. Platelet counts ↓ 
with UFP at 0 days, 3days 
and 5 day average.  
Validated 
method. Low 
attrition rate.  
Confounding 
by other 
inflammatory 
causes.  
Platelet activation 
and reduction in 
number occurred 
rapidly. leukocyte 
numbers reduced.  
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Author and 
study type 
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technique 
Exposure 
type 
Outcomes Results Study strengths Study 
weaknesses 
Conclusion 
Timonen et 
al 2006 
longitudinal 
cohort 
(Timonen 
et al., 
2006). 
131 elderly 
subjects with 
CAD 
Ambient 
exposure. 
<100nm 
ambient 
particles. 6 
month follow 
up. 17,000 
particles/cm3 
in two 
centres, and 
21,000 in the 
third. 
SDNN, HF, 
LF/HF 
Results for overall pooled 
effect only. SDNN, HF─. 
LF/HF↓ as particle count 
rose and 1,2,3 day lag and 
5 day average.  
Large, high risk 
population.  
Diagnosis self-
reported by 
patient. Lag 
time of 0-5 
days only.  
At a 2 day lag, for 
every 10,000 
particle/cm3 
increase there was 
a  13.5% drop in 
LF/HF ratio.  
Wu et al 
2012 
Longitudin
al cohort 
(Wu et al., 
2012). 
17 postmen 
on delivery 
routes with 
no CAD, 
travelling by 
motorcycle. 
Ambient 
particulate 
exposure.  
5-6 days 
ambient 
exposure to 
PM0.25. HRV 
measuremen
ts made 
during 
exposure, 
and cardio-
ankle 
vascular 
index, after.  
Cardio-ankle 
vascular index 
(arterial 
stiffness 
index). LF, HF, 
LF:HF ratio, 
SDNN, 
rMSSD. 
No significant changes fpr 
PM0.25 throughout. 
Manganese↑ cardio-ankle 
vascular index. Calcium 
↓rMSSD. Nickel, zinc and 
chromium↓ LF:HF ratio. 
Personal 
exposure and 
ambient city 
levels measured. 
Realistic particle 
exposure. 
Few outcomes 
from multiple 
comparison 
testing. No lag 
effects 
measured.  
Some PM0.25 
components 
increase arterial 
stiffness, and alter 
cardiac autonomic 
function.  
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Table 5.a. Controlled animal experiment (instillation of suspended nanoparticles). The table is alphabetically. All positive outcomes are reported positive at a 
p=0.05 significance level regardless of the included study’s definition of significance. Where subject age or gender is reported by the study it is included in column two 
and the age at the start of the study is used.  Where animals have been randomized to groups, this is included in column 7 under study strengths, and the trial is 
referred to as a controlled trial.  Subject numbers reported in this table are taken from the subject numbers used only for included experiments. Definitions: ↑= 
increase, ↓= decrease,  ─ no change,  hrs= hours, expts= experiments,  mins= minutes.  
Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Bourdon 
et al 2012 
Controlled 
trial 
(Bourdon 
et al., 
2012). 
Female 
C57B1/6 
mice 5-6 
weeks old. 
Intra-
tracheal 
instillation. 
Single dose 
of 0, 0.018, 
0.054 and 
0.162mg 14 
nm CB. 
Tests 
conducted 
at 1, 3 and 
28 days 
post 
exposure. 
n=6 per 
group. 
Hepatic 
inflammatory 
and acute 
phase gene 
expression. 
Lipid profile.  
Saa3 experienced a 4 fold 
increased; Orm3, a 2 fold 
increase; Saa1, a 1.5 fold 
increase at 1 day. CRP 
gene raised 1 fold at 28 
days. HMG-CoA reductase 
genes all increased 
approximately 2 fold at day 
1, and 2/9 genes at 28 
days. Serum amyloid A 
rose at 1 and 28 days, 
HDL at 3 and 28, LDL at 
28 days.  
Equivalent to 
human 
exposure in 
working 
environment. 
Non 
physiological 
exposure. 
Agglomeration 
not prevented. 
Broncho-
alveolar 
lavage (BAL) 
fluid could 
form protein 
corona around 
nanoparticles, 
limiting 
surface 
exposure. 
Acute phase genes, and 
HMG-CoA reductase genes, 
including the rate limiting step 
gene, Hmgcr, were up-
regulated. The acute phase 
pathway activates the HMG-
CoA reductase pathway. 
Chang et 
al 2007 
Controlled 
trial 
(Chang et 
al., 2007). 
60 
spontaneou
sly 
hypertensiv
e rats. 11 
weeks old.  
Intra-
tracheal 
instillation. 
14 nm CB at 
415 
μg/animal 
and 830 
μg/animal. 
Low dose 
group (n=4) 
High dose 
group (n=4). 
Measures 
made for 2 
weeks 10 
days post 
instillation. 
 
 
Normal-to-
normal 
intervals 
(NN), natural 
logarithm 
transformatio
n of SDNN 
and RMSSD.  
Low and high dose ↓ ANN 
and  ↑ LnSDNN. 
Particles 
sonicated for 
30 minutes 
pre-instillation. 
No 
measurement
s made for 
HRV between 
1-10 days 
post 
exposure. 
CB alters HRV similarly at 
high and low doses. 
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Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Cho et al 
2009 
Controlled 
trial (Cho 
et al., 
2009). 
Female 
CD-1 mice 
and hearts 
isolated 
from CD-1 
female 
mice.  197 
mice for 
blood/tissu
e 
experiment
s, 40 mice 
for cardiac 
injury 
experiment.  
Oropharyn
geal 
instillation 
and bolus 
injection 
into heart 
model. 
Ambient 
UFP 
≤100nm 
exposure 
near road 
and far from 
road.  
Administere
d as 25 or 
100μg bolus 
for 
biomarker 
tests, and 
100µg for 
cardiac 
injury 
experiment. 
Biomarkers 
tested at 4 
and 18hrs. 
Cardiac 
injury tested 
at 18hrs. 
Cell numbers, 
platelets, 
haematocrit, 
CRP, LDH, 
liver function 
markers. 
Coronary flow 
Left 
ventricular 
end diastolic 
pressure, 
ventricular 
contraction. 
Cardiac- 
ischaemia-
reperfusion 
injury.  
Cell numbers, platelets, 
haematocrit, CRP, LDH, 
liver function markers ─. 
Coronary flow↓ (near road 
only) left ventricular 
diastolic pressure and 
ventricular contraction─. 
Myocardial infarction size 
greater after UFP infusion 
and left ventricular diastolic 
pressure slower to recover 
(far road group only).  
Ambient PM 
collected over 
2 weeks, for 
reasonable 
representation 
of 'average' 
exposure.  
Nanoparticles 
sonicated and 
centrifuged for 
30 minutes.  
Non 
physiological 
exposure 
method.  Cell 
isolated from 
in vivo cellular 
and hormonal 
effects.  
Ambient exposure worsens 
cardiac injury after an 
ischaemic event.  
Courtois 
et al 2008 
Controlled 
trial 
(Courtois 
et al., 
2008). 
Adult male 
Wister rats 
12-14 
weeks old.  
Intra-
tracheal 
instillation 
5mg of TiO2 
13, 15 and 
21 nm. 
PM2.5 
comparator 
and control. 
Tests 
conducted 
at 12 hours 
Nitric oxide 
response 
Nitric oxide dependent 
vasodilation not affected 
by Ti02. PM2.5 did impair 
responsiveness.  
Similar sized 
particles (I.e., 
not large range 
of particle sizes 
around mean 
diameter) 
strengthen the 
conclusion of 
specific 
nanoparticle 
effects.  
 
Particle 
agglomeration 
not 
determined. 
Ti02 does not alter nitric 
oxide dependent 
vasoreactivity. Possibly due 
to low reactivity, not size. 
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Author 
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type 
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type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Cui et al 
2010 
Controlled 
trial (Cui 
et al., 
2010). 
80 ICR 
mice 
exposed to 
TiO2. Age 
not 
reported. 
Intra-
gastric 
administrat
ion 
Control 
group and 5, 
10, 50 
mg/kg 7nm 
TiO2 NPs 
administere
d every 
48hrs for 60 
days. Tests 
conducted 
at 60 days. 
Lipid 
peroxidation, 
ROS, mRNA 
expression 
SOD, CAT, 
GSH-Px, MT, 
HSP70, 
CYPA1, P53, 
GST and TF.  
MDA↑, NO↑, H2O2↑, O2-↑, all anti-oxidant 
genes↓. All detoxification genes↓ except 
CYPA1↑. 
 
Nanoparticles 
were sonicated 
for 15-20 
minutes and 
vibrated for 2-3 
prior to 
instillation. 
Exposure type 
not wholly 
relevant. 
Assumes 
nanoparticles 
cross the 
alveolar 
barrier in great 
amounts.  
On exposure to TiO2, the 
liver suffered ROS damage 
and cell membrane 
peroxidation, Particles 
impaired antioxidant and 
defence mechanisms.  
Cui et al 
2012 
Controlled 
trial (Cui 
et al., 
2012). 
40 ICR 
female 
mice. Age 
not 
reported. 
Intra-
gastric 
administrat
ion 
Control 
group 
(n=20) and 
TiO2 10 
mg/kg 
(n=20). 90 
days of 
exposure. 
Experiments 
conducted 
at 90 days.  
NP 
deposition. 
Histopatholog
y. 
Lymphocytes, 
neutrophils 
and white 
blood cell 
number. ALT, 
AST, ALP, 
LDH, total 
cholesterol 
and 
triglycerides. 
Genetic 
regulation. 
NP deposited in liver. 
Inflammatory cell 
infiltration, vein congestion, 
nuclear vacancy and 
oedema and apoptosis 
observed in hepatic tissue. 
Lymphocytes, neutrophils 
and white blood cell 
number↓. ALT, AST, ALP, 
LDH, total cholesterol and 
triglycerides↑. Apoptosis, 
oxidative stress, 
inflammation, response to 
stress, metabolism and 
other genes up/down-
regulated.  
 
 
 
 
 
 
 
Randomized to 
groups. 
Genetic 
changes with 
Illumina 
BeadChip 
confirmed with 
RT-PCR 
False positive 
findings for 
the 1142 
genes. Very 
high dose 
used. None of 
the genetic 
markers 
followed up to 
detect protein 
changes. 
Histopathology suggests an 
inflammatory response. Liver 
function is impaired and 
genetic changes signal a 
stress response. 
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Study 
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Conclusion 
Folkmann 
et al 2012 
Controlled 
trial 
(Folkmann 
et al., 
2012). 
72 obese 
and 72 lean 
female 
Zucker rats 
(metabolic 
syndrome) 
Gastrointe
stinal 
exposure 
1)32 lean, 
32 obese 
rats 
exposed to 
single dose 
0, 0.064, 
0.064 or 
6.4mg/kg 
CB. Tests 
conducted 
at 24hrs. 
2)24 
obese,24 
lean rats 
exposed to 
weekly 
doses for 
ten weeks at 
0, 0.064 or 
0.64mg/kg 
CB. Tests 
conducted 
at 24 hrs.  3) 
16 lean, 16 
obese rats 
exposed to 
0 or 
0.64mg/kg 
CB, weekly 
for 10 
weeks. 
Tests 
conducted 
at 13 weeks. 
CB mode 
size 86nm 
Endothelium 
dependent 
(acetylcholine
), 
endothelium 
independent 
(nitric oxide), 
voltage 
dependent 
calcium 
channel 
(felodopine) 
vaso-
relaxation. 
Receptor 
dependent 
vasoconstricti
on 
(phenylepheri
ne). mRNA 
expression in 
aortic tissue.   
Protocols 1 and 3 showed 
no change. 2) CB 0.064 
mg/kg doubled EC50, 
0.064 mg/kg quadrupled 
EC50 vs. control p<0.05 
for both obese and lean. 
Emax also lower p<0.05. 
No nitric oxide, felodipine 
or phenylepherine related 
changes occurred. 1)  
Nos2, CP-1, chrm-3, Nos3 
genes-no change. Hmox1 
increased at all doses in 
obese vs. lean p<0.05. 2) 
Hmox-1 no change. 3) 
Increased Hmox-1 in 
obese vs. lean p<0.05. 
Ocln increased in all 
obese, reduced in all lean 
at 0.064 and 0.06mg/kg 
p<0.05.  
Subjects 
randomized. 
Highly 
susceptible 
animal model. 
Particles 
sonicated. 
Buffered 
washouts of 
neurotransmitt
ers before tests 
on aorta 
segments. 
Non-
physiological 
delivery of 
nanoparticles.  
Very high 
exposure 
doses. 
Repeated exposure to CB 
nanoparticles caused 
endothelium dependent vaso-
relaxation to be impaired in 
lean rats and further 
impairment in obese rats. 
This effect was not apparent 
13 weeks later. Single doses 
had no effect. No 
inflammatory genes up-
regulated. 
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Study 
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Conclusion 
Furuyama 
et al 2009 
Controlled 
trial 
(Furuyam
a et al., 
2009).  
Male 
BALB/c 
mice. 6 
weeks old. 
Intra-
tracheal 
instillation. 
50μg 20nm, 
200nm gold 
and 
fluorescein-
labelled 
carboxy- 
polystyrene 
particles. 
Both 
negatively 
charged.  
Particle 
deposition in 
organs (of 
relevance to 
this review) 
20 and 200nm gold 
particles deposited in heart 
and liver. Polystyrene 
20nm particles detected in 
the liver, on vascular 
endothelium and on 
ventricular endothelium 
where the 20nm particles 
associated with small 
thrombi.  
Particles 
shown to 
directly interact 
with thrombi, 
regardless of 
possible distant 
effect from lung 
inflammation.  
No sonication 
of particles, 
but serum 
used to limit 
aggregation.  
Nanoparticles deposit in extra 
pulmonary organs after 
crossing the alveolar barrier 
and may cause thrombi 
formation.  
Gilmour et 
al 2007 
Controlled 
trial 
(Gilmour 
et al., 
2007).  
BALB/c 
female 
mice 8-
10weeks 
old. 
Oropharyn
geal 
aspiration 
50µl saline 
containing 
50 or 100µg 
UFP from 
four 
locations. 
Tests 
conducted 
18hrs post 
instillation. 
Creatine 
kinase and 
other 
haematologic
al 
measurement
s. 
No change. Wide variety of 
PM used. 
Non-
physiological 
exposure, 
where 
particles may 
not have 
reached the 
lung. Very 
large range of 
results 
between mice 
suggesting 
inconsistent 
dosing. 
 
 
 
 
 
 
 
 
 
 
Ambient UFP may not be 
toxic when instilled 
oropharyngeally. 
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Hwang et 
al 2010 
Controlled 
trial 
(Hwang et 
al., 2010).  
20 C57BL/6 
mice 3 
weeks of 
age. 
Intra-
tracheal 
instillation 
Exposure to 
TiO2 
<100nm 
(n=10) at 
20mg/kg/ml 
(0.5mg/mou
se) and 
saline 
control 
(n=10). 
Instillations 
were 2 x 
week, for 12 
weeks.  
Oxidative 
damage in 
peripheral 
mononuclear 
cells. 
Oxidative damage in 
peripheral mononuclear 
cells↑. 
 Relevant 
material to 
industrial 
exposures. 
Particles 
autoclaved 
prior to 
exposure.  
Mouse 
matches 
human 
autonomic 
balance better 
than other 
strains. 
Not well 
defined in 
particle size. 
Not sonicated.  
Few useful 
outcomes. 
Oxidative stress raised post 
exposure to UFP in 
mononuclear cells. 
Jia et al 
2012 
Controlled 
trial (Jia et 
al., 2012). 
Male 
C57BL/6 
mice 10-11 
weeks old.  
Intra-
tracheal 
instillation 
CB 19nm at 
0.05, 0.15 
and 0.6 
mg/kg 3x 
over 6 days. 
Cage 
control 
vehicle 
control and 
3 exposure 
groups. 
N=10/ 
group. Tests 
conducted 
24hrs post 
exposure. 
MDA in heart 
muscle, 
cardiac 
troponin I, 
CRP and 
white blood 
cell count in 
plasma. 
SDDN, 
rMSSD, low 
and high 
frequency 
domain and 
their ratio (LF, 
HF). 
 
 
 
 
 
 
MDA─, cardiac troponin I 
↑. CRP and white blood 
cell count ─. SDNN and 
rMSSD↓ for 0.15, 
0.6mg/kg. LF─, HF↓ for 
0.6mg/kg. LF/HF ratio ─. 
20 min 
sonication 
time. 
Assessors 
blinded. Mouse 
matches 
human 
autonomic 
balance better 
than other 
strains. 
No 
measurement
s made at 0-
24 hours post 
exposure.  
Cardiac parasympathetic 
function is impaired without 
cardiac injury in response to 
ultrafine CB. 
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Jun et al 
2011 
Controlled 
trial(Jun et 
al., 2011). 
Platelets 
extracted 
from 
human 
blood in 
healthy 
male 
donors and 
male 
Sprague-
Dawley 
rats. 
In vitro 
incubation. 
IV bolus 
and intra-
tracheal 
instillation 
Silver 10-
100nm at 
doses 
0,10,100,20
0 and 
250µg/ml for 
aggregation 
experiment. 
In vivo IV 
dose 0, 
0.05, 0.1 
mg/kg. Intra-
tracheal 
instillation 0-
250µg/ml.  
Platelet 
aggregation. 
Phospholipid 
(phosphotadyl
serine) 
expression. 
Thrombin 
generation. 
Calcium (flow 
cytometry) 
and serotonin 
release, 
CD62P 
expression. In 
vivo thrombus 
formation 
(weight). Ex 
vivo platelet 
aggregation, 
phospholipid 
expression.  
IN VITRO platelet 
aggregation ↑ in dose 
dependent manner from 
50µg/ml and was markedly 
increased with sub-
threshold/minute doses of 
thrombin to almost 100% 
at 250µg/ml. Phospholipid 
exposure ↑ in a dose 
dependent manner from 
200µg/ml, reaching almost 
100% expression at 
250µg/ml. Thrombin 
generation↑ at 250µg/ml 
and in a dose dependent 
manner from 200µg/ml 
with thrombin incubation. 
Calcium release ↑ 
(250µg/ml), enhanced with 
thrombin and aggregation 
effect blunted by use of 
calcium chelator. Serotonin 
release ↑ at 250µg/ml and 
enhanced with thrombin. 
CD62P↑ at 100, 250 µg/ml 
and enhanced with 
thrombin. IN VIVO 
thrombus formation↑ at 
0.1mg/kg. EX VIVO 
platelet aggregation ↑from 
50µg/ml and 100µg/ml with 
thrombin in dose 
dependent manner. 
Phospholipid expression↑ 
at 250µg/ml with and 
without thrombin. 
Sonication and 
vigorous 
vortexing of 
nanoparticles 
pre-exposure. 
Spurious 
nanoparticle 
effect on 
platelet 
aggregation 
avoided by cell 
counting. Very 
comprehensive 
investigation of 
coagulability in 
several 
models.  
Non-
physiological 
exposure 
methods. In 
the in vitro 
experiment 
the cells were 
isolated from 
in vivo cellular 
and hormonal 
effects.  
Platelet aggregation and 
coagulability is enhanced by 
silver nanoparticles. A hyper 
coagulable state might pre 
dispose to enhanced 
negative effects.  
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Inoue et al 
2006 
Controlled 
trial(Inoue 
et al., 
2006). 
33 ICR 
mice 6 
weeks old 
Intra-
tracheal 
instillation 
14 and 
56nm at 
4mg/kg.  
LPS 
at2.5mg/kg 
via 
intratracheal 
instillation.  
29-33 mice 
divided into 
1) control 
group 
2)2.5mg/kg 
LPS 3,4) 
4mg/kg 
carbon 
black 
nanoparticle
s 14 and 
56nm. 5,6) 
the 
nanoparticle 
groups with 
LPS 
.Assessmen
ts made 24 
hours later. 
 
 
 
 
 
 
 
 
 
 
Activated 
protein C, 
prothrombin 
time, 
Activated 
Partial 
Thromboplast
in Time and 
fibrinogen 
LPS +14nm particle 
increased fibrinogen levels 
compared to LPS alone. 
P<0.01. No other results 
were significant for 
nanoparticles.  
Strain of mice 
highly 
responsive to 
LPS possibly 
accentuating 
LPS and 
nanoparticle 
effect above 
significance 
24 hour delay 
between 
exposure and 
assessment 
may miss 
transient 
changes as 
observed in 
other included 
trials. 
14nm particles are more toxic 
than 56nm. LPS accentuates 
the prothrombotic effect of 
14nm nanoparticles. PS does 
not adhere to nanoparticles 
(unpublished data) 
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Kim et al 
2012 
Controlled 
trial (Kim 
et al., 
2012). 
Male 
Sprauge-
Dawley 
rats, 5 
weeks old. 
Intra-
tracheal 
instillation. 
40nm and 
202nm CB 
0, 1, 3, or 10 
mg/kg 
bolus. Tests 
conducted 
at 24hrs and 
1 week. 
Platelet 
Aggregation 
(platelet 
function 
analyzer-
100).  Plasma 
Coagulation 
(In vitro and 
In vivo). 
Blood cell 
count. IL-6 
snd TNF-α. 
Homocystein
e and 
cysteine. 
GSH. Heart 
rate and wave 
features. 
SDNN, 
RMSSD, LF, 
HF, LF/HF. 
Deposition of 
CB 
PFA-100 closure time↓ at 1 
week with 40nm only. 
Prothrombin time ─ and 
Activated Partial 
Thromboplastin Time↑ for 
both at 1 week at 3mg/kg 
in vivo, in vitro ─. Blood 
cell count─ IL-6 snd TNF-
α─. 202nm ↑ 
homocysteine at 3mg/kg at 
1 week only. Cysteine and 
GSH─. CB deposition in 
liver ─ 
In vitro testing 
of clotting time 
used to prove 
clotting time 
alterations 
concerned with 
impaired 
production, not 
function of 
clotting factors. 
Mild 
agglomeration 
seen. No 
measurement
s made 
between 
24hrs and 1 
week.  
CB of 40nm produces a 
hypercoagulable state. CB of 
202nm raises homocysteine 
and possibly atherosclerotic 
risk. Mild impairment of 
clotting factor production is 
seen probably due to 
impaired production.  
Li et al. 
2010 
Controlled 
trial (Li et 
al., 
2010c). 
Kunming 
mice 7 
weeks old.  
Intra-
tracheal 
instillation 
TiO2 3nm 
instilled 
once 
weekly, for 4 
weeks to 
accumulate 
13.3mg/kg. 
Tests 
conducted 
24hrs post 
exposure.  
 
 
Histopatholog
ical 
examination 
protein exudate in liver, 
liver cell necrosis, 
exudation blood cells in 
liver 
Sonicated 
particles prior 
to use. 
Possible 
contamination 
of TiO2 
sample by 
larger 
particles. 
In vivo, hepatic cells are 
stressed by 3nm TiO2 
exposure.  
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Mikkelsen 
et al 2011 
Controlled 
trial 
(Mikkelse
n et al., 
2011). 
42 ApoE-/- 
mice. 
Human 
umbilical 
vein 
endothelial 
cells.  
Intra-
tracheal 
instillation. 
4 groups of 
10-11 ApoE-
/- mice. 
Control. 
Fine TiO2, 
photocatalyti
c and nano 
TiO2 bolus 
doses at 
0.5mg/kg. 
Vasoreactivi
ty- All 4 
groups 
received 2 
doses 24 
hours apart. 
Assessment 
was at 26 
hours. 
Plaque 
progression- 
nanoparticle 
and control 
group 
received 
weekly 
doses for 4 
weeks. 
Tests 
conducted 
at 9 weeks. 
 
 
 
 
 
IN VIVO 
Endothelium 
dependent: 
(ACh, 
calcitonin-
gene related 
peptide) and 
independent 
(nitroglycerin 
and 
felodipine) 
vasoactivity. 
Plaque 
progression. 
IN VITRO 
HUVEC NO 
release on 
particle 
exposure. 
IN VIVO No vasoactive 
effect.  Nanoparticles 
increased plaque area. 
5.5% vs. 4.1% control. 
p=0.018. IN VITRO 
Moderate dose increased 
NO release in HUVEC for 
nanoTiO2. NOS inhibitor 
reduced this effect. 
Centrifuged for 
30 minutes.  
Per-protocol 
analysis. BAL 
fluid vehicle 
could cause 
protein corona 
on the 
nanoparticle 
surface 
Exposure to nanoparticles 
progresses atherosclerosis. 
There is no effect on 
vasodilation.  
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Mo et al 
2008 
Controlled 
trial (Mo et 
al., 2008). 
Male Wister 
rats 7-8 
weeks of 
age. 
Neutrophils 
from rats.   
In vitro and 
intra-
tracheal 
instillation.  
Nickel, 
cobalt and 
TiO2 at 
20nm 0-
10μg/ml in 
vitro 
experiments
. 12hr 
culture. Ex 
vivo used 
one dose of 
0.1, 0.5 or 
1mg in 1ml 
saline. 12 
hour 
exposure. 3 
days post 
exposure, 
neutrophils 
isolated and 
cultured for 
12, 24 and 
48 hrs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IN VITRO 
LDH, TNF-α, 
MIP-2 and 
NO release. 
EX VIVO 
TNF-α, MIP-2 
and NO 
release.  
IN VITRO LDH release at 
10µg/ml. Neutrophil TNF-
α, MIP-2 and NO ↑with 
nickel and coblt exposure, 
not TiO2. EX VIVO TNF-α, 
MIP-2 and NO ↑ with nickel 
and cobalt exposure. TiO2 
↑ TNF-α .  
Particles 
centrifuged for 
30 minutes 
prior to use. Ex 
vivo 
experiments 
used alongside 
in vitro 
exposures, to 
describe 
biological 
plausibility and 
real effect.  
Non 
physiological 
exposure 
type. 
Confirmation 
of in vitro 
results in vivo 
might have 
been more 
useful than 
isolated 
neutrophils. 
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Exposure to 3 different 
nanoparticles types caused 
neutrophil release of TNF-α, 
MIP-2 and NO. TiO2 was 
less potent.  
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Subject 
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Study 
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Conclusion 
Mo et al 
2009 
Controlled 
trial (Mo et 
al., 2009b) 
C57BL/6J 
and 
gp91phox 
knock-out 
mice. 
Pulmonary 
vascular 
endothelial 
cells from 
male 
C57BL/6J 
and 
gp91phox 
KO mice.  
In vitro 
incubation 
and intra-
tracheal 
instillation.  
Ambient 
UFP 
<160nm at 
0, 10, 20, 
50, 100 
μg/ml for 12 
hours in 
ROS study. 
And 
200μg/ml for 
12-72hrs for 
cytotoxicity 
studies. 
IN VITRO 
Cytotoxicity, 
ROS 
generation 
(DCF 
florescence). 
P67phox 
knockout 
(essential 
regulatory 
component of 
NADPH 
oxidase).  
gp91phox 
knock out to 
confirm. 
p47phox, 
67phox and 
Rac 1 
translocation. 
p38 and 
ERK1/2 
MAPK 
activation. IL-
6 expression. 
IN VIVO ROS 
generation. 
IN VITRO In wild type 
murine cells, cytotoxicity 
occurred at 100 and 
200μg/ml. DCF 
florescence from 10µg/ml ↑ 
dose response with UFP. 
Inhibited with catalase, DPI 
and NAC. P67 KO 
ameliorated UFP effect. 
Effect confirmed with 
gp91phox knock out cells 
and confirmed in vivo. IL-6 
gene ↑ and dependent on 
NADPH and P38 
(endothelial cell). 47phox, 
p67phox and Rac 1 were 
all translocated to the 
plasma membrane 
(endothelial cell). p38 and 
ERK1/2 MAPKs activated 
and NADPH dependent.  
IN VIVO ROS generation 
confirmed in vivo in 
C57BL/6J mice, and not 
gp91phox knockout mice, 
demonstrating NADPH 
dependence. Effect 
attenuated by NAC, CAT 
and DPI.  
 
 
 
 
 
 
 
Mediating 
biomarkers 
were 
demonstrated 
by inhibition 
studies. ROS 
demonstrated 
in both 
exposure 
types. Realistic 
particle 
exposure. 
Limited 
outcomes 
examined in 
vivo.  
 
UFP exposure caused 
endothelial cell ROS 
generation. NADPH oxidase 
produces this ROS.  MAP 
kinases activation due to 
oxidative stress up-regulates 
IL-6. 
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Nemmar 
et al 2002 
Controlled 
trial 
(Nemmar 
et al., 
2002). 
Male and 
female 
hamsters 
between 
100-110g.  
Intra-
tracheal 
instillation 
and intra-
venous 
injection. 
60nm un-
modified 
polystyrene 
nano-
particles at 
 50, 500, 
5000 µg/kg, 
amine 
modified 
polystyrene 
at 50, 100, 
500 µg/kg 
and carbo-
xylate 
modified 
nano-
particles  
at 5, 50 
500µg/kg. 
All groups 
had 4-5 
hamsters 
/exposure 
concen-
tration. For 
intra-
tracheal 
instillation, 6 
each were 
used / 
exposure 
concen-
tration. 
Assess-
ments made 
at 30 min 
and at 1 hr.  
Arterial and 
venous 
thrombus 
formation in 
ultraviolet 
light and free-
radical 
mediated 
endothelial 
injury. 
Intravenous instillation of 
unmodified particles ─ at 
any concentration. 
Carboxylate-modified 
particles inhibit thrombus 
formation at 100 and 500 
µg/kg. Amine-modified 
particles ↑ thrombus 
formation at 50 and 500 
µg/kg. Intra-tracheal 
instillation at 5mg/kg of 
amine modified particles ↑ 
thrombus formation 
compared to control. 
Particle 
induced 
thrombus 
histologically 
matched to 
control 
thrombus. 
Sonication and 
then Immediate 
vortexing of 
particles before 
instillation to 
prevent 
aggregation. 
Intra-tracheal 
instillation 
verified 
observations.  
Less 
physiologic 
approaches 
used. Not true 
pollutant 
particles used.  
Intravenous instillation of 
positively charged amine 
particles are prothrombotic at 
50 µg/kg. Negatively charged 
caboxylate particles inhibit 
thrombus formation and 
unmodified polystyrene 
particles have no effect. Intra-
tracheal instillation of 
positively charged particles 
causes a thrombotic effect. 
46 
 
Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study 
strengths 
Study 
weaknesses 
Conclusion 
Nemmar 
et al 2003  
Controlled 
trial(Nem
mar et al., 
2003).  
Male and 
female 
hamsters 
between 
100-110g.  
Intra-
tracheal 
instillation.  
60nm 
unmodiﬁed, 
amine, or 
carboxylate
d 400-nm 
amine-
modiﬁed 
polystyrene 
particles. All 
at 500 
μg/animal, 
except 
60nm 
amine, at 5, 
50 and 500 
μg/animal. 
Measureme
nts made at 
1 hour.  
Thrombus 
measured by 
ultraviolet 
light and free-
radical 
mediated 
endothelial 
injury 
technique. 
Lung micro-
circulation 
histology. 
Closure time 
in the Platelet 
Function 
Analyser 
(PFA). 
Aminated particle↑ 
thrombus size in dose 
response. Larger amine 
particle did not. In 
circulatory thrombi, platelet 
marker G28E5 ↑in lung. 60 
and 400nm aminated 
particles shortened PFA 
closure time.  
Prior sonication 
used to de-
aggregate 
particles. 
Non-
physiological 
exposure 
type. 
Polystyrene 
nanoparticles 
are not found 
in ambient 
UFP. 
Aminated particles enhance 
peripheral thrombosis in rats.  
Nemmar 
et al 2004 
Controlled 
trial(Nem
mar et al., 
2004b). 
Male and 
female 
hamsters 
between 
100-110g.  
Intra-
tracheal 
instillation 
500µg per 
animal of 
400nm 
aminated 
polystyrene 
particles. 24 
hours post 
exposure.  
Venous 
thrombus 
formation in 
ultraviolet 
light and free-
radical 
mediated 
endothelial 
injury. Plasma 
histamine and 
plasma vWF.  
Thrombus size ↑ with 
400nm particles compared 
to control. Plasma 
histamine ↑ from 
21.6nmol/l to 37.6nmol/l in 
400nm particles compared 
to control and no 
difference in plasma vWF.  
Lysis of blood 
cells 
demonstrated 
lower 
histamine 
levels after in 
vivo exposure 
to 
nanoparticles, 
proving the 
histamine is 
released from 
blood cells, not 
pulmonary 
inflammation.  
Large 
nanoparticles. 
No steps 
taken to 
observe them 
within 
circulation. 
Effect may not 
be 
nanoparticle 
mediated. 
(Conhaim et al 
suggests only 
2% of lung 
pores are 
400nm in 
size). 
 400nm particles promote 
thrombus formation and 
histamine release from 
basophils. As no vWF was 
detected, thrombosis may not 
depend on endothelial 
activation. 
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Niwa et al 
2007 
Controlled 
trial (Niwa 
et al., 
2007). 
Male 
LDLR/KO 
mice. 6 
weeks old.   
Intra-
tracheal 
dispersion. 
CB as 10mg 
over 10 
weeks with 
a particle 
size of 
121nm,  
(n=10) with 
half of these 
on a high 
cholesterol 
diet. 
Exposure to 
air (n=10), 
half on a 
high 
cholesterol 
diet. A 
group were 
exposed to 
CB after 3 
days of high 
cholesterol 
diet. 
Histological 
analysis of 
the aorta. 
Microscopic 
analysis of 
aorta liver, 
kidney and 
spleen. Lipid 
levels. CRP. 
Group on high cholesterol 
diet and CB exposure had 
a higher percentage of 
atherosclerotic change and 
CRP levels compared to 
air and cholesterol diet 
group. CB not detected by 
microscopic analysis.  
Study time 
period and diet 
optimized to 
detect an 
effect. Mice 
randomized to 
each group. 
Exposure 
mice smaller 
at baseline vs. 
control group 
P values not 
available. 
Statistical 
adjustment 
not reported in 
multiple 
comparison 
tests. 
Infrequent 
exposures.  
Atherosclerosis is advanced 
by CB exposure. CRP levels 
are also increased.  
Park et al 
2009 
Controlled 
trial (Park 
et al., 
2009). 
ICR mice. 
Gender, 
age not 
reported. 
Intra-
tracheal 
instillation. 
21nm TiO2 
administere
d at 5, 20 
and 50 
mg/kg.  
(n=10-12/ 
group) Tests 
conducted 
at 1, 3, 7 
and 14 
days.  
 
Lymphocyte 
phenotypes, 
genetic 
expression, 
serum 
biochemistry 
and 
cytokines. 
Mortality. 
Lymphoctye phenotypes 
were not reported with 
confidence intervals or 
significance. 38 genes up-
regulated, some markers 
of inflammation.IL-1  IL-6, 
IL- 12 and TNF-α, IL- 3-5,  
IL-10,  IFN gamma, IL-2 
was increased. No rats 
died during exposure. 
Long period for 
assessments 
post exposure. 
No rat deaths 
despite high 
exposure 
levels. 
No 
randomization
. Non-
physiological 
exposure. 
Many particles 
were 
agglomerated 
at ~200nm.  
Inflammatory genes were up-
regulated after TiO2 
exposure.  
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Park et al 
2009 
Controlled 
trial (Park 
and Park, 
2009). 
ICR mice. 
Gender, 
age not 
reported. 
RAW 264.7 
murine 
macrophag
es. 
Intraperiton
eal 
exposure. 
12nm silica 
nanoparticle
s at 50, 100, 
and 
250mg/kg 
for 
splenocyte 
proliferation 
test. Other 
tests used a 
50mg/kg 
dose. Tests 
conducted 
at 12, 24, 48 
and 72 
hours post 
exposure.  
IN VIVO 
Splenocyte 
proliferation, 
lymphocyte 
distribution, Il-
1β, TNF-α, 
macrophage 
activation.  
NO 
production. IN 
VITRO ROS 
generation 
(DCF). GSH 
oxidation. NO 
production. 
Cytotoxicity. 
IN VIVO Splenocytes 
proliferated to 180% 
compared to the control 
group at 50mg/kg but 
viable cell numbers ↓ past 
100mg/kg.  NK and T-cells 
both ↑ but B-cell levels↓ 
compared to control. Both 
pro-inflammatory cytokines 
↑ at 12, 24, 28 and 72 
hours. Cytotoxic effect 
shown in activated 
macrophages at 24, 48 
and 72 hours. NO level ↑ 
above control at 24, 48 
and 72 hours. IN VITRO 
ROS ↑ in concentration 
dependent manner. GSH 
↓. NO ↑ in concentration 
dependent manner. 
Cytotoxicity ↑ in conc 
dependent manner. 
Sonicated 
nanoparticles 
to prevent 
aggregation.  
No 
randomisation
. Non 
physiological 
method of 
delivery. Silica 
may not all 
have been 
absorbed 
across the 
peritoneum.  
Splenocytes exhibit a dose 
dependent proliferation. The 
nanoparticles affected 
cellular immunity. Level of 
secondary messenger of 
inflammation (NO) increased. 
Levels of pro inflammatory 
cytokines were also 
increased  
Park et al 
2010 
Controlled 
Trial(Park 
et al., 
2010). 
Male and 
female ICR. 
6 weeks old 
Oral 
instillation. 
22, 42, 71, 
and 323 nm 
silver 
nanoparticle
s, 1 mg/kg 
for 14 days 
(5 mice per 
group), or, 
0.5 or 
1.0mg/kg for 
28 days (6 
mice per 
group). 
TGF-β. Nk B 
cell and 
CD8+ 
distribution.  
ALT, AST, 
ALP, protein, 
albumin, 
creatinine. IL-
1, TNF-α, and 
IL-6, Th1-type 
cytokines (IL-
12 and IFN-
γ), Th2-type 
cytokines (IL-
4, IL-5, IL-10).  
22-71nm particles ↑ TGF-β 
levels, NK +B cell and 
CD8+ T-cell numbers. 
ALT, ALP and AST↑. IL-1, 
4, 6, 10, 12 and IgE↑ TNF-
α, IL-5, IFN-γ─. 
Long exposure 
duration.  
No sonication 
of particles 
reported. 
Exposure type 
not wholly 
relevant to 
inhalation 
exposure.  
Repeated doses of silver 
nanoparticles induce 
cytotoxicity and inflammatory 
responses.  
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Sharma et 
al 2012 
Controlled 
trial 
(Sharma 
et al., 
2012). 
75 Swiss 
albino 
mice. 6 
weeks old.   
Oral 
instillation. 
30nm ZnO. 
Group 1- 
vehicle 
control. 2)  
ZnO 
nanoparticle
s at 
300mg/kg 
body weight. 
3) 50mg/kg. 
14 days 
exposure.  
ALT, ALP, 
bilirubin, 
blood urea 
nitrogen, 
creatinine 
levels. Lipid 
peroxidation. 
Necrosis and 
apoptosis. 
Oxidative 
stress (Fpg-
modiﬁed 
Comet 
assay). 
ALT and ALP↑.  Bilirubin, 
blood urea nitrogen, 
creatinine ─ for 300mg/kg 
vs. control. Lipid 
peroxidation↑ at 300mg/kg 
only. A 14 day exposure at 
300mg/kg showed liver cell 
necrosis and apoptosis. 
Oxidative stress in DNA 
increased in 300mg/kg 
group in AU, not 50mg/kg. 
(Comet assay).  
Nanoparticles 
sonicated for 
10 minutes 
prior to use.  
Non 
physiological 
exposure 
type. High 
doses 
administered.  
ZnO nanoparticles induced 
oxidative stress and 
apoptosis in liver cells.  
Silva et al 
2005 
Controlled 
trial (Silva 
et al., 
2005). 
7 male 
Fisher rats 
weighing 
250-300g. 
(Population 
number 
estimated 
from 
results)  
Intra-
tracheal 
and 
intravenou
s exposure 
of 
nanoparticl
es with a 
free-radical 
mediated 
endothelial 
injury (RB). 
Ultrafine 
aminated 
polystyrene 
particles at 
0.02, 0.5, 50 
mg/kg. 
60nm 
carboxy-
lated 
nanoparticle
s at 0.1 and 
50 mg/kg for 
one hour 
exposure.  
Thrombus 
formation 
after intra 
tracheal and 
intravenous 
instillation. 
Thrombus formation was 
achieved faster for 
aminated nanoparticles 
compared to carboxylated, 
which experienced no 
significant change. 
Aminated UFP at 0.02, 0.5 
and 50mg/kg were all 
significantly prothrombitic 
compared to vehicle alone. 
IV administered 
nanoparticles at 0.5mg/kg 
induced similar effects with 
Rose-Bengal dye to 
accentuate thrombosis, but 
longer illumination time 
needed.  
 
 
 
 
Each animal 
was its own 
control. Prior 
sonication and 
vortex of 
particles 
reduced 
aggregation. 
Demonstrated 
similar effects 
when particles 
were 
administered 
either side of 
the alveolar 
barrier. 
Polystyrene 
particles are a 
proxy for true 
pollutants. 
Small number 
of subjects.  
Positively charged 
polystyrene particles are 
prothrombotic whilst 
negatively charged particles 
are not. Large doses are not 
as prothrombotic, possibly 
due to agglomeration. 
Administering particles either 
side of the alveolar barrier 
causes similar thrombi.  
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Tong et al 
2010 
Controlled 
trial (Tong 
et al., 
2010).  
Female 
CD-1 mice 
12 mice for 
inflammator
y study, 10 
for cardiac 
perfusion.  
Oropharyn
geal 
instillation. 
Direct 
infusion 
into 
perfused 
heart 
circulation.  
100µg of 
<100nm 
UFP. 
Measureme
nts made 
24hrs post-
exposure.  
Plasma blood 
count and 
biochemistry. 
Haemodynam
ics, cardiac 
perfusion. 
Recovery of 
ischaemic 
heart and 
necrotic area. 
No change in blood cell 
count or biochemistry. HR 
and flow rate decreased. 
No other haemodynamic 
change. LVDP post 
ischaemia reduced with 
UFP. Infarct size 
increased.  
Infarct size 
measured, not 
just perfusion 
changes.  
Non-
physiological 
exposure. 
Cardiac 
perfusion 
measurement
s made at 24 
hrs, potentially 
missing 
changes 0-
24hrs. 
UFP exacerbated cardiac 
ischaemia and reperfusion 
injury.  
Vesterdal 
et al 2009 
Controlled 
trial(Veste
rdal et al., 
2009). 
ApoE-/- 
mice 11-13 
and 40-42 
weeks old. 
Intraperiton
eal 
exposure. 
Old and 
young 
female mice 
exposed to 
0.05 and 
0.5mg/kg 
0.7nm CB 
(n=9-11 per 
4 groups). 
Old male 
mice 
exposed to 
0.5mg/kg 
(n=5). 
Emax of 
endothelium 
dependent 
vaso-
relaxation. 
EC50 value of 
SNP induced 
vaso-
relaxation. 
Receptor 
dependent 
vasoconstricti
on (% 
increase) 
Emax values ↓ at both 
doses in young females 
58.7 and 60.0% versus 
70.8% control, and in old 
female mice at low dose 
37.8% compared to the 
control group (60.4%) . 
High dose females and 
males did not reach 
significance. EC50 value of 
old age mice ─. In young 
female mice a 16.5 nM 
EC50 value existed 
(Control 10.1 nM). The 
EC50 for mice treated with 
the lower dose─. No 
receptor dependent 
vasoconstriction tests 
reached significance. 
Pre-validated 
doses. 
Stratified by 
gender and 
age. 
Non-
physiological 
delivery of 
nanoparticles. 
Sonication 
was 
ineffective.  
Low subject 
number in 
male group. 
Pre-existing 
poor 
vasomotor 
function in 
male mice. 
Atheroscleroti
c plaque 
impairment of 
vasoactivity. 
 
 
Endothelium dependent and 
independent vasorelaxation 
is impaired by CB. Receptor 
mediated relaxation is not. 
Younger mice were affected 
more than older mice. 
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Vesterdal 
et al 2010 
Controlled 
trial 
(Vesterdal 
et al., 
2010). 
Female 
ApoE-/- 
mice. 
Young (13 
weeks) 
group and 
old 
group.(49 
weeks) . 
Intra-
tracheal 
instillation 
14nm CB 
particles at 
0.05, 0.5, 
0.9 and 2.7 
mg/kg for 
the young 
group. 
Assessment 
24 hours 
later. Group 
2 0, 
0.9mg/kg 
assessed 2 
hours post 
exposure. 
Old group at 
0 or 0.5 
mg/kg 
assessed 5 
weeks after 
a 2 weekly 
exposure.  
Endothelium 
in/dependent 
and receptor 
mediated 
vasoreactivity
. Plaque 
progression. 
Endothelial 
activation 
0.5mg/kg exhibited 
acetylcholine -dependent 
relaxation. Sodium 
nitroprusside ─. 0.05 and 
0.5 mg/kg of carbon black 
exhibited phenylepherine-
induced vasoconstriction 
24 hours later. Plaque size 
was similar for 
nanoparticles and control. 
Endothelial activation─.  
Well 
characterized 
particles, used 
in other 
outcomes. 
Lowest dose 
used reflected 
normal 
exposure to 
carbon black. 
Blinded 
experiment.  
BAL fluid 
vehicle could 
cause protein 
corona 
reacting with 
the 
nanoparticle 
surface. 
Nanoparticles 
polluted with 
PM2.5. 
Inflammation 
from an intra-
tracheal dose 
may increase 
permeability 
for second 
doses. 
Several mince 
died post 
exposure.  
Endothelial NO availability is 
reduced by carbon 
nanoparticles causing 
vasomotor impairment.  
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Table 5.b. Controlled animal experiments (Injection of nanoparticles into circulation). The table is ordered alphabetically. All positive outcomes are reported 
positive at a p=0.05 significance level regardless of the included study’s definition of significance. Where subject age or gender is reported by the study it is included in 
column two and the age at the start of the study is used.   Where animals have been randomized to groups, this is included in column 7 under study strengths, and the 
trial is referred to as a controlled trial.  Subject numbers reported in this table are taken from the subject numbers used only for included experiments. Definitions: ↑= 
increase, ↓= decrease,  ─ =no change, hrs= hours, expts= experiments, mins= minutes.  
Author and 
study type 
Subject 
type 
Exposure 
technique 
Exposure type Outcomes Results Study 
strengths 
Study weaknesses   Conclusion 
Bihari et al 
2010 
Controlled trial 
(Bihari et al., 
2010). 
C57BL 
mice. 
Whole 
blood 
from 
C57BL 
mice. Age 
not 
reported.  
Intravenous 
injection 
and in vitro 
incubation. 
TiO2 40nm at 1 
mg/kg. 60nm 
Amine- and 
carboxyl- 
polystyrene 
nanoparticles at 
0.5 mg/kg. 
Negative control. 
Positive control- 
epinephrine 12.5 
μM. Thrombosis 
experiments 
conducted 10 mins 
after infusion. 
Platelet 
CD26P 
expression. 
Platelet–
granulocyte 
complexes. 
Platelet-
platelet 
aggregation. 
Platelet, 
leukocyte and 
erythrocyte 
counts, 
haematocrit, 
haemoglobin 
concentration, 
mean 
corpuscular 
volume, mean 
corpuscular 
haemoglobin, 
and mean 
corpuscular 
haemoglobin 
concentration 
of 
erythrocytes. 
Mesenteric 
thrombosis 
formation. 
Microvascular 
thrombosis.  
IN VITRO Platelet 
CD26P and Platelet–
granulocyte complexes 
─ for TiO2 and 
carboxyl-particles, 
SWCNT and aminated 
particles↑.  Platelet-
platelet aggregation ─ 
for aminated particles.                                 
IN VIVO No differences 
in platelet, leukocyte 
and erythrocyte counts, 
haematocrit, 
haemoglobin 
concentration, mean 
corpuscular volume, 
mean corpuscular 
haemoglobin, and 
mean corpuscular 
haemoglobin 
concentration of 
erythrocytes. 
Mesenteric thrombus 
formation time↑ with 
carboxylated particles, 
↓ with aminated 
particles, TiO2. TiO2, 
polystyrene particles─ 
on thrombus cessation 
time.  
Positive 
control 
used for 
proof of 
experime
ntal 
feasibility. 
Wide 
range of 
particles 
used.  
Multiple 
arteries 
used in 
identical 
experime
ntal 
condition
s. 
It is assumed that 
nanoparticles can 
pass via the lung 
into the circulation 
in large quantities.  
Aminated particles 
increase platelet 
activity and enhance 
thrombus formation.  
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Cho et al 
2009 
Controlled 
trial(Cho 
et al., 
2009). 
Female 
CD-1 
mice. 
Hearts 
isolated 
from CD-
1 
mice.197 
for 
biomarker 
experime
nts, 40 
mice for 
cardiac 
injury.  
Oropharyn
geal 
instillation 
and bolus 
injection 
into heart 
model. 
Ambient UFP 
≤100nm near 
road and far 
from road.  
Administered as 
25 or 100μg 
bolus for 
biomarker tests, 
and 100µg for 
cardiac injury. 
Biomarkers 
tested at 4 and 
18hrs. Cardiac 
injury at 18hrs. 
Cell numbers, 
platelets, 
haematocrit, 
CRP, LDH, liver 
function 
markers. 
Coronary flow, 
Left ventricular 
end diastolic 
pressure, 
ventricular 
contraction. 
Cardiac- 
ischaemia-
reperfusion 
injury.  
Cell numbers, platelets, 
haematocrit, CRP, LDH, 
liver function markers ─. 
Coronary flow↓ (near 
road only) left ventricular 
diastolic pressure and 
ventricular contraction─. 
Myocardial infarction size 
greater after UFP 
infusion and left 
ventricular diastolic 
pressure slower to 
recover (far road group 
only).  
Ambient PM 
collected 
over 2 
weeks, for 
reasonable 
representati
on of 
'average' 
exposure.  
Nano-
particles 
sonicated 
and 
centrifuged 
for 30 
minutes.  
Non physiological 
exposure method.  Cell 
isolated from in vivo 
cellular and hormonal 
effects.  
Ambient exposure 
worsens cardiac 
injury after an 
ischaemic event.  
Downs et 
al 2012 
Controlled 
trial 
(Downs et 
al., 2012).  
Adult 
male 
Wister 
rats. Age 
not 
reported.  
IV 
injection. 
Gold 2, 20 and 
200nm at 6.00 × 
10^−5 1.12 × 
10^−4 1.41 × 
10^−3 g/ml 
respectfully. 
Silica 15, and 
55nm Quartz 
400nm at 
particle numbers 
1.75 × 10^17 
4.14 × 10^15 
1.68 × 10^12 
respectfully. 
DNA damage, 
Liver injury, 
peroxidation 
and oxidation. 
Inflammatory 
markers.  
Small DNA damage was 
made at 15nm 50mg/kg. 
15nm silica increase 
micro nucleated 
reticulocytes at 50mg/kg. 
55nm increased at 
125mg/kg. Liver 
peroxidation non-
significant. 8-oxoGua 
ELISA not raised. 
50mg/kg of 15nm silica 
doses raised IL-6 and 
TNF-α. Quartz also 
raised TNF-alpha at 
100mg/kg Gold was 
deposited in the liver, but 
did not reach any 
significant end points.  
 
Neutral gold 
used as a 
controlled 
exposure 
alongside 
vehicle. 
Wide array 
of 
observation
s 
determined 
for liver 
injury.  
92nm particles were 
intended as 2nm 
particles. Wide size 
range of silica 
nanoparticles. Low gold 
doses greatly limited the 
surface area available. 
Aminotransferases not 
measured.  Quartz 
control not well defined 
nanoparticles, not 
included in this data.  
Raised 
inflammatory 
markers and liver 
injury resulted from 
several silica sizes 
and concentration, 
possibly from a 
secondary effect 
rather than direct 
ROS production.   
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Hwang et 
al 2008 
Controlled 
trial(Hwan
g et al., 
2008).  
Spontane
ously 
hypertensi
ve rats 
and Wister 
rats. 13-14 
weeks old 
used for 
Langendor
ff isolated 
heart 
perfusion 
models. 
Perfusion 
of isolated 
heart  
Diesel exhaust 
UFP <100nm 
from12.5mg of 
diesel exhaust. 
Control used.  
(av.n=11 per 
group) UFP and 
control within 
each rat type.  
LVDP, dp/dimin, 
dp/dt max 
(ventricular 
contractility), 
Coronary flow. 
LVDP and Coronary flow 
decreased in WKY rats.  
LVDP, dp/dimin, dp/dt 
max, Coronary flow all 
reduced in SHR.  No 
significant difference 
between the two rats at 
any measurement. 
Age 
matched 
between rat 
types. 
Similar 
inhalation 
exposure to 
real-world 
human 
exposure.  
Heart isolated from 
hormones and nerves. 
Perfusion pressure low. 
Myocardial 
contraction 
impaired in SHR 
and WKY. 
Hypertension 
does not worsen 
the response to 
nanoparticle 
infusion. 
Jun et al 
2011 
Controlled 
trial (Jun 
et al., 
2011). 
Platelets 
extracted 
from 
human 
blood in 
healthy 
male 
donors 
and male 
Sprague-
Dawley 
rats. 
In vitro 
incubation
. IV bolus 
and intra-
tracheal 
instillation 
Silver 10-100nm 
at doses 0, 10, 
100, 200 and 
250µg/ml for 
aggregatory 
experiment. In 
vivo IV dose 0, 
0.05, 0.1 mg/kg. 
Intra-tracheal 
instillation 0-
250µg/ml.  
Platelet 
aggregation. 
Phospholipid 
(phosphotadylse
rine) 
expression. 
Thrombin 
generation. 
Calcium (flow 
cytometry) and 
serotonin 
release, CD62P 
expression. In 
vivo thrombus 
formation 
(weight). Ex vivo 
platelet 
aggregation, 
phospholipid 
expression.  
IN VIVO thrombus 
formation ↑at 0.1mg/kg. 
EX VIVO platelet 
aggregation ↑from 
50µg/ml and 100µg/ml 
with thrombin in dose 
dependent manner. 
Phospholipid 
expression↑ at 250µg/ml 
with and without 
thrombin. 
Sonication 
and 
vigorous 
vortexing of 
nanoparticle
s pre-
exposure. 
Spurious 
nanoparticle 
effect on 
platelet 
aggregation 
avoided by 
cell 
counting. 
Very 
comprehen
sive 
investigatio
n of 
coagulabilit
y in several 
models.  
Non-physiological 
exposure methods. In 
the in vitro experiment 
the cells were isolated 
from in vivo cellular and 
hormonal effects.  
Platelet 
aggregation and 
co-agulability is 
enhanced by 
silver 
nanoparticles. A 
hyper coagulable 
state might pre 
dispose to 
enhanced 
negative effects.  
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Khandoga 
et al 2004 
Controlled 
trial 
(Khandog
a, 2004). 
Female 
C57B1/6 
mice 5-7 
weeks old. 
CB 
suspensio
n 
administer
ed via 
polyethyle
ne 
catheter 
into left 
carotid 
artery as a 
bolus. 
14nm CB 
1x10^7 and 
5x10^7 
nanoparticl
es for 2 
hours.  n=6 
buffered 
control. 
n=6 high 
dose. n=6 
low dose. 
n=6 
GP2b3a 
blocker, 
(tirofiban). 
Tests 
conducted 
at 2 hours. 
Platelet-endothelial 
and leukocyte-
endothelial 
interactions. 
Endothelial 
activation. Sinusoidal 
perfusion, fibrinogen 
deposition. All in 
hepatic circulation. 
Adherent platelet 
numbers ↑ 3 fold in 
sinusoids and venules 
for both UFP groups. 
GP2b3a blockade 
inhibited this effect. 
No platelet rolling. 
Fibrin deposition in 
both coronary and 
hepatic vasculature, 
and vWF for hepatic 
vasculature. 
Leukocyte interactions 
and sinusoidal 
perfusion was not 
affected by UFPs. 
Infusion 
represents 
the same 
range of 
systemically 
absorbed 
particles with 
24hr 
exposure in 
a human  
Partial particle aggregation 
in the suspension was 
recorded. Experimental 
design assumes UFP 
passes the alveolar barrier 
in large concentrations.  
UFP causes 
platelet 
accumulation on 
the hepatic post 
arterial 
endothelium 
associated with 
fibrin and vWF 
deposition. Lack 
of p-selectin 
suggests no 
inflammatory 
character. 
Nishimori 
et al 2009 
Controlled 
trial 
(Nishimori 
et al., 
2009). 
BALB/c 
mice 
Intravenou
s injection. 
Silica 
76nm, 0.3 
and 1µg. 
70nm was 
delivered 
at 
25mg/ml, 
and then 
varying 
doses to 
measure 
dose 
response.  
Liver, spleen, kidney 
injury. ALT levels, 
inflammatory 
markers. 
Hepatocyte death, 
ALT ↑ when Kupfer 
cells inhibited. When 
sinusoidal membrane 
disrupted, ALT levels 
─. Hepatocytes 
histologically 
denatured and ↑ 
collagen deposition, 
hydroxyproline 
contents ↑. No other 
organ changes. ALT 
levels, IL-6, TNF-α ↑ 
at 20mg/ml. ALT ↑with 
chronic 
administration. 
Particles not 
aggregated 
upon 
injection. 
Non physiological 
exposure type. Injection 
with 70nm particles was 
often lethal. 
Sinusoidal cells 
may not act as a 
barrier against 
nanoparticles. 
Nanoparticles 
cause liver injury 
and continued 
administration 
causes fibrosis, 
possibly altering 
coagulation 
protein 
production.  
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Radomski 
et al 2005 
Controlled 
trial 
(Radomsk
i et al.). 
Platelets 
separated 
from blood 
from 
healthy 
human 
volunteers. 
Wistar–
Kyoto rats. 
Age not 
reported.  
In vitro 
incubation 
and IV 
injection. 
Mixed 
carbon 
nanoparticl
es, purified 
carbon 
fullerenes 
at 50µg/ml 
in vivo for 
thrombosis 
experiment
, 200µg/ml 
in vivo. 5-
500µg/ml 
in vitro.  
IN VITRO Platelet 
aggregation.  ATP 
release. 
Degranulation. 
GP2b3a expression. 
P-selectin 
expression Gp1b 
expression 
Aggregation 
inhibition by 
prostacyclin and S-
nitroso-
glutathione,(endogen
ous inhibitors of 
haemostasis) and 
aspirin (GP2b3a 
inhibitor. MMP-
9/MMP-2 ratio. PKC 
dependence. IN 
VIVO Platelet 
aggregation. 
IN VITRO Mixed 
carbon NPs ↑ platelet 
aggregation. Carbon 
fullerenes─. Mixed 
carbon NPs caused 
ATP release and 
platelet degranulation. 
Mixed carbon NPs 
↑GP2b3a expression. 
P-selectin↑ for mixed 
carbon NPs. GP1b↓ 
for mixed carbon NPs. 
Mixed carbon NPs ↓ 
aggregation with 
prostacyclin and S-
nitroso-glutathione, 
not with aspirin. MMP-
9/MMP-2 ratio↑ in 
carbon fullerenes 
only. PKC 
dependence─ for all 
particles. IN VIVO. 
Mixed carbon 
nanoparticles ↑ 
platelet aggregation at 
50µg/ml. Carbon 
fullerenes─. 
 
 
 
 
 
 
 
 
 
Nano-
particles 
sonicated for 
2 minutes. 
vortexed 
prior to 
testing. 
Investigated 
aggregation 
through 
several 
methods, 
and 
confirmed in 
vivo.  
Limited in vivo 
experiments. IV injection 
assumes that all particles 
pass the alveolar barrier.  
Carbon 
nanoparticles and 
materials activate 
platelet and 
enhance vascular 
thrombosis, but 
might do through 
different 
mechanisms.  
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Silva et al 
2005 
Controlled 
trial (Silva et 
al., 2005). 
7 male 
Fisher rats 
weighing 
250-300g. 
(Population 
number 
estimated 
from results)  
Intra-
tracheal 
and 
intravenous 
exposure 
of 
nanoparticl
es with a 
free-radical 
mediated 
endothelial 
injury (RB). 
Aminated 
polystyrene 
particles at 
0.02, 0.5, 50 
mg/kg. 60nm 
Carboxylated 
nanoparticles 
at 0.1 and 50 
mg/kg for one 
hour 
exposure.  
Thrombus 
formation after 
intra tracheal 
and 
intravenous 
instillation. 
Thrombus formation 
was achieved faster for 
aminated nanoparticles 
compared to 
carboxylated, which 
experienced no 
significant change. 
Aminated UFP at 0.02, 
0.5 and 50mg/kg were 
all significantly 
prothrombitic compared 
to vehicle alone. IV 
administered 
nanoparticles at 
0.5mg/kg induced 
similar effects with 
Rose-Bengal dye to 
accentuate thrombosis, 
but longer illumination 
time needed.  
Each animal 
was its own 
control. Prior 
sonication and 
vortex of 
particles 
reduced 
aggregation. 
Demonstrated 
similar effects 
when particles 
administered 
either side of 
the alveolar 
barrier. 
Polystyrene 
particles are 
a proxy for 
true 
pollutants. 
Small 
number of 
subjects.  
Positively charged 
polystyrene 
particles are 
prothrombotic whilst 
negatively charged 
particles are not. 
Administering 
particles either side 
of the alveolar 
barrier causes 
similar thrombi.  
Simkhovich 
et al 2007 
Controlled 
trial 
(Simkhovich 
et al., 2007). 
Langendorff 
heart 
models from 
4month old 
and 26 
months from 
female 
Fisher 334 
rats.  
Direct 
infusion 
into 
perfused 
heart 
circulation.  
9 young and 
10 old hearts 
in control 
group,  15 
young and 13 
old hearts 
exposed to 
diesel UFP 
<100nm. 
Tests at 0, 
10, 20, 
30mins. 
Developed 
pressure. Left 
ventricular end 
diastolic 
pressure, 
positive and 
negative left 
ventricular 
pressure (+ve 
dP/dt and -ve 
dP/dt). 
Coronary flow.  
In young and old, 
developed pressure ↓ 
by 33 and 35%.  
LVEDP ↓in young 
hearts only. +ve dP/dt ↓ 
in young hearts at 20, 
30mins and in old 
hearts at all times.  -ve 
dP/dt↓ for both hearts 
at all times. Coronary 
flow ↓ at 20, 30mins in 
young and all times in 
old heart. For all 
measurements there 
was highly significant 
group x age effect.  
Relevant for 
true human 
exposure over 
one day.   
Non-
physiologic 
exposure. 
Heart 
removed 
from 
hormonal 
and vagal 
input.  
Young and old 
hearts are equally 
affected by UFP. 
Cardiac 
haemodynamic 
performance is 
impaired.  
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Stampfl et 
al 
2011(Sta
mpfl et al., 
2011).  
Langendorf
f heart 
model 
(guinea 
pig). 
Direct 
infusion 
into 
perfused 
heart 
circulation.  
14nm CB 
(4-8x 10^9) 
120nm CB 
(8 x 10^9, 
and TiO2 
(2-4 x 
10^9) 
50nm SiO2 
7nm (1 x 
10^9) 
particles. 
Heart rate. 
Noradrenaline (NA) 
concentration 
changes. 
At 1 hour, HR↑ by 
5% (CB14) and 
6% (TiO2) 
10%(CB120); at 2 
hours and double 
dose, 15% (CB), 
13% (CB120) and 
13% (TiO2). SiO2 
↑ 7% during 2nd 
hour (lowest 
concentration).  
NA↑69% for 
CB14 and Ti02.                                                        
Suitable heart 
model for 
electrophysiologic
al studies. 
 Limited 
reporting of 
P-values did 
not allow 
inclusion of 
some 
results. 
Heart rate 
results are 
considered 
with vagal 
input 
removed.
HR is increased by 
exposure to UFP when 
isolated. 
Noradrenaline release 
is increased.  
 
Tong et al 
2010 
Controlled 
trial (Tong 
et al., 
2010). 
Female CD-
1 mice 12 
mice for 
inflammator
y and, 10 
for 
perfusion 
study.  
Oropharyn
geal 
instillation. 
Direct 
infusion 
into 
perfused 
heart 
circulation.  
100µg of 
<100nm 
UFP. 
Measureme
nts made 
24hrs post-
exposure.  
Plasma blood 
count and 
biochemistry. 
Haemodynamics, 
cardiac perfusion. 
Recovery of 
ischaemic heart 
and necrotic area. 
No change in blood 
cell count or 
biochemistry. HR 
and flow rate 
decreased. No 
other 
haemodynamic 
change. LVDP post 
ischaemia reduced 
with UFP. Infarct 
size increased.  
Infarct size 
measured, not 
just perfusion 
changes.  
Non-
physiological 
exposure.  
Heart rate 
results are 
considered 
with vagal 
input removed. 
Cardiac 
perfusion 
measurements 
made at 24 hrs 
only. 
UFP exacerbated 
cardiac ischaemia and 
reperfusion injury.  
Wang et 
al 2009 
Controlled 
trial 
(Wang et 
al., 2009). 
40 
Sprague-
Dawley rats 
180-200g. 
Intra 
articular 
injection 
46nm TiO2 
at 0, 0.2, 2 
and 
20mg/ml 
(n=10/group
). Tests 
conducted 7 
days later. 
AST, ALT, alkaline 
phosphatase, LDH. 
Heart and 
hepatocyte 
damage. 
AST /ALT ratio and 
LDH↑ at 2 and 
20mg/ml. Swollen 
vascular 
endothelium in 
heart. Fatty 
degeneration of 
hepatocytes, 
inflammatory 
response, dose 
dependently. 
Nanoparticles 
sonicated for 50 
minutes. 
Random 
assignment to 
groups. 
Highly 
aggregated. 
Cardiovascular 
outcomes 
were 
secondary 
endpoints. Not 
a useful 
exposure 
method. 
Both the liver and heart 
are damaged by 
translocation of 
particles to these 
organs. 
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Wold et al 
2006 
Controlled 
trial (Wold 
et al., 
2006). 
Female 
Sprague-
Dawley 
rats, and 
isolated 
Langendorff
-perfusion 
model from 
rats. 
Intravenou
s infusion. 
Diesel 
exhaust 
≤100nm at 
50µg/ml  
(n=3). 
Ambient 
UFP 
≤150nm 
(n=4) and 
control 
(n=3) tests 
conducted 
at 0, 5, 30, 
60mins. 
Industrial 
diesel 
≤100nm at 
50µg/ml, 
(n=6), its 
soluble 
component 
(n=5), 
control 
(n=8).  
IN VIVO ventricular 
premature beats. 
Heart rate and 
blood pressure. 
Ejection fraction. 
EX VIVO left 
ventricular end 
diastolic pressure. 
Left ventricular 
contractility. 
Coronary flow.  
IN VIVO Diesel 
exhaust caused 
ventricular 
premature beats in 
2/3 rats. Ambient 
UFP caused 
severe 
hypotension, heart 
block and death in 
one rat. No 
haemodynamic 
changes. Ejection 
fraction ↑for 
ambient UFP only.  
EX VIVO Left 
ventricular end 
diastolic pressure↑ 
for diesel exhaust. 
ventricular 
contractility ↓ for 
diesel exhaust. Left 
ventricular systolic 
pressure, 
contractility and 
coronary flow↓ for 
industrial diesel c.f. 
baseline. For 
soluble fraction, left 
systolic pressure 
and coronary flow↓ 
c.f. baseline.  
 
 
 
 
 
Particles were 
sonicated for 
30mins prior to 
use. Particles 
used are highly 
relevant to 
ambient 
exposure to 
UFP. 
Intervention 
groups had 
lower blood 
pressure, 
lower heart 
rate and lower 
ejection 
fractions 
compared to 
control at 
baseline. 
Industrial 
diesel exhaust 
outcome 
changes 
statistically 
compared to 
own baseline, 
not control 
changes. 
Concentrations 
estimated from 
PM-UFP 
amount.   
Injected nanoparticles 
can reduce cardiac 
function, but soluble 
components may not 
have an effect.  
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Aung et 
al. 2011 
Controlled 
trial (Aung 
et al., 
2011). 
Human 
aortic 
endotheli
al cells. 
In vitro 
incubation
. 
0.056, 0.1, 
0.18, 
0.32, 
0.56nm 
ambient 
UFP at 
10μg/ml for 
all studies 
except 
immunofluo
rescence 
(50 μg/ml).  
Genetic 
expression. 
Stress (SAPK/JNK), 
transcription factors (ATF-
3), and inﬂammatory 
responses (E-selectin, 
PTGS2, MIP-2, MCP-1) All 
NPs increased secretion 
of IL-6 and MCP-1 .  
Particle type 
represents 
ambient UFP 
well. Cell type 
useful 
endothelial 
representation. 
Limited relevant 
outcomes. Cell 
isolated from in 
vivo cellular and 
hormonal effects.  
Oxidative stress 
and inflammatory 
responses up-
regulated in aortic 
cells exposed to 
UFP. 
Chen et al 
2011 
Controlled 
trial 
(Chen et 
al., 2011). 
Human 
fibrinoge
n 
In vitro 
incubation
. 
Gold 10nm 
particle. 
Concentrati
ons of 
0.775nM 
and 2.48nM 
used.  
Fibrinogen-
particle binding.  
Fibrinogen-particle 
binding↑ in dose and time 
dependent manner.  
Result 
confirmed by 
separate 
methods (UV 
absorbance 
spectrum, 
dynamic light 
scattering and 
visualisation) 
Experiment media 
was un 
physiological 
(Buffered saline). 
Gold is a poor 
surrogate 
nanoparticle due to 
its low reactivity 
and absence in 
ambient PM. 
Gold nanoparticles 
can form 
complexes with 
fibrinogen. 
Corbolan 
et al 
2011(Cor
balan et 
al., 2011). 
Human 
umbilical 
vein 
endotheli
al cells. 
In vitro 
incubation
. 
Cells were 
exposed to 
11nm silica 
at 10 μg/mL 
for 1 hr, 53, 
148 and 
496nmsilica 
at 50 μg/mL 
for 3 hours.  
NO and ONOO− 
production. NF-
κB 
binding activity 
and 
downstream 
genetic 
activation. 
Cytokine 
release. 
NO↑ and ONOO−↑. NO 
/ONOO−↓.  NF-κB 
binding activity↑. ICAM1, 
VCAM1, SELE, MMP9, 
COX2, F3, IL6, and IL8↑. 
Il-6 and 8↑ 
Sonication for 
2 minutes and 
vortexing of 
particles 
before use. 
Positive 
control, 
calcium 
ionophore 
used. 
Corona formation 
with bovine serum. 
Cell isolated from 
in vivo cellular and 
hormonal effects.  
In endothelial cells 
exposed to silica 
NP's, an 
unfavourable shift 
of NO /ONOO− 
ratio occurred, 
suggesting 
oxidative damage. 
Many inflammatory 
genes up-
regulated. 
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Corbolan 
et al 2012 
controlled 
trial 
(Corbalan 
et al., 
2012). 
Blood 
from 
healthy 
human 
volunteer
s. 
In vitro 
incubation
. 
11 nm, 53 
nm, 118 
nm, and 
496 nm 
silica NPs 
at 1-200 
μg/ml. 
Negative 
control.  
P-Selectin and 
GPIIb/IIIa 
activation. 
Platelet 
aggregation. 
Concentration of 
NO and 
ONOO−. TXA2 
(ASA), ADP 
(apyrase), and 
MMP2 
(phenanthroline) 
pathway 
inhibitors used 
to determine 
pathways 
involved in 
aggregation. 
P-selectin↑ GPIIb/IIIa and 
platelet aggregation ↑.  
NO↑ and ONOO−↑. NO 
/ONOO−↓ MMP2 and ADP 
pathways involved in 
agglomeration of platelets.  
Nanoparticles 
sonicated for 2 
minutes prior 
to use. 
Inhibition tests 
could have shown 
if inflammatory 
expressions were 
oxidative stress 
dependent.  
In human platelets 
exposed to silica 
NP's, an 
unfavourable shift 
of NO 
/ONOO−occurred 
suggesting 
oxidative damage 
and aggregation 
markers were 
raised, alongside 
increased 
aggregation.  
Deng et al 
2011 
Controlled 
trial 
(Deng et 
al., 2011).  
plasma 
samples 
from 8 
healthy 
human 
volunteer
s 
In vitro 
incubation 
Negatively 
charged 
poly (acrylic 
acid)-
coated gold 
particles of 
5, 10 and 
20nm.  
Fibrinogen-
particle binding. 
Binding of 
ﬁbrinogen to 
Mac-1-receptor-
positive THP-1 
cell. NF-kB 
activation. IL-8, 
TNF-α 
secretion. 
Particle charge 
effects.  
Fibrinogen-particle 
binding↑. Mac-1 receptor 
binding↑. Fibrinogen/NP 
complexes ↑NF-kB. IL-8, 
TNF-α↑ neutral charge 
inhibited binding to 
fibrinogen. Other particles 
all bound fibrinogen with 
the smaller ones promoted 
fibrinogen-THP-1 cells 
more. This process was 
partly MAC-1 dependent. 
 
 
 
 
Many 
outcomes 
assessed to 
determine 
conclusion. 
Relevant 
plasma type.  
Cell isolated from 
in vivo cellular and 
hormonal effects.  
Negatively charged 
nanoparticles 
cause fibrinogen 
unfolding and 
activate the MAC-1 
pathway. 
Inflammatory 
mediators are 
released.  
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Forestier 
et al 2012 
controlled 
trial(Fores
tier et al., 
2012). 
Blood 
from 
healthy 
human 
volun-
teers. 
In vitro 
incubation 
14nm CB 
0.1 μg/ml 
I-1b, IL-8, 
thrombin. 
Coagulation- 
prothrombin 
time, aPTT, 
ﬁbrinogen levels 
and d-dimers. 
Platelet plug 
formation 
speed. 
Collagen-
induced platelet 
aggregation. 
I-1b−, IL-8−. Thrombin 
formation↑ in a platelet 
dependent fashion.  
Coagulation markers−. 
Plug formation 
speed−.Platelet 
aggregation↑ 
Piloted to 
ensure capture 
of all changes. 
Nanoparticles 
sonicated for 
10 minutes 
prior to 
exposure. 
More outcomes 
existed for DEP 
than for UFCB. Cell 
isolated from in 
vivo cellular and 
hormonal effects.  
Coagulation 
accentuated after 
UFCB exposure.  
Foucard 
et al 2010 
Controlled 
trial 
(Foucaud 
et al., 
2010). 
human 
mono-
cytic cell 
line THP-
1 
In vitro 
incubation 
14 and 
260nm CB 
0-500μg/mg 
Cell-free (14 
and 260nm) and 
within 4-HNE 
production 
(14nm). HO-1 
and HSP70, 
GSH and 
GSSG. 4-HNE 
treatments  
Cell-free oxidative stress 
for 14nm↑ 260nm↓. 14nm 
only 4-HNE production↑ 
HO-1─, HSP70↑, GSH↓, 
and GSSG↑. 4-HNE 
treatment caused HO-1↑ 
and glutathione↓.  
 
 
Positive 
control used 
(4-HNE) to 
elicit 
inflammatory 
response. 
Spontaneous 
oxidation of  
fluorescent dye 
when measuring 
oxidative stress. 
Cell isolated from 
in vivo cellular and 
hormonal effects.  
Exposure to UFCB 
elicits a oxidative 
stress response. 
CB causes 4-HNE 
production The 4-
HNE produced 
elicits a cellular 
stress response. 
Gojova et 
al 2007 
Controlled 
trial 
(Gojova 
et al., 
2007).  
Human 
aortic 
endotheli
al cells 
In vitro 
Incubation 
Fe2O3 5 
and 45nm. 
Y2O3 20-
60nm. ZnO 
100-200nm 
Control 
used. 1 and 
10 μg/mL 
for mRNA 
studies. 1, 
10 and 0 
μg/mL for 
protein 
levels.  
HAEC, ICAM-1, 
IL-8, and MCP-1 
mRNA 
expression and 
blood levels. 
Fe2O3 exposure= ICAM-1 
─ IL-8─,MCP-1─ mRNA 
levels. Y2O3 and ZnO 
exposure= ICAM-1↑, IL-
8↑, and MCP-1↑ mRNA 
levels.  ZnO ld50 4hrs. 
Fe2O3 and Y2O3 did not. 
Fe2O3= ICAM-1 ─, MCP-
1─ protein serum levels. 
Y2O3 caused I C A M - 1 
─, MCP-1↑ protein serum 
levels.  ICAM-1 ↑, MCP-1↑ 
protein serum levels with 
ZnO.  
Nanoparticles 
sonicated for 5 
minutes prior 
to incubation. 
Wide range of 
nanoparticle 
exposures and 
concentrations
. Useful cell 
type. 
Positive control 
may have been 
useful considering 
the large number of 
negative results. 
Nanoparticles elicit 
an inflammatory 
response in aortic 
endothelial cells in 
vitro.  
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Gonçalve
s et al 
2010 
Controlled 
trial 
(Goncalve
s et al., 
2010).  
Neutroph
ils 
isolated 
from 
healthy 
human 
volunteer
. 
In vitro 
incubation
.. 
TiO2 
nanoparticle
s at 0, 2 10, 
20, 50 or 
100 μg/ml. 
Cell 
morphology. 
TiO2-induced 
phosphorylation. 
P38- and ERK 
1/2- MAPK 
activation. 
Neutrophil 
apoptosis. 
GRO-α and IL-8 
production. 
Neutrophil morphology 
suggests activation on 
TiO2 exposure. TiO2-
induced tyrosine 
phosphorylation of several 
proteins. ERK1/2 MAPK↑ 
P38 MAPK↑. TiO2 
signiﬁcantly inhibited PMN 
apoptosis. IL-8 and GRO-
α production↑. 
Wide range of 
concentrations 
used. Relevant 
cell type used.  
MAPK pathway not 
shown to causally 
influence 
downstream cell 
reactions. Cell 
isolated from in 
vivo cellular and 
hormonal effects.  
Neutrophils 
activated by in vitro 
exposure to TiO2.  
Jun et al 
2011 
Controlled 
trial (Jun 
et al., 
2011). 
Platelets 
extracted 
from 
human 
blood in 
healthy 
male 
donors 
and male 
Sprague-
Dawley 
rats. 
In vitro 
incubation
. IV bolus 
and intra-
tracheal 
instillation. 
Silver 10-
100nm at 
doses 
0,10,100,20
0 and 
250µg/ml 
for 
aggregation 
experiment. 
In vivo IV 
dose 0, 
0.05, 0.1 
mg/kg. 
Intra-
tracheal 
instillation 
0-250µg/ml.  
Platelet 
aggregation. 
Phospholipid 
(phosphotadylse
rine) 
expression. 
Thrombin 
generation. 
Calcium (flow 
cytometry) and 
serotonin 
release, CD62P 
expression. In 
vivo thrombus 
formation 
(weight). Ex vivo 
platelet 
aggregation, 
phospholipid 
expression.  
IN VITRO platelet 
aggregation ↑ in dose 
dependent manner from 
50µg/ml and was 
markedly increased with 
sub-threshold/minute 
doses of thrombin to 
almost 100% at 250µg/ml. 
Phospholipid exposure ↑ 
in a dose dependent 
manner from 200µg/ml, 
reaching almost 100% 
expression at 250µg/ml. 
Thrombin generation↑ at 
250µg/ml and in a dose 
dependent manner from 
200µg/ml with thrombin 
incubation. Calcium 
release ↑ (250µg/ml), 
enhanced with thrombin 
and aggregation effect 
blunted by use of calcium 
chelator. Serotonin 
release ↑ at 250µg/ml and  
Sonication and 
vigorous 
vortexing of 
nanoparticles 
pre-exposure. 
Spurious 
nanoparticle 
effect on 
platelet 
aggregation 
avoided by cell 
counting. Very 
comprehensiv
e investigation 
of coagulability 
in several 
models. 
 
 
enhanced with 
thrombin. 
CD62P↑ at 
100, 250 µg/ml 
and enhanced 
with thrombin. 
Non-physiological 
exposure methods. 
In the in vitro 
experiment the 
cells were isolated 
from in vivo cellular 
and hormonal 
effects.  
Platelet 
aggregation and 
coagulability is 
enhanced by silver 
nanoparticles. A 
hyper coagulable 
state might pre-
dispose to 
enhanced negative 
effects.  
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Karoly et 
al 2007 
Controlled 
trial 
(Karoly et 
al., 2007). 
Human 
pulmonar
y artery 
endotheli
al cells. 
In vitro 
incubation
. 
0-100 
μg/mL UFP 
or vehicle 
for 4 hours. 
n=4 per 
group 
Genetic 
expression. 
Quantitative 
polymerase 
chain reaction 
with UFP, 
insoluble and 
soluble 
fractions. 
Cytokine 
expression. 
Anti-Tissue-
Factor blocking 
agent 
experiment. 
320 genes↑ 106 genes↓ 
coagulation, Tissue 
Factor↑ polymerase chain 
reaction= F3↑ cytokine 
signalling eg MCP-1, IL-8, 
CXCL1-3 ↑. Wnt 
signalling↑. MAPK 
signalling↑. Water-soluble 
UFP fractions induced F3, 
F2RL2, and heme-
oxygenase 1 expression. 
IL-6 and IL-8 levels↑.  
Tissue factor blocking 
agent attenuated IL-6 and 
IL-8 release. 
 
Ambient UFP 
used. Tissue 
factor shown 
to mediate IL-
6, 8 releases. 
Huge amount of 
outcomes. Cell 
isolated from in 
vivo cellular and 
hormonal effects.  
Genetic expression 
of clotting factors is 
enhanced post 
UFP exposure in 
vitro. 
Kennedy 
et al 2009 
Controlled 
trial(Kenn
edy et al., 
2009). 
Human 
aortic 
endotheli
al cells. 
In vitro 
incubation 
0.001–50 
µg/ml of 
Fe2O3 5-
90nm, 
Y2O3 20 to 
60 nm, 
CeO2, 
ZnO rods 
100 to 200 
nm x 20 to 
70 nm .  
ICAM-1, IL-8,, 
MCP-1 
mRNA levels. 
ICAM-1 and 
MCP-1 protein 
expression. Nrf2 
translocation. 
ROS production 
(DHE stain).  
GCLC, HMOX1, 
and NOX4 
mRNA 
expression 
mRNA = Y2O3 ↑ ICAM-1, IL-8, 
MCP-1 at  50 µg/ml and ICAM-1 
at 10µg/ml. ZnO ↑ ICAM-1 and 
IL-8at 50µg/mL, and ICAM-1 at 
10µg/ml, CeO2↑ IL-8 at 50µg/ml 
all at 4 hrs. At 1, 2 an 8 hrs at 
10µg/ml, ZNO↑ ICAM-1, IL-8, 
MCP-1. MCP-1 protein i↑ at 10, 
50Iµg/ml for ZNO, ICAM-1 ↑ at 
50µg/ml for ZnO only.  Nrf2 
translocation ─ for all NPs. 
ROS↑ 10 and 50 µg/ml ZnO, 50 
µg/ml Y2O3, Fe2O3─. HMOX-
1↑ at 10µg/ml ZnO.,Y2O3, 
Fe2O3─ 
 
 
 
 
Nanoparticles were 
sonicated for 5 
minutes prior to 
use.  
Cell isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Various 
nanoparticles 
induce 
reactive 
oxygen 
species 
formation, and 
an 
inflammatory 
response. 
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Kendall et 
al 2011 
Controlled 
trial 
(Kendall 
et al., 
2011). 
Fibrinoge
n 
exposure 
In vitro 
incubation 
Amino, 
carboxyl, 
hydroxylate 
and 
sulphate 
Polystyrene
, 100, 200 
and 500nm. 
Hydrophillic 
silica 12nm. 
CB 76nm. 
Particle 
aggregation in 
saline. 
All particles had similar 
aggregation speeds in 
fibrinogen except for aminated 
polystyrene particles, due to 
bridge flocculation from particle 
adsorption to NP surface.  
Nanoparticles 
sonicated before 
use. Control 
inspected for 
contamination.  
Saline is not 
wholly 
relevant to in 
vivo effects in 
real life. 
Nanoparticle 
interaction with 
fibrinogen 
alters 
Nanoparticle 
surface 
available for 
cellular effects. 
Aminated 
particles may 
remain in the 
body  
Kim et al 
2012 
Controlled 
trial (Kim 
and Choi, 
2012). 
U937 
Monocyt
e cells. 
In vitro 
incubation
. 
Silver 5nm  
particles at 
doses 0-
0.8µg/ml. 
Cytotoxicity 
(Time taken for 
50% cell death). 
IL-8 production. 
50% cytotoxicity occurred at 
0.36 µg/ml  IL-8 production ↑ at 
0.5 µg/ml. 
Endotoxin tested 
for in silver 
nanoparticles to 
limit particle 
pollution. 
Single NP 
dose used for 
IL-8 and the 
main 
experimental 
outcome was 
not of 
interest. No 
sonication 
used to de-
aggregate 
particles. 
IL-8 is release 
from 
macrophages 
exposed to 
modest doses 
of silver NPs. 
Li et al 
2009 
Controlled 
trial (Li et 
al., 2009). 
Human 
aortic 
artery 
endotheli
al cells 
In vitro 
incubation
. 
Diesel UFP 
12.5, 25, 50 
μg/ml or 
control. 
Incubated 
for 1 hour. 
Superoxide 
production and 
protein 
cabonylation. 
HO-1 and tissue 
factor 
expression. JNK 
activation, its 
inhibition and 
silencing. 
Intracellular and mitochondrial 
superoxide production ↑. Protein 
carbonylation↑. Heme 
oxygenase-1 and tissue factor 
mRNA expression↑, O2− 
scavengers attenuated this 
effect.  JNK 
activated/phosphorylated. 
Inhibition of JNK attenuated 
superoxide production and 
genetic expression. JNK 
silencing enhanced this effect. 
30 min sonication 
of UFP prior to use.  
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Diesel UFP 
induces 
oxidative 
stress in aortic 
endothelial 
cells via JNK 
activation. 
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Li et al 
2010 
Controlled 
trial (Li et 
al., 
2010a). 
Human 
aortic 
endotheli
al cells 
(HAEC)  
and 
Monocyti
c THP-1 
cells. 
In vitro 
incubation
. 
Diesel 
UFP1 
(Idling 
engine) 
UFP 2 (city 
driving 
conditions) 
10-18, 18-
32, 32- 56, 
56-100, 
100-180 at 
50 μg/ml or 
control. 
Superoxide 
production. HO-
1, OKL38 and 
TF mRNA . IL-8, 
MCP-1, VCAM 
genes. Dose 
response HO-1 
and VCAM 
genes. 
Monocytic 
binding. NF-kB 
activation. 
(HAEC) superoxide↑ for 
UFP1+2. HO-1, OKL38 and TF 
genes↑ for 1+2. UFP1 VCAM↓, 
MCP-1, IL-8─. UFP2 VCAM, 
MCP-1, IL-8↑. Dose response 
UFP1= HO-1↑ and VCAM gene 
↓. UFP 2= HO-1gene↑, VCAM 
gene↑.  UFP1↑ monocytic 
binding. UFP2 greatly↑ binding. 
UFP1↓ UFP2↑ NFkB. Inhibition 
of NFkB abrogated IL-8, MCP-1, 
VCAM expressions and 
partially- monocyte binding. 
 
Use of different 
exhaust types to 
quantify how city 
driving specifically 
contributes to 
ambient UFP.  
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Both UFP 
types cause 
monocytic 
binding. UFP2 
was more 
potent and 
partially 
dependent of 
NF-kB 
signalling.  
McGuinne
s et al 
2010 
Controlled 
trial 
(McGuinn
es et al., 
2011).  
Whole 
blood 
and 
isolated 
platelets 
from 
healthy 
human 
volunteer
s. 
In vitro 
incubation
. 
Polystyrene 
uncharged 
particle 
88nm, 
carboxylate
d 79nm and 
aminated 
75nm or 
control. 
Incubated 
for 20 
minutes at 
260 μg/ml. 
Platelet 
aggregation. 
Polymorphonucl
ear 
neutrophilic 
leucocyte-
platelet 
aggregates. 
Combined 
CD14 + CD42b 
positive events. 
Expression of 
CD62P and 
PAC-1 in whole 
blood and on 
platelets. 
Annexin V 
binding. 
Haemoglobin 
release. 
Positively charged particles 
associate with platelets in 
platelet-platelet or monocyte-
platelet aggregates. Both 
charged particles caused 
agglomeration of platelets. 
Uncharged no effect. 
Polymorphonuclear 
neutrophilic leucocyte-platelet 
aggregates no change for any 
particle type. CD14 + CD42b 
positive events for both charged 
particles.  Carboxylated particles 
showed increased expression of 
CD62P and PAC-1 in whole 
blood and platelets. Both 
charged particles induced 
Annexin V binding. Aminated 
particles only caused 
Heamoglobin release, but even 
small plasma concentrations 
diminished this effect.  
Sonicated for 10 
minutes prior to 
incubation. 
Relevant cell types 
used.   
Short 
incubation 
time. Cells 
isolated from 
in vivo 
cellular and 
hormonal 
effects.  
Oppositely 
charged 
particles had  
similar 
platelet-
activating 
properties, but 
through 
different 
mechanisms. 
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Mayer et 
al 2009 
Controlled 
trial(Maye
r et al., 
2009). 
Whole 
human 
blood 
samples. 
In vitro 
incubation
. 
Carboxylate
d 
polystyrene 
particles 
between 
33-212nm. 
Amide 
polystyrene 
particles, 
300nm. 
0.05 mg/ml, 
0.5 mg/ml, 
2 mg/ml 
and 2.5 
mg/ml for 
10-120 
minutes. 
LDH release. 
Complement 
activation. 
Coagulation. 
Thrombocyte 
activation. 
Granulocyte 
activation. 
Haemolysis. 
LDH release ─. C3a-. D-dimer-. 
Prothrombin-. CD42b and 
CD62P-. Granulocyte activation- 
for amide, ↑ for carboxylated 
particles 33-160nm. Hb release↑ 
in all particles. 
Sonicated for 15 
minutes prior to 
use. Positive 
controls used for 
proving experiment 
plausibility.  
Charge 
neutralized 
by protein 
solution. 
Short 
incubation 
time. Cells 
isolated from 
in vivo 
cellular 
effects. 
Neutral 
particles 
would have 
been useful 
to delineate 
between 
'charge' and 
'size' effect. 
Negatively and 
positively-
charged 
polystyrene 
particles 
induce cellular 
damage and 
possibly 
granulocyte 
activation for 
negatively-
charged 
particles only.  
Metassan 
et al 2010 
controlled 
trial 
(Metassa
n et al., 
2010). 
Purified 
human 
fibrinoge
n and 
human 
thrombin. 
In vitro 
incubation
. 
Ambient 
UFP 
≤220nm at 
17, 34 and 
60μg/ml 
and 380 
μg/ml for 
plasma 
experiment. 
FIBRINOGEN 
Fibrin clot pore 
size. Fibrin 
polymerisation 
(rate of 
polymerization 
and maximum 
optical density). 
Visualised fibrin 
network 
structure. IN 
PLASMA fibrin 
clot pore size. 
ROS generator 
added to 
fibrinogen. ROS 
scavenger. 
FIBRINOGEN  PM↑ clot porosity 
at 17 and 34 μg/ml. 68μg/m 
caused faster clot formation with 
formation of altered fibrin fibres, 
optical density increased for 34 
and 68μg/ml. Fibrin network 
decreased in density, 68μg/ml 
increased network heterogeneity 
with fibrin clustering. A decrease 
in fibre density was seen. Fibre 
diameter not altered. IN 
PLASMA 380μg/ml ↑ increased 
fibrin clot pore size. ROS 
produced similar findings to PM, 
but additionally decrease fibre 
diameter. ROS scavenger 
attenuated effect of PM on clot.  
Nanoparticles 
centrifuged for 30 
minutes prior to 
use.  
Plasma 
fibrinogen not 
additionally 
tested with 
identical PM 
due to PM 
shortage. 
Fibre network 
heterogeneity 
and fibrin 
clustering may 
explain the 
increased 
porosity of the 
nanoparticle 
bathed fibrin 
clots. To 
change pore 
size in plasma, 
much higher 
concentrations 
were needed.  
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Napierska 
et al 2009 
Controlled 
trial 
(Napiersk
a et al., 
2009).  
The 
human 
endotheli
al cells 
(EAHY92
6 cell 
line). 
In vitro 
incubation
. 
Silica 16, 
19, 60, 104, 
335nm and 
Ludox® 
Silica 14 
and 15nm. 
Cell 
cytotoxicity 
and viability 
studies 
conducted 
over 24 
hours. 
Cell viability and 
cytotoxicity 
(TC50). 
Cell death ↑ in a dose 
dependent and inverse- size 
dependent  manner for both 
Silica types. Cytotoxicity (TC50) 
↓ as size↓.  Cell death was 
predominantly by necrosis, 
peaking at silica 14nm, with 
apoptosis peaking at 16nm.  
Wide range of 
exposure sizes.  
Outcomes 
may not have 
relevance for 
real life 
exposures 
where much 
lower 
concentration
s would be 
experienced. 
Cells isolated 
from in vivo 
cellular 
effects.  
Cell death 
occurred via 
necrosis, and 
apoptosis. Cell 
death was 
dose and 
inverse-size 
dependent.  
Napierska 
et al 2012 
Controlled 
trial 
(Napiersk
a et al., 
2012).  
The 
human 
endotheli
al cells 
(EAHY92
6 cell 
line). 
In vitro 
incubation
. 
60 and 
16nm silica 
particles. 
Iron doped 
silica (FeSi) 
16nm. 
Incubated 
for 30 
minutes for 
ROS 
experiment, 
4 hours for 
GSH 
oxidation 
and 24hrs 
for 
cytotoxicity. 
 
 
 
 
 
 
Cell free ROS. 
GSSG/GSH 
ratio.  
Cytotoxicity 
(TC50). Lipid 
peroxidation. 
HO-1 mRNA.  
ROS= FeSi↑ Silica 60nm↓ 
16nm─. FeSi= cell glutathione ↓. 
GSSG/GSH and MDA and 
HAE↑, pure silica─. Cytoxicity ↑ 
in a concentration dependent 
and inverse particle size 
manner. Ho-1 expression for all 
particles ↑. NADPH oxidase-1 
and glutathione reductase↑ for 
FeSi only. Antioxidant treatment 
prevented the HO-1 increase 
but not the glutathione↓ or 
glutathione ratio↑.  
Relevant cell line 
used. Relevant 
UFP particle and 
engineered 
nanoparticles used. 
The authors 
consider 
whether SFe 
nanoparticles 
are also able 
to quench the 
fluorescence 
signal. Cells 
isolated from 
in vivo 
cellular and 
hormonal 
effects.  
Iron doped 
silica 
nanoparticles 
are 
considerably 
more toxic and 
up-regulate 
oxidative 
stress markers 
more than 
pure silica.  
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Peters et 
al 2007 
Controlled 
trial 
(Peters et 
al., 2007). 
Human 
dermal 
micro 
vascular 
endotheli
al cells. 
In vitro 
incubation
. 
Cobalt 
28nm, 
nickel  
62nm at 0, 
0.5, 5, 10, 
25 and 
50µg/ml.  
Cytotoxicity. 
ROS production 
and GSH 
production. IL-8 
protein release. 
ICAM-1 
expression. 
MCP- 1 release. 
Concentration dependent drop 
reduction of cell number within 
24hrs. CO ↑ ROS and GSH in 
dose dependent fashion, Ni ─.  
CO↑ IL-8 at 50µg/ml, NI ↑ in 
dose dependent fashion.  ICAM-
1 ↑ at 50µg/ml Co, Ni ─. Co↑ 
MCP-1 in a dose dependent 
manner, Ni─. 
H2O2 added to NI-
ROS experiment to 
confirm Nickel’s 
lack of effect. 
Cell type 
from a 
vascular bed 
which may 
not be 
physiologicall
y similar to 
larger 
arteries.  
Co increased 
oxidative 
stress levels, 
and exhibits 
an 
inflammatory 
response. Ni 
might elicit 
inflammation. 
Radomski 
et al 2005 
Controlled 
trial 
(Radomsk
i et al.). 
Platelets 
separate
d from 
blood 
from 
healthy 
human 
volunteer
s. 
Wistar–
Kyoto 
rats. Age 
not 
reported.  
In vitro 
incubation 
and IV 
injection. 
Mixed 
carbon 
nanoparticle
s, purified 
carbon 
fullerenes at 
50µg/ml in 
vivo for 
thrombosis 
experiment, 
200µg/ml in 
vivo. 5-
500µg/ml in 
vitro.  
IN VITRO 
Platelet 
aggregation.  
ATP release. 
Degranulation. 
GP2b3a 
expression. P-
selectin 
expression 
Gp1b 
expression 
Aggregation 
inhibition by 
prostacyclin and 
S-nitroso-
glutathione,(end
ogenous 
inhibitors of 
haemostasis) 
and aspirin 
(GP2b3a 
inhibitor. MMP-
9/MMP-2 ratio. 
PKC 
dependence. IN 
VIVO Platelet 
aggregation. 
IN VITRO Mixed carbon NPs ↑ 
platelet aggregation. Carbon 
fullerenes─. Mixed carbon NPs 
caused ATP release and platelet 
degranulation. Mixed carbon 
NPs ↑GP2b3a expression. P-
selectin↑ for mixed carbon NPs. 
GP1b↓ for mixed carbon NPs. 
Mixed carbon NPs ↓ 
aggregation with prostacyclin 
and S-nitroso-glutathione, not 
with aspirin. MMP-9/MMP-2 
ratio↑ in carbon fullerenes only. 
PKC dependence─ for all 
particles. IN VIVO. Mixed 
carbon nanoparticles ↑ platelet 
aggregation at 50µg/ml. Carbon 
fullerenes─. 
 
Nanoparticles 
sonicated for 2 
minutes. vortexed 
prior to testing. 
Investigated 
aggregation 
through several 
methods, and 
confirmed in vivo.  
Limited in 
vivo 
experiments. 
IV injection 
assumes that 
all particles 
pass the 
alveolar 
barrier.  
Carbon 
nanoparticles 
and materials 
activate 
platelet and 
enhance 
vascular 
thrombosis, 
but might do 
through 
different 
mechanisms.  
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Sharma 
et al 2011 
Controlled 
trial 
(Sharma 
et al., 
2011).  
Human 
liver cell 
HepG2. 
In vitro 
incubation
. 
30nm ZnO. 
12 and 24 h 
at 14 and 
20 μg/ml for 
cytotoxicity 
and 6hrs for 
DNA 
damage 
experiment. 
Cytotoxicity. 
DNA damage 
(Olive tail 
moment and 
%DNA in comet 
assay). ROS 
production 
(DCF) 
Cytotoxicity ↑ in a dose and time 
dependent manner.  DNA 
damage↑. ROS↑. 
DNA damage 
identified through 
two mechanisms.  
Non 
physiological 
medium. 
ZnO causes 
cyto- and 
genotoxicity, 
possibly via 
ROS 
production.  
Sharma 
et al 2012 
(Sharma 
et al., 
2012). 
Human 
liver cell 
HepG2. 
In vitro 
incubation
. 
30nm ZnO 
at 0.8, 2, 8, 
14-20µg/ml. 
(300 mg/kg) 
for 14 
consecutive 
days. 
Cytotoxicity 
(50% cell 
death). ROS 
production 
(DCF). Lipid 
peroxidation.  
Oxidative DNA 
damage (Olive 
tail moment and 
%DNA tail) and 
NAC inhibition. 
Apoptosis. Bax, 
Bcl2 , 
procaspase-9. 
P53 and Nf-kB. 
MAPK (ERK1/2, 
JNK, p38 
kinase) 
activation. NAC 
inhibition. Cell 
death pathway. 
Cytotoxicity ↑ in a dose and time 
dependent manner.   (CC50 
14.5µg/ml). ROS↑ 31% at 
20µg/ml at 6hrs. Lipid 
peroxidation↑ at 20µg/ml. DNA 
damage↑ at 6 and 14hrs at 
20µg/ml in Comet assay, Fpg 
modified Comet assay showed 
significantly higher values 
suggesting DNA damage; NAC 
was protective in dose 
dependent manner. Apoptosis ↑ 
at 14 and 20µg/ml.  Bax↑ Bcl2↓ 
procaspase 9↓ P53 and Nf-kB─.  
JNK and p38 activation↑ 
proteins─. Both activations NAC 
inhibited. ERK1/2 activation─. 
Cell viability unaffected after NP 
exposure with NAC, Vitamin C. 
Viability↓ with vitamin E, JNK 
and p38 inhibitor. 
 
 
 
 
 
 
Sonication 30mins. 
Inhibition tests 
allowed mediators 
to be ascertained. 
Relevant cell type. 
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
After ZnO 
exposure, 
cytotoxicity is 
seen after 
ROS 
generation. 
NAC inhibited 
this effect.  
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Trpkovic 
et al 2010 
Controlled 
trial 
(Trpkovic 
et al., 
2010).  
Blood 
from 
healthy 
human 
volunteer
s. 
In vitro 
incubation
. 
CB 55, 100 
and 125nm 
0.25-
10µg/ml for 
1, 6, 18hrs 
hour for 
haemolytic 
studies, and 
1 for ROS 
measureme
nt.  
Erythroctye 
haemolysis. 
Oxidative stress 
(fluorescence 
marker). 
CB55↑haemolysis in time and 
dose dependent manner. 
Albumin reduced haemolytic 
activity. Oxidative stress (AU) ↑ 
and inhibited by NAC 
(antioxidant) No change for 
larger particles in any outcome. 
Relevant tissue 
type.  
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects. 
Plasma 
restored to 
erythrocytes 
impeded the 
haemolytic 
effect 
observed 
with NPs. 
CB raises 
erythrocyte 
oxidative 
stress in-vitro. 
Haemolysis 
caused in vitro 
is reversed by 
albumin.  
Vesterdal 
et al 2012 
Controlled 
trial 
(Vesterdal 
et al., 
2012).  
Human 
umbilical 
vein 
endotheli
al cells 
and 
aortic 
segment
s from 
C57BL/6 
mice. 
In-vitro 
incubation
. 
CB 295nm 
at 10- 
100μg/ml in 
ex-vivo 
vasomotor 
experiment. 
CB 85nm 0, 
0.1, 10, 50 
and 
100μg/ml 
for cell 
experiments
. 
ROS production 
in HUVEC 
(DCFH assay 
and 
fluorescence 
microscopy) NO 
production. 
VCAM-1 and 
ICAM-1 
expression. 
LDH% max. Cell 
cytotoxicity and 
proliferation. 
Endothelium 
dependent 
/independent 
vasorelaxation- 
Emax 
(Ach/SNP). 
Receptor 
dependent 
vasoconstriction 
Emax. (PE).  
HUVEC- DCFH assay- acellular 
ROS↑ 10, 50, 100μg/ml. Cellular 
0.1, 10, 50μg/ml↑.  Microscopy- 
additional cellular ROS increase 
at 100μg/ml. UFP stimulated 
NO─. In presence of DPI, NO↓. 
10μg/ml increased insulin-
stimulated NO production, 
100μg/ml decreased it.   VCAM-
1 and ICAM-1↑at 100μg/ml. LDH 
↑ at 100μg/ml.  
Cell viability and proliferation─ 
at 0-100μg/ml.                                                               
Vasomotor function-  Ach- 
10μg/ml NPs↑, 100μg/ml NPs↓ 
Emax. SNP Emax- ↓. PE Emax- 
↓. Vessel diameter ↓with 
10μg/ml exposure.  
 
 
 
 
 
 
Nanoparticles 
sonicated for 1 
hour before use. 
NO dependent 
vasoactivity tested 
in cellular NO 
release and NO 
dependent 
vasodilation in 
aortic rings. 
Assumes 
direct action 
on cells by 
nanoparticles
. Aortic rings 
removed 
from nervous 
and 
hormonal 
input. 
CB 
nanoparticles 
increase ROS 
production, up-
regulation of 
immune cell 
recruitment 
and a 
vasoconstrictiv
e effect. Cell 
membranes 
are damaged. 
NO production 
may arise from 
NADPH and 
NOS. 
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Wan et al 
2008 
Controlled 
trial(Wan 
et al., 
2008). 
 U937 
monocyt
es. 
In vitro 
incubation
. 
TiO2 20nm, 
Cobalt 
20nm at 0, 
0.625, 1.25, 
2.5 and 
5µg/ml.  
Cytotoxicity. 
Oxidative stress 
(DCF 
fluorescence). 
MMP-2, 9 
mRNA 
expressions.  
TIMP-1,2 
expression  . 
AP-1/ PTK 
pathway 
inhibition 
(curcumin/ 
genistein, 
herbimycin A) 
No significant cytotoxic effects 
for doses used. Oxidative 
stress; TiO2─, Cobalt↑ all 
doses, in dose dependent 
fashion. Effect supressed by 
ROS scavenger and inhibitor 
(NAC and CAT). MMP-2,9 
mRNA expression and activity↑ 
at 2.5µg/ml + for Cobalt, not 
TiO2 These effects were 
supressed by NAC and CAT. 
TIMP-1─. TIMP-2 dose 
response↓ to Cobalt at 5µg/ml, 
TiO2─ (Effect prevented by CAT 
and NAC). AP-1 and PTK 
inhibitors ↓ MMP-2, 9. 
Nanoparticles 
sonicated for 
30minutes pror to 
use. Inhibitors of 
ROS used to 
demonstrate 
mediation in TIMP 
increases.  
Assumes 
direct action 
on cells by 
nanoparticles
. Cells 
removed 
from nervous 
and 
hormonal 
input. 
ROS are 
increased post 
exposure. 
MMP-s up-
regulated, 
activity 
increased and 
their inhibitors 
down-
regulated. 
Wilson et 
al 2002 
Controlled 
trial 
(Wilson et 
al., 2002).  
Human 
monocyt
e (Mono 
Mac 6). 
J774 
mouse 
macroph
age cell 
line. 
In vitro 
incubation
. 
260nm and 
14nm CB at 
10-
130µg/ml 
for 10 
minutes for 
both ROS 
experiments 
and 24 hrs 
in the 
murine 
macrophag
e cell line 
J774. 
 
 
 
 
Cell free ROS. 
Intracellular 
ROS (CuSO4, 
FeCl3 
and FeSO4 
incubation also). 
GSH. TNF-α 
expression.  
14nm CB ↑260nm─cell-free 
oxidative stress. For 14nm CB, 
oxidative stress ↑ and further↑ 
with metal salts, 260nm─. 
Cellular oxidative stress↑ for 
14nm ─ for 260nm. GSH and 
ATP↓ with 14nm CB and 
further↓ with FeSO4, CB─.  For 
14nm CB TNF-α↑ 
Multiple cell types 
used.  
Cells 
removed 
from nervous 
and 
hormonal 
input. 
14nm CB 
particles 
increase 
oxidative 
stress and 
TNF-α 
release. Iron 
salts 
accentuate 
oxidative 
stress cell free 
and 
intracellularly. 
73 
 
Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study strengths Study 
weaknesses 
Conclusion 
Yamawak
i et al 
2006 
Controlled 
trial 
(Yamawa
ki and 
Iwai, 
2006). 
Human 
umbilical 
vein 
endotheli
al cells. 
In vitro 
incubation
. 
CB 248nm 
mean (1, 10 
and 100 
µg/ml) 
LDH release. 
Cell 
proliferation. 
PCNA 
expression 
(expressed  
in S phase of 
cell cycle). 
MCP-1 protein 
expression. 
VCAM-1 protein 
expression.  
Connexin37 
expression. 
eNOS 
expression. 
Inflammatory 
gene 
expression. 
LDH ↑ in a dose dependent 
manner. Proliferation inhibited at 
10 and 100 µg/ml. PCNA ↓at 
100µg/ml. MCP-1 expression↑. 
VCAM-1─. Connexin expression 
↓. eNOS expression↓.  
Inﬂammatory genes; ICAM1, IL-
8, HO-1, VCAM-1, PTGS2 
(prostaglandin-endoperoxide 
synthase 2), SELE (selectin E), 
CCL2 (chemokine (C-C motif), 
MCP-1 ↑. 
Relevant cell line 
used. Relevant 
UFP particle used. 
Cells 
removed 
from nervous 
and 
hormonal 
input. Large 
nanoparticles 
used, which 
may not 
cross the 
alveolar 
barrier. 
Antiproliferativ
e effects, Pro-
inﬂammatory, 
eNOS 
expression 
and inhibition 
of gap 
junctions seen 
after HUVEC 
exposure to 
CB.  
Ye et al 
2010 
Controlled 
trial (Ye et 
al., 
2010a). 
Human 
hepatic 
cells. 
In vitro 
incubation
. 
0.2, 0.4, 0.6 
mg/ml SiO2 
of sizes 21, 
48 and 86 
nm. 12, 24, 
36 and 48hr 
exposures 
Cell cytotoxicity. 
LDH release. 
ROS, lipid 
peroxidation 
and GSH levels. 
Annexin V-
FITC/PI double-
staining and 
DNA ladder 
assay. p53, Bax 
and Bcl-2 
expression 
Cell viability decreased in a 
dose dependent fashion with 
↑concentration and ↓size. LDH↑ 
with concentration for 21nm 
particle only. 21 nm SiO2   dose 
dependent ↑ in lipid 
peroxidation, ROS and ↓ GSH. 
No change for 48 and 86nm 
particles. Assay showed 21nm 
particles cause apoptosis by 
dose-dependent manner. p53, 
Bax and ↑ by 21nm particles. 
Bcl-2─ 
Relevant cell line 
used. Relevant 
UFP particle used. 
Did not 
examine 
potential 
mediating 
effects of 
oxidative 
stress on 
apoptotic 
changes. 
Cells 
removed 
from nervous 
and 
hormonal 
input. 
 
 
21nm particles 
are cytotoxic. 
Oxidative 
stress is 
mediated by 
ROS. 
Apoptotic 
pathways are 
up-regulated 
by 21nm SiO2.   
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Zhu et al 
2011 
Controlled 
trial (Zhu 
et al., 
2011). 
Human 
aortic 
endotheli
al cells 
from a 
38-year 
old 
female 
donor 
and 
U937 
monocyti
c cells 
from a 
38-year 
old 
donor. 
In vitro 
incubation
. 
Fe2O3 
22nm. 
Fe3O4 
43nm. Both 
at 2, 20, 
100 µg/mL 
for 1-
400min 
exposure. 
Cell cytotoxicity. 
ROS generation 
(DCF). U937 
cells adhesion 
to HAECs. NOS 
activity and NO 
release.  ICAM-
1 and IL-8 
protein 
expression 
Both iron oxides ↑ cellular 
cytotoxicity. Both↑ ROS 
production 20-100µg/ml at 6hrs. 
Both HAEC-U937 adhesion↑ at 
20µg/mL after 4 hours. Both 
↑NOS activity and NO release at 
2µg/mL. ICAM-1 and IL-8↑with 
both nanoparticles.  
30 min sonication 
of nanoparticles 
prior to use. Useful 
nanoparticle 
material used. 
No ROS-
cytotoxicity/u
p 
regulation/il-8 
expression 
dependency 
shown. Cells 
removed 
from nervous 
and 
hormonal 
input. 
Iron oxides 
generate 
monocyte 
adhesion. This 
might be due 
to ROS and 
NO production 
up-regulating 
ICAM-1 and 
IL-8 
expression.  
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Table 6.b. Controlled In vitro experiment- animal tissues. The table is ordered by strength of evidence. All positive outcomes are reported positive at a p=0.05 
significance level regardless of the included study’s definition of significance. Where subject age or gender is reported by the study it is included in column two and the 
age at the start of the study is used. Definitions: ↑= increase, ↓= decrease,  ─ = no change, hrs= hours, expts= experiments, mins= minutes.  
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Choi et al 
2008 
Controlled 
trial (Choi 
et al., 
2009).  
RAW 
264.7 
macroph
ages. 
In vitro 
incubation
. 
Photo 
luminescent 
silicon 3nm 
particles at 
1-200µg/ml. 
NO, Il-6 and TNF-α 
production. 
 Il-6 and TNF-α ↓. NO−. Very small 
nanoparticles 
used.  
Cell deaths 
at higher 
doses. Cell 
isolated from 
in vivo 
cellular and 
hormonal 
effects.  
Unexpected 
observation of 
reduction in 
inflammatory 
mediators at higher 
doses. 
Heng et al 
2011 
Controlled 
trial 
(Heng et 
al., 2011). 
RAW 
264.7 
murine 
macroph
age line. 
In vitro 
incubation 
ZnO sphere 
113nm and 
ZnO sheet 
420nm at 5, 
10, 15, 
20µg/ml. 
Cytotoxicity 
(Concentration 
applied for 50% cell 
death). TNF-α 
production.  
50% cytotoxicity for 113nm 
was 11.7µg/ml, 420nm was 
12.3µg/ml. 114nm and 
420nm↑ TNF-α in a dose 
dependent fashion, 114nm 
more so.  
Nanoparticles 
sonicated 
(duration not 
reported). 
Cell isolated 
from in vivo 
cellular and 
hormonal 
effects.  
In macrophages ZnO 
NP exposure 
increases 
inflammatory 
mediator release. 
Li et al 
2003 
Controlled 
trial (Li et 
al., 2003). 
Murine 
RAW 
264.7 
macroph
age cell 
line 
In vitro 
incubation
.  
Ambient 
UFP < 
150nm at 8-
12µg/ml 
and 
50µg/ml for 
HO-1 
experiment. 
 
 
 
 
 
 
 
 
 
ROS (DTT assay) 
HO-1 expression. 
GSG/GSSH. 
Mitochondrial 
damage. 
ROS↑. HO-1↑. GSG/GSSH↓. 
Extensive disruption of 
mitochondrial cristae. 
Positive controls 
used to 
demonstrate 
plausibility of cell 
experiments. 
Good reference 
material for 
ambient UFP. 
Positive 
controls used 
to 
demonstrate 
plausibility of 
cell 
experiments. 
UFPs generate 
oxidative stress in 
vitro.  
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Mo et al 
2008 
Controlled 
trial (Mo 
et al., 
2008). 
Male 
Wister 
rats 7-8 
weeks of 
age. 
Neutroph
ils from 
rats.   
In vitro 
and intra-
tracheal 
instillation.  
Nickel, 
cobalt and 
TiO2 at 
20nm 0-
10μg/ml for 
in vitro test. 
12hr 
culture. Ex 
vivo used 
one dose of 
0.1, 0.5 or 
1mg in 1ml 
saline. 12 
hour 
exposure. 3 
days post 
exposure, 
neutrophils 
isolated and 
cultured for 
12, 24 and 
48 hrs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IN VITRO LDH, TNF-
α, MIP-2 and NO 
release. EX VIVO 
TNF-α, MIP-2 and NO 
release.  
IN VITRO LDH release at 
10µg/ml. Neutrophil TNF-α, 
MIP-2 and NO ↑with nickel 
and coblt exposure, not TiO2. 
EX VIVO TNF-α, MIP-2 and 
NO ↑ with nickel and cobalt 
exposure. TiO2 ↑ TNF-α.  
Particles 
centrifuged for 30 
mins prior to use. 
Ex vivo 
experiments used 
alongside in vitro 
exposures, to 
describe 
biological 
plausibility and 
real effect.  
Non-
physiological 
exposure 
type. 
Confirmation 
of in vitro 
results in vivo 
might have 
been more 
useful than 
isolated 
neutrophils. 
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Exposure to 3 
different 
nanoparticles types 
caused neutrophil 
release of TNF-α, 
MIP-2 and NO. TiO2 
was less potent.  
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Mo et al 
2009 
Controlled 
trial (Mo 
et al., 
2009a). 
C57BL/6
J and 
gp91pho
x knock-
out mice. 
Mouse 
pulmonar
y 
microvas
cular 
endotheli
al cells 
from 
male 
C57BL/6
J and 
gp91pho
x knock-
out mice.  
In vitro 
incubation 
and intra-
tracheal 
instillation.  
Ambient 
UFP 
<160nm at 
0, 10, 20, 
50, 100 
μg/ml for 12 
hours in 
ROS study. 
And 
200μg/ml 
for 12-72hrs 
for 
cytotoxicity 
studies. 
IN VITRO 
Cytotoxicity, ROS 
generation (DCF 
florescence). 
P67phox knockout 
(essential regulatory 
component of NADPH 
oxidase).  gp91phox 
knock out to confirm. 
p47phox, 67phox and 
Rac 1 translocation. 
p38 and ERK1/2 
MAPK activation. IL-6 
expression. IN VIVO 
ROS generation. 
IN VITRO In wild type murine 
cells, cytotoxicity occurred at 
100 and 200μg/ml. DCF 
fluorescence from 10µg/ml ↑ 
dose response with UFP. 
Inhibited with catalase, DPI 
and NAC. P67 KO 
ameliorated UFP effect. 
Effect confirmed with 
gp91phox knock out cells and 
confirmed in vivo. IL-6 gene ↑ 
and dependent on NADPH 
and P38 (endothelial cell). 
47phox, p67phox and Rac 1 
were all translocated to the 
plasma membrane 
(endothelial cell). p38 and 
ERK1/2 MAPKs activated 
and NADPH dependent.  IN 
VIVO ROS generation 
confirmed in vivo in C57BL/6J 
mice, and not gp91phox 
knock-out mice, 
demonstrating NADPH 
dependence. Effect 
attenuated by NAC, CAT and 
DPI.  
 
 
 
 
 
 
 
Mediating 
biomarkers were 
demonstrated by 
inhibition studies. 
ROS 
demonstrated in 
both exposure 
types. Realistic 
particle exposure. 
Limited 
outcomes 
examined in 
vivo.  
 
UFP exposure 
caused endothelial 
cell ROS generation. 
NADPH oxidase 
produces this ROS.  
MAP kinases 
activation due to 
oxidative stress up-
regulates IL-6. 
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Mo et al 
2012 
Controlled 
trial(Mo et 
al., 2012). 
Mouse 
pulmonar
y 
microvas
cular 
endotheli
al cells 
from 
male 
C57BL/6
J and 
gp91pho
x knock-
out mice.  
In vitro 
incubation
. 
Ambient 
UFP 
<160nm at 
0, 10, 20, 
50 μg/ml for 
ROS study 
for 2 hours 
and 100-
200μg/ml 
for 
cytotoxicity 
studies over 
24 hours 
exposure. 
Cytotoxicity, ROS 
generation (DCF 
fluorescence). P38 
and ERK1/2 MAPK 
activation.  Erg-1 
regulation and MAPK 
dependence. IL-6 
expression. 
In wild type murine cells, 
cytotoxicity occurred at 100 
and 200 μg/ml, DCF 
fluorescence from 20μg/ml ↑ 
dose response with UFP. P38 
and ERK1/2 MAPKs 
activated in wild type, not 
gp91 KO. ↑ erg-1 expression 
at mRNA and protein level. 
UFPs did not induce Egr-1 in 
gp91phox KO mice. Inhibition 
of p38 and ERK1/2 MAPKs 
attenuated UFP-induced Egr-
1 up-regulation. IL-6 
expression ↑ with UFP 
exposure, in mRNA and 
protein form in wild type mice, 
not gp91 KO. This was a P38 
and erg-1 dependent effect.  
Mediating 
biomarkers were 
demonstrated by 
inhibition studies.  
Realistic particle 
exposure. 
Cells isolated 
from in vivo 
cellular and 
hormonal 
effects.  
Cells exposed to UFP 
generated ROS, 
activated MAPK-1 
and increased IL-6 
expression. Erg-1 
was also up-
regulated.  NAPH 
oxidase is a key 
mediator in ROS 
driven biomarker 
expression.  
Nishanth 
et al 2011 
Controlled 
trial 
(Nishanth 
et al., 
2011). 
RAW 
264.7 
murine 
macroph
ages. 
In vitro 
incubation
. 
Silver 15, 
40nm, 
Aluminium 
20, 50nm, 
CB 20, 
40nm. Gold 
20,40nm. 
Carbon 
coated 
silver 25, 
45nm at 0-
150µg/ml 
for 0-72 
hours. 
 
ROS production 
(DCFH fluorescence). 
Nf-kB activation. 
COX-2, TNF-α mRNA 
and protein 
expression. IL-6 
release. 
ROS= 5µg/ml silver ↑. 
Aluminium↑ CB↑ Carbon 
coated silver ↑ all doses, 
Gold ↓. Nf-kB↑ with all except 
Au─.  After exposure, Silver, 
aluminium, CB, carbon 
coated silver ↑COX-2 and 
TNF-α mRNA, and protein. 
Au only at 24hrs (mRNA) and 
48 (protein).  IL-6 protein↑ for 
all except Au.  
Positive control 
(LPS) considered 
and investigated.  
Wide range 
of size and 
economically 
useful 
particles.  
ROS release is 
increased post 
exposure to NPs, 
gold is not as reactive 
as the other particles.  
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Radomski 
et al 2005 
Controlled 
trial 
(Radomsk
i et al.). 
Platelets 
separate
d from 
blood 
from 
healthy 
human 
volunteer
s. 
Wistar–
Kyoto 
rats. Age 
not 
reported.  
In vitro 
incubation 
and IV 
injection. 
Mixed 
carbon 
nanoparticle
s, purified 
carbon 
fullerenes at 
50µg/ml in 
vivo for 
thrombosis 
experiment, 
200µg/ml in 
vivo. 5-
500µg/ml in 
vitro.  
IN VITRO Platelet 
aggregation.  ATP 
release. 
Degranulation. 
GP2b3a expression. 
P-selectin expression 
Gp1b expression 
Aggregation inhibition 
by prostacyclin and S-
nitroso-
glutathione,(endogen
ous inhibitors of 
haemostasis) and 
aspirin (GP2b3a 
inhibitor. MMP-
9/MMP-2 ratio. PKC 
dependence. IN VIVO 
Platelet aggregation. 
IN VITRO Mixed carbon NPs 
↑ platelet aggregation. 
Carbon fullerenes─. Mixed 
carbon NPs caused ATP 
release and platelet 
degranulation. Mixed carbon 
NPs ↑GP2b3a expression. P-
selectin↑ for mixed carbon 
NPs. GP1b↓ for mixed carbon 
NPs. Mixed carbon NPs ↓ 
aggregation with prostacyclin 
and S-nitroso-glutathione, not 
with aspirin. MMP-9/MMP-2 
ratio↑ in carbon fullerenes 
only. PKC dependence─ for 
all particles. IN VIVO. Mixed 
carbon nanoparticles ↑ 
platelet aggregation at 
50µg/ml. Carbon fullerenes─. 
 
Nanoparticles 
sonicated for 2 
minutes. vortexed 
prior to testing. 
Investigated 
aggregation 
through several 
methods, and 
confirmed in vivo.  
Limited in 
vivo 
experiments. 
IV injection 
assumes that 
all particles 
pass the 
alveolar 
barrier.  
Carbon nanoparticles 
and materials 
activate platelet and 
enhance vascular 
thrombosis, but might 
do through different 
mechanisms.  
Rosas-
Hernande
z et al 
2009. 
Controlled 
trial 
(Rosas-
Hernande
z et al., 
2009). 
Sprague-
Dawley 
rat 
coronary 
endotheli
al cells 
and rat 
aortic 
rings.  
Ex vivo 
and in 
vitro 
incubation
. 
Silver, 
45nm 
particles at 
0-100µg/ml 
(Incubations 
2min-2hrs) 
in vitro, and 
5 µg/ml ex 
vivo.  
IN VITRO cell 
proliferation. NO 
production. EX VIVO 
Vasoconstriction 
with/without 
phenylepherine. Ach 
effect.  
IN VITRO cell proliferation 
inhibited at low doses and 
LDH released, ↑ at doses 50-
100μg/ml. 10 μg/ml + 
stimulated NO production. 
Proliferation was NO 
dependent, shown by L-
NAME blocking (shows 
eNOS dependent) 10μg/ml +.  
EX VIVO At 5μg/ml dose, 
vasoconstriction ↑ 
with/without phenylepherine 
and effect↓ when 
endothelium was removed. 
UFP inhibited Ach mediated 
vasorelaxation. ─ at high 
dose (45μg/ml).  
Brief sonication 
used to 
disaggregate 
particles. Air 
bolus used to 
follow the intra-
tracheal 
instillation. 
Vasoactivity tests 
in two different 
models.  
NO 
dependent 
effects in 
vitro not 
similarly 
demonstrate
d in vivo. Non 
physiological 
exposure 
type.  
A low concentration 
of silver was 
vasoconstrictive, a 
high concentration 
was vasodilatory. 
Vasoconstriction 
inhibited Ach 
induced, NO 
dependent 
vasorelaxation. 
Vasodilation partially 
abolished by L-
NAME.  
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Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study strengths Study 
weaknesses 
Conclusion 
Xia et al 
2008 
Controlled 
trial (Xia 
et al., 
2008). 
RAW 
274.7 
cells. 
In vitro 
incubation
. 
TiO2 
284nm, 
ZnO 36nm, 
CeO2 
323nm. For 
0-20hrs and 
50µg/ml. 
Cytotoxicity. ROS 
generation (DCF-
H2O2 production and 
MitoSOX Red=O2- 
production). HO-1 
protein expression. 
Nrf2, NQO-
1mRNAexpression. 
JNK activation.. IL-8 
and TNF-α protein 
expression.Ca2+ 
release. CeO2 
protective effect.  
TiO2 ↑ cytotoxicity. O2-and 
H2O2↑for ZnO only. HO-1 
protein ↑ for ZnO only. Nrf2 
and NQO-1 mRNA↑ with 
ZnO. JNK↑ with ZnO. IL-8 
and TNF-α↑ with ZnO. Ca2+↑ 
with ZnO. CeO2 reduced cell 
death count and oxidative 
stress (MitoSOX Red) when 
administered to cells with 
DEP vs. DEP alone.  
Wide range of 
industrial 
nanoparticles 
used. 
Cells 
removed 
from nervous 
and 
hormonal 
input. Murine 
macrophages 
used. 
Assumes 
direct effect 
upon cells.  
All 3 tiers of oxidative 
stress defence were 
overcome by ZnO, 
but not the other 
particles. This could 
be due to size 
difference between 
particles, and not 
Inherent reactivity.  
Ye et al 
2010b 
Controlled 
trial(Ye et 
al., 
2010b). 
Rat 
embryoni
c 
ventricul
ar 
myocardi
al cell 
line 
H9c2(2-
1). 
In vitro 
incubation
. 
21 and 
49nm SiO2 
particles at 
0.1 to 0.3 
mg/ml. 
(1.6mg/ml 
for 
cytotoxicity)
. Incubated 
12-48hr. 
Cytotoxicity (50% cell 
death). Cell viability. 
LDH levels. 
Intracellular ROS, 
GSH. MDA levels. 
Cell cycle flow 
cytometry.  p53, p21 
and Bax protein 
levels. 
21nm= 0.32 and 49= 1.29 
mg/ml for 50% cell death. 
Cell viability↓ for 49nm and 
more rapidly at 21nm, both 
time and dose dependent. 
0.3mg/ml for 24 hrs↑ LDH. 
Only 0.3mg/ml ↑ROS, GSH↓ 
and MDA↑. Cell cycle arrest 
in G1, S phase% of cells↓. 
P53 and P21↑at both doses 
at 21hr and P53 at high 
dose+ 48hrs, Bax─.  
 
 
 
 
 
 
 
 
 
 
 
Pre-determined 
dosing from pilot 
work. Relevant 
cell type used.  
Cells 
removed 
from nervous 
and 
hormonal 
input. High 
doses used.  
SiO2 particles have a 
toxic effect on 
H9c2(2-1) cells, with 
oxidative stress being 
a component of this. 
p53 and p21 proteins 
are likely involved in 
the G1 phase arrest.  
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Author 
and study 
type 
Subject 
type 
Exposure 
technique 
Exposure 
type 
Outcomes Results Study strengths Study 
weaknesses 
Conclusion 
Yu et al 
2010 
Controlled 
trial (Yu et 
al., 2010). 
Pulmona
ry micro 
vascular 
endotheli
al cells 
from 
male 
C57BL/6
J mice. 
In vitro 
incubation
. 
TiO2 28nm, 
CuO 42nm 
0-10 µg/ml 
for cell 
viability. 
0.625-
2.5µg/ml for 
other 
experiments
. 
Cell viability. ROS 
generation (DCF). 
P38 MAPK activation. 
PAI-1 mRNA and 
protein expression. 
(NAC, CAT, DPI 
inhibition/scavenger 
of ROS, mRNA and 
protein expression) 
P38 inhibition of PAI-1 
expression. 
Cell viability, TioO2─, CuO 
toxic from 5-10 µg/ml in a 
dose responsive manner.  
EC50 approx. 7.5µg/ml. 
ROS↑ at 0.625µg/ml CuO for 
12hrs in a dose responsive 
fashion, TiO2─. NAC, CAT, 
DPI all attenuated ROS 
production. P38 MAPK↑ CuO 
0.625-2.5µg/ml after 3 hrs, 
and 2.5µg/ml at 1-12 hours, 
TiO2─. NAC, CAT, DPI↓ P38 
MAPK. CuO 1-3hr 2.5µg/ml↑ 
PAI-1 mRNA and 12hr 
protein. NAC, CAT, DPI↓ 
these effects. P38 
inhibition↓PAI-1 expression. 
Multiple assay 
types used. 
(AlamarBlue™an
d MTS). Tested 
ROS pathway in 
several ways. 
Agglomerate
d to 280 Ti 
and CuO 
220nm. Cells 
removed 
from nervous 
and 
hormonal 
input. 
CuO is more toxic 
than TiO2. During 
oxidative stress, PAI-
1 is up-regulated, and 
is dependent on the 
p38 MAPK pathway. 
Zhang et 
al 2011 
Controlled 
trial 
(Zhang et 
al., 2011). 
Murine 
RAW 
274.7 
macroph
ages 
In vitro 
incubation
. 
Gold 97nm 
from 0-
100µg/ml 
measureme
nts made at 
24- 48hrs.  
Cytotoxicity. TNF-α 
and IL-6 protein 
release.  NO release. 
ROS production 
(DCF). 
No change in cell viability or 
LDH release occurred. IL-6 
and TNF-α─.  NO─. ROS 
production─ 
Nanoparticles 
inspected for 
LPS. LPS and 
H2O2 used as 
positive control. 
Assay 
absorbance 
adjusted for 
nanoparticle 
interference.  
Cells 
removed 
from nervous 
and 
hormonal 
input. Not a 
useful 
nanoparticle 
material.  
High 
agglomeratio
n rates.  
Gold particles are 
unreactive when 
exposed to 
macrophages at 
varying doses in vitro.  
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Figure captions 
 
Figure 1. Method adapted from the German Institute for Quality and Efficiency in Health Care. 
 
Figure 2. QUORUM Flow chart 
 
